

第 1 章

子宫内膜癌的流行病学和病因学

Descriptive Epidemiology and Etiology of Endometrial Cancer

- [1] Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. *Best Pract. Res. Clin. Obstet. Gynaecol.*, 2006; vol.20, n.2, pp.: 207–225.
- [2] National Cancer Institute. *Endometrial Cancer*. 2014. Available from: <http://www.cancer.gov/cancertopics/types/endometrial>.
- [3] Memon A. Epidemiological understanding: An overview of basic concepts and study designs. In: Pencheon D et al., editors. *Oxford Handbook of Public Health Practice*, Second Edition: Oxford University Press; 2006, pp.: 100–111.
- [4] Memon A. Epidemiology of gynaecological cancers. In: Shafi M et al., editors. *Gynaecological Oncology*. Cambridge University Press; 2010; pp.: 1–13.
- [5] Centers for Disease Control and Prevention (CDC), *National Programme of Cancer Registries (NPCR)*. Available from: <http://apps.nccd.cdc.gov/uscs> and <http://www.cdc.gov/cancer/npcr>.
- [6] Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). *Global Cancer Observatory: Cancer Today*. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.fr/today>, accessed 15/12/21.
- [7] Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay (2017). *Cancer Incidence in Five Continents*, Vol. XI (electronic version) Lyon, IARC. Available from: <http://ci5.iarc.fr>, accessed 15/12/21.
- [8] Seigel R L, Miller K D, Jemal A. Cancer statistics 2018. *Ca Cancer J. Clin.*, 2018; vol.68, n.1, pp.: 7–30.
- [9] *Surveillance, Epidemiology and End Results (SEER) Program*. National Cancer Institute. Available from: <https://seer.cancer.gov/>, accessed 15/12/21.
- [10] *Cancer Research UK*. Available from: <http://info.cancerresearchuk.org>.
- [11] Long B, Liu F W, Bristow R E. Disparities in Uterine Cancer Epidemiology, Treatment, and Survival Among African Americans in the United States. *Gynecol. Oncol.*, 2013; vol.130, n.3, pp.: 652–659.
- [12] Weiderpass E, Antoine J, Bray F I, Oh J K, Arbyn M. Trends in corpus uteri cancer mortality in member states of the European Union. *Eur. J. Cancer*. 2014 Jun; 50(9): 1675–84. <https://doi.org/10.1016/j.ejca.2014.02.020>. Epub 2014 Mar 20. PMID: 24656568.
- [13] Persson I, Adami H O, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. *BMJ*. 1989 Jan 21; 298(6667): 147–51. <https://doi.org/10.1136/bmj.298.6667.147>. PMID: 2538173; PMCID: PMC1835464.
- [14] Iversen L, Sivasubramaniam S, Lee A J. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. *Am. J. Obstet. Gynecol.*, 2017; vol.216, n.6, pp.: 580.
- [15] Lauritzen C, Meier F. Risks of endometrial and mammary cancer morbidity and mortality in long-term oestrogen treatment. In *The Climacteric: An Update*, 1984; pp.: 207–216.
- [16] Potischman N, Hoover R N, Brinton L A, Siiteri P, Dorgan J F, Swanson C A, Berman M L, Mortel R, Twigg L B, Barrett R J, Wilbanks G D, Persky V, Lurain J R. Case-control study of endogenous steroid hormones and endometrial cancer. *J. Natl. Cancer Inst.* 1996 Aug 21; 88(16): 1127–35. <https://doi.org/10.1093/jnci/88.16.1127>. PMID: 8757192.
- [17] Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. *Lancet Oncol.*, 2015; vol.16, n.9, pp.: 1061–1070.
- [18] Key T J, Pike M C. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. *Brit. J. Cancer* 1988; vol.57, n.2, pp.: 205–212.
- [19] Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. *Obstet. Gynecol. Surv.*, 2005; vol.60, n.9, pp.: 595–597.
- [20] Pike M C, Peters R K, Cozen W, Probst-Hensch N M, Felix J C, Wan P C, Mack T M. Estrogen-progestin replacement therapy and endometrial cancer. *J. Natl. Cancer Inst.* 1997 Aug 6; 89(15): 1110–1116. <https://doi.org/10.1093/jnci/89.15.1110>. PMID: 9262248.
- [21] Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet. Gynecol.* 1995 Feb; 85(2): 304–313. [https://doi.org/10.1016/0029-7844\(94\)00383-O](https://doi.org/10.1016/0029-7844(94)00383-O).

- PMID: 782425-1.
- [22] Trabert B, Wentzensen N, Yang H P, Sherman M E, Hollenbeck A R, Park Y, Brinton L A. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? *Int. J. Cancer*. 2013 Jan 15; 132(2): 417–426. <https://doi.org/10.1002/ijc.27623>. Epub 2012 Aug 30. PMID: 22553145; PMCID: PMC3427719.
- [23] Weiderpass E, Adami H O, Baron J A, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. *J. Natl. Cancer Inst.* 1999 Jul 7; 91(13): 1131–1137. <https://doi.org/10.1093/jnci/91.13.1131>. PMID: 10393721.
- [24] McPherson C P, Sellers T A, Potter J D, Bostick R M, Folsom A R. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. *Am. J. Epidemiol.* 1996 Jun 15; 143(12): 1195–1202. <https://doi.org/10.1093/oxfordjournals.aje.a008707>. PMID: 8651218.
- [25] Brown S B, Hankinson S E. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. *Steroids*, 2015; vol.99, n.Pt A, pp.: 8–10.
- [26] Wernli K J, Ray R M, Gao D L, De Roos A J, Checkoway H, Thomas D B. Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. *Cancer Causes Control*. 2006 Sep; 17(7): 949–955. <https://doi.org/10.1007/s10552-006-0034-6>. PMID: 16841262.
- [27] Coulman C B, Annegers J F, Kranz, J S. Chronic anovulation syndrome and associated neoplasia. *Obstet. & Gynecol.*, 1983; vol.61, n.4, pp.: 403–407.
- [28] Soliman P T, Oh J C, Schmeler K M, Sun C C, Slomovitz B M, Gershenson D M, Burke T W, Lu K H. Risk factors for young premenopausal women with endometrial cancer. *Obstet. Gynecol.* 2005 Mar; 105(3): 575–580. <https://doi.org/10.1097/01.AOG.0000154151.14516.f7>. PMID: 15738027.
- [29] Xu W H, Xiang Y B, Ruan Z X, Zheng W, Cheng J R, Dai Q, Gao Y T, Shu X O. Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai. *Int. J. Cancer*. 2004 Feb 10; 108(4): 613–619. <https://doi.org/10.1002/ijc.11598>. PMID: 14696129.
- [30] Wernli K J, Ray R M, Gao D L, De Roos A J, Checkoway H, Thomas D B. Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. *Cancer Causes Control*. 2006 Sep; 17(7): 949–955. <https://doi.org/10.1007/s10552-006-0034-6>. PMID: 16841262.
- [31] Escobedo L G, Lee N C, Peterson H B, Wingo P A. Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. *Obstet. Gynecol.* 1991 Jan; 77(1): 124–128. PMID: 1984211.
- [32] Salazar-Martinez E, Lazcano-Ponce E C, Gonzalez Lira-Lira G, Escudero-De los Rios P, Salmeron-Castro J, Hernandez-Avila M. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. *Cancer Res*. 1999 Aug 1; 59(15): 3658–3662. PMID: 10446978.
- [33] Gong T, Wang Y L, Ma X. Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies. *Sci. Rep.*, 2015; vol.5.
- [34] Sponholtz T R, Palmer J R, Rosenberg L, Hatch E E, Adams-Campbell L L, Wise L A. Reproductive factors and incidence of endometrial cancer in U.S. black women. *Cancer Causes Control*. 2017 Jun; 28(6): 579–588. <https://doi.org/10.1007/s10552-006-0034-6>. Epub 2017 Mar 30. PMID: 28361447; PMCID: PMC5634741.
- [35] Brinton L A, Berman M L, Mortel R, Twiggs L B, Barrett R J, Wilbanks G D, Lannom L, Hoover R N. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. *Am. J. Obstet. Gynecol.* 1992 Nov; 167(5): 1317–25. [https://doi.org/10.1016/s0002-9378\(11\)91709-8](https://doi.org/10.1016/s0002-9378(11)91709-8). PMID: 144–2985.
- [36] La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at different ages. *J. Natl. Cancer Inst.* 1984 Sep; 73(3): 667–671. PMID: 6590913.
- [37] Henderson B E, Casagrande J T, Pike M C, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. *Br. J. Cancer*. 1983 Jun; 47(6): 749–756. doi: 10.1038/bjc.1983.127. PMID: 6860544; PMCID: PMC2011352.
- [38] Bergström A, Pisani P, Tenet V, Wolk A, Adami H O. Overweight as an avoidable cause of cancer in Europe. *Int. J. Cancer*. 2001 Feb 1; 91(3): 421–430. [https://doi.org/10.1002/1097-0215\(200002\)9999:9999<:aid-ijc1053>3.0.co;2-t](https://doi.org/10.1002/1097-0215(200002)9999:9999<:aid-ijc1053>3.0.co;2-t). Erratum in: *Int. J. Cancer* 2001 Jun 15; 92(6): 927. PMID: 11169969.
- [39] Calle E, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat. Rev. Cancer*, 2004; vol.4, n.8, pp.: 579–591.
- [40] Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin J K, Fraumeni J F, Adam H O. A prospective study of obesity and cancer risk (Sweden). *Cancer Causes Control*. 2001 Jan; 12(1): 13–21. <https://doi.org/10.1023/a:1008995217664>. PMID: 11227921.
- [41] Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland S K. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. *Br. J. Cancer*. 2005 Oct 31; 93(9): 1062–1067. doi: 10.1038/sj.bjc.6602819. PMID: 16234822; PMCID: PMC2361672.
- [42] Chang S C, Lacey J V Jr, Brinton L A, Hartge P, Adams K, Mouw T, Carroll L, Hollenbeck A, Schatzkin A, Leitzmann M F. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. *Cancer Epidemiol. Biomarkers Prev.* 2007 Apr; 16(4): 723–730. <https://doi.org/10.1158/1055-9965.EPI-06-0675>. PMID: 17416763.
- [43] MacDonald P C, Edman C D, Hemsell D L, Porter J C, Siitleri P K. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. *Am. J. Obstet. Gynecol.* 1978 Feb 15; 130(4): 448–455. [https://doi.org/10.1016/0002-9378\(78\)90287-9](https://doi.org/10.1016/0002-9378(78)90287-9). PMID: 629289.
- [44] Anderson K E, Anderson E, Mink P J, Hong C P, Kushi L H, Sellers T A, Lazovich D, Folsom A R. Diabetes and endometrial cancer in the Iowa women's health study.

- Cancer Epidemiol. Biomarkers Prev.* 2001 Jun; 10(6): 611–616. PMID: 11401910.
- [45] Parazzini F, La Vecchia C, Negri E, Riboldi G L, Surace M, Benzi G, Maina A, Chiaffarino F. Diabetes and endometrial cancer: an Italian case-control study. *Int. J. Cancer.* 1999 May 17; 81(4): 539–542. [https://doi.org/10.1002/\(sici\)1097-0215\(19990517\)81:4<539::aid-ijc6>3.0.co;2-q](https://doi.org/10.1002/(sici)1097-0215(19990517)81:4<539::aid-ijc6>3.0.co;2-q). PMID: 10225441.
- [46] Friberg E, Orsini N, Mantzoros C S, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. *Diabetologia.* 2007 Jul; 50(7): 1365–1374. <https://doi.org/10.1007/s00125-007-0681-5>. Epub 2007 May 3. PMID: 17476474.
- [47] Vrachnis N, Iavazzo C, Iliodromiti Z, Sifakis S, Alexandrou A, Siristatidis C, Grigoriadis C, Botsis D, Creatas G. Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives. *Arch. Gynecol. Obstet.* 2016 Feb; 293(2): 239–246. <https://doi.org/10.1007/s00404-015-3858-z>. Epub 2015 Sep 4. PMID: 26338721.
- [48] Yang H P, Gierach G L, Danforth K N, Sherman M E, Park Y, Wentzensen N, Hollenbeck A, Schatzkin A, Brinton L A. Alcohol and endometrial cancer risk in the NIH-AARP diet and health study. *Int. J. Cancer.* 2011 Jun 15; 128(12): 2953–2961. <https://doi.org/10.1002/ijc.25623>. Epub 2010 Oct 8. PMID: 20725997; PMCID: PMC3020256.
- [49] Zhou Q, Guo P, Li H, Chen X D. Does alcohol consumption modify the risk of endometrial cancer? A dose-response meta-analysis of prospective studies. *Arch. Gynecol. Obstet.* 2017 Feb; 295(2): 467–479. <https://doi.org/10.1007/s00404-016-4263-y>. Epub 2016 Dec 14. PMID: 27975130.
- [50] Friberg E, Orsini N, Mantzoros C S, Wolk A. Alcohol intake and endometrial cancer risk: a meta-analysis of prospective studies. *Br. J. Cancer.* 2010 Jun 29; 103(1): 127–131. <https://doi.org/10.1038/sj.bjc.6605698>. Epub 2010 May 18. PMID: 20485288; PMCID: PMC2905297.
- [51] Fedirko V, Jenab M, Rinaldi S, Biessy C, Allen N E, Dossus L, Onland-Moret N C, Schütze M, Tjønneland A, Hansen L, Overvad K, Clavel-Chapelon F, Chabbert-Buffet N, Kaaks R, Lukanova A, Bergmann M M, Boeing H, Trichopoulou A, Oustoglu E, Barbitsioti A, Saieva C, Tagliabue G, Galasso R, Tumino R, Sacerdote C, Peeters P H, Bueno-de-Mesquita H B, Weiderpass E, Gram I T, Sanchez S, Duell E J, Molina-Montes E, Arriola L, Chirlaque M D, Ardanaz E, Manjer J, Lundin E, Idahl A, Khaw K T, Romaguera-Bosch D, Wark P A, Norat T, Romieu I. Alcohol drinking and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Ann. Epidemiol.* 2013 Feb; 23(2): 93–98. <https://doi.org/10.1016/j.annepidem.2012.11.009>. Epub 2012 Dec 25. PMID: 232–73691.
- [52] Turati F, Gallus S, Tavani A, Tramacere I, Polesel J, Talamini R, Montella M, Scotti L, Franceschi S, La Vecchia C. Alcohol and endometrial cancer risk: a case-control study and a meta-analysis. *Cancer Causes Control.* 2010 Aug; 21(8): 1285–1296. <https://doi.org/10.1007/s10552-010-9556-z>. Epub 2010 Apr 16. PMID: 20396942.
- [53] Sun Q, Xu L, Zhou B, Wang Y, Jing Y, Wang B. Alcohol consumption and the risk of endometrial cancer: a meta-analysis. *Asia Pac. J. Clin. Nutr.* 2011; 20(1): 125–133. PMID: 21393120.
- [54] Swerdlow A J, Jones M E. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. *J. Nat. Cancer Inst.*, 2005; vol.97, n.5, pp.: 375–384.
- [55] van Leeuwen F E, Benraadt J, Coebergh J W, Kiemeny L A, Gimbrère C H, Otter R, Schouten L J, Damhuis R A, Bontenbal M, Diepenhorst F W, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. *Lancet.* 1994 Feb 19; 343(8895): 448–452. [https://doi.org/10.1016/s0140-6736\(94\)92692-1](https://doi.org/10.1016/s0140-6736(94)92692-1). PMID: 79–05955.
- [56] Bergman L, Beelen M L, Gallee M P, Hollema H, Benraadt J, van Leeuwen F E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. *Lancet.* 2000 Sep 9; 356(9233): 881–887. [https://doi.org/10.1016/s0140-6736\(00\)02677-5](https://doi.org/10.1016/s0140-6736(00)02677-5). PMID: 11036892.
- [57] Rutqvist L E, Johansson H, Signomklo T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. *J. Natl. Cancer Inst.* 1995 May 3; 87(9): 645–651. <https://doi.org/10.1093/jnci/87.9.645>. PMID: 7752269.
- [58] Karageorgi S, Hankinson S E, Kraft P, De Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976–2004. *Int. J. Cancer.* 2010 Jan 1; 126(1): 208–216. <https://doi.org/10.1002/ijc.24672>. PMID: 19551854; PMCID: PMC2784268.
- [59] Mogren I, Stenlung H, Högborg U. Long-term Impact of Reproductive Factors on the Risk of Cervical, Endometrial, Ovarian and Breast Cancer. *Acta Oncologica*, 2001; vol.40, n.7, pp.: 849–854.
- [60] Inoue M, Okayama A, Fujita M, Enomoto T, Tanizawa O, Ueshima H. A case-control study on risk factors for uterine endometrial cancer in Japan. *Jpn. J. Cancer Res.* 1994 Apr; 85(4): 346–350. <https://doi.org/10.1111/j.1349-7006.1994.tb02365.x>. PMID: 8200846; PMCID: PMC5919475.
- [61] Zhan B, Liu X, Li F, Zhang D. Breastfeeding and the incidence of endometrial cancer: A meta-analysis. *Oncotarget.* 2015 Nov 10; 6(35): 38398–38409. <https://doi.org/10.18632/oncotarget.5049>. PMID: 26384296; PMCID: PMC4742008.
- [62] Rosenblatt K A, Thomas D B. Prolonged lactation and endometrial cancer. *Int. J. Epidemiol.*, 1995; vol.24, n.3, pp.: 499–503.
- [63] Okamura C, Tsubono Y, Ito K, Niikura H, Takano T, Nagase S, Yoshinaga K, Terada Y, Murakami T, Sato S, Aoki D, Jobo T, Okamura K, Yaegashi N. Lactation and risk of endometrial cancer in Japan: a case-control study. *Tohoku J. Exp. Med.* 2006 Feb; 208(2): 109–115. <https://doi.org/10.1620/tjem.208.109>. PMID: 16434833.
- [64] Shu X O, Hatch M C, Zheng W, Gao Y T, Brinton L A. Physical activity and risk of endometrial cancer. *Epidemiology.* 1993 Jul; 4(4): 342–349. <https://doi.org/10.1093/epi/km001>.

- org/10.1097/00001648-199307000-00010. PMID: 8347745.
- [65] Goodman M T, Hankin J H, Wilkens L R, Lyu L C, McDuffie K, Liu L Q, Kolonel L N. Diet, body size, physical activity, and the risk of endometrial cancer. *Cancer Res.* 1997 Nov 15; 57(22): 5077–5085. PMID: 9371506.
- [66] Schouten L J, Goldbohm R A, Van Den Brandt P A. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. *J. Natl. Cancer Inst.*, 2004; vol. 96, n.21, pp.: 1635–1638.
- [67] Moradi T, Nyrén O, Bergström R, Gridley G, Linet M, Wolk A, Dosemeci M, Adami H O. Risk for endometrial cancer in relation to occupational physical activity: a nationwide cohort study in Sweden. *Int. J. Cancer.* 1998 May 29; 76(5): 665–670. [https://doi.org/10.1002/\(sici\)1097-0215\(19980529\)76:5<665::aid-ijc9>3.0.co;2-o](https://doi.org/10.1002/(sici)1097-0215(19980529)76:5<665::aid-ijc9>3.0.co;2-o). PMID: 9610723.
- [68] Soliman P T, Bassett R L Jr, Wilson E B, Boyd-Rogers S, Schmeler K M, Milam M R, Gershenson D M, Lu K H. Limited public knowledge of obesity and endometrial cancer risk: what women know. *Obstet. Gynecol.* 2008 Oct; 112(4): 835–842. <https://doi.org/10.1097/AOG.0b013e318187d022>. PMID: 18827126.

第2章

子宫内膜肿瘤的病理与分子诊断

Pathology and Molecular Diagnosis of Endometrial Tumors

- [1] Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecologic Oncology*. 1983 Feb; 15(1): 10–7.
- [2] Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. *Cancer*. 1985 Jul 15; 56(2): 403–412.
- [3] Jobo T, Tateoka K, Kuramoto H. Study on the long-term follow-up of endometrial hyperplasia. *Int J Clin Oncol*. 1996 Nov 1; 1(3): 163–169.
- [4] Baak JP, Mutter GL, Robboy S, van Diest PJ, Uytterlinde AM, Ørbo A, Palazzo J, Fianne, B, Løvslett, K, Burger, C, Voorhorst, F, & Verheijen, RH. (2005). In Endometrial hyperplasias, the molecular-genetics and morphometry-based EIN classification more accurately predicts cancer-progression than the WHO94. *Cancer*. 2005 Jun 1; 103(11): 2304–2312.
- [5] Mutter GL, Kauderer J, Baak JPA, Alberts D. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. *Human Pathology*. 2008 Jun; 39(6): 866–874.
- [6] Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA. Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P, editors. *Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours*. Lyon (France): IARC Press; 2003. pp. 221–232.
- [7] Zaino R, Carinelli SG, Ellenson LH, Eng C, Katabuchi H, Konishi I, Lax S. Epithelial tumors and precursors. In: Kurman, RJ, Carcangiu, M.L., Herrington, C.S., Young, R.H, editors. *WHO Classification of Tumours of Female Reproductive Organs*. IARC: Lyon 2014. pp. 1210–1154.
- [8] Endometrial intraepithelial neoplasia. Committee Opinion No. 631. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2015 125: 1272–1278.
- [9] Mutter GL. Histopathology of genetically defined endometrial precancers. *Int J Gynecol Pathol*. 2000 Oct; 19(4): 301–309.
- [10] Mutter GL. Diagnosis of premalignant endometrial disease. *J Clin Pathol*. 2002 May; 55(5): 326–331.
- [11] Hecht JL, Ince TA, Baak JPA, Baker HE, Ogdan MW, Mutter GL. Prediction of endometrial carcinoma by subjective EIN diagnosis. *Mod Pathol*. 2005 Mar; 18(3): 324–330.
- [12] Lacey JV, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME. Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. *Cancer*. 2008 Oct 15; 113(8): 2073–2081.
- [13] Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz, AP, Ngan HY, Pecorelli S (2006) Carcinoma of the Corpus Uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. *Int J Gynecol Obstet*. 2006 Nov; 95: S105–143.
- [14] Malpica A. How to approach the many faces of endometrioid carcinoma. *Mod Pathol*. 2016 Jan; 29(S1): S29–44.
- [15] Bartosch C, Manuel Lopes J, Oliva E. Endometrial Carcinomas: A Review Emphasizing Overlapping and Distinctive Morphological and Immunohistochemical Features. *Adv Anat Pathol*. 2011 Nov; 18(6): 415–437.
- [16] Eichhorn JH, Young RH, Clement PB. Sertoliform endometrial adenocarcinoma: a study of four cases. *Int J Gynecol Pathol*. 1996 Apr; 15(2): 119–126.
- [17] Murray SK, Clement PB, Young RH. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. *Am J Surg Pathol*. 2005 Feb; 29(2): 157–166.
- [18] Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M, Pecorelli S. Carcinoma of the corpus uteri. *J Epidemiol Biostat*. 2001; 6(1): 47–86.
- [19] Gatus S, Matias-Guiu X. Practical issues in the diagnosis of serous carcinoma of the endometrium. *Mod Pathol*. 2016 Jan; 29(S1): S45–58.
- [20] Clement PB, Stall JN, Young RH. Chapter 8: Endometrial Hyperplasia and Carcinoma. *Atlas of Gynecologic Surgical Pathology*. Elsevier. 2020.p.199.
- [21] Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal Uterine Serous Carcinoma: Diagnosis and Clinicopathologic Correlation. *Am J Surg Pathol*. 2000 Jun; 24(6): 797–806.
- [22] Zheng W, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. *Gynecol*

- Oncol.* 2005 Mar; 96(3): 579–582.
- [23] Stewart CJR, Doherty DA, Havlat M, Koay MHE, Leung YC, Naran A, O'Brien, D, Ruba, S, Salfinger, S, & Tan J.T ranstubal spread of endometrial carcinoma: correlation of intra-luminal tumour cells with tumour grade, peritoneal fluid cytology, and extra-uterine metastasis. *Pathology.* 2013 Jun; 45(4): 382–387.
- [24] Chiang S, Soslow RA. Updates in diagnostic immunohistochemistry in endometrial carcinoma. *SeminDiagn Pathol.* 2014 May; 31(3): 205–215.
- [25] Abdulfatah E, Sakr S, Thomas S, Al-Wahab Z, Mutch DG, Dowdy S, Bandyopadhyay S, Munkarah A, Elshaikh M, Morris R, and Ali-Fermi R. Clear cell carcinoma of the endometrium. *Int J Gynecol Cancer.* 2017 Oct; 27(8): 1714–1721.
- [26] Varughese J, Hui P, Lu L, Yu H, Schwartz PE. Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression. *J Oncol.* 2011; 2011: 1–6.
- [27] Bartosch C, Pires-Luis AS, Meireles C, Baptista M, Gouveia A, Pinto C, Shannon, KM, Jerónimo C, Teixeira MR, Lopes, JM, & Oliva E. Pathologic findings in prophylactic and nonprophylactic hysterectomy specimens of patients with Lynch Syndrome. *Am J Surg Pathol.* 2016; 40(9): 1177–1191.
- [28] Broaddus RR, Lynch HT, Chen L, Daniels MS, Conrad P, Munsell MF, White, KG, Luthra, R, & Lu, KH. Pathologic features of endometrial carcinoma associated with HNPCC. *Cancer.* 2006; 106(1): 87–94.
- [29] Fadare O, Zheng W, Crispens MA, Jones HWI, Khabele D, Gwin K, Lian ShX, Mohammed Kh, Desouki MM, Parkash V, and Hecht JL. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. *Am J Cancer Res.* 2013 Jan 18; 3(1): 70–95.
- [30] Zannoni GF, Santoro A, Angelico G, Spadola S, Arciuolo D, Valente M, Inzani F, Pettinato A, Vatrano S, Fanfani F, Scambia G, & Fraggetta F. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases. *Hum Pathol.* 2019 Oct; 92: 10–17.
- [31] Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. *Appl Immunohistochem Mol Morphol.* 2012 Dec; 20(6): 580–587.
- [32] Altrabulsi B, Malpica A, Deavers M, Bodurka D, Broaddus R, Silva E. Undifferentiated carcinoma of the endometrium. *Am J Surg Pathol.* 2005 Oct; 29(10): 1316–1321.
- [33] Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. *Pathology.* 2007 Feb; 39(1): 134–138.
- [34] Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. *Mod Pathol.* 2010 Jun; 23(6): 781–789.
- [35] Silva E, Deavers M, Bodurka D, Malpica A. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? *Int J Gynecol Pathol.* 2006 Jan; 25(1): 52–58.
- [36] Huntsman DG, Clement PB, Gilks CB, Scully RE. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. *Am J Surg Pathol.* 1994 Apr; 18(4): 364–375.
- [37] van Hoeven KH, Hudock JA, Woodruff JM, Suhlrand MJ. Small cell neuroendocrine carcinoma of the endometrium. *Int J Gynecol Pathol.* *Int J Gynecol Pathol.* 1995 Jan; 14(1): 21–29.
- [38] Soslow RA. Endometrial carcinomas with ambiguous features. *Semin Diagn Pathol.* 2010 Nov; 27(4): 261–273.
- [39] Lax SF, Kendall B, Tashiro H, Slebos RJC, Ellenson LH. The frequency of p53, k-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. *Cancer.* 2000 88: 814–824.
- [40] Lynch syndrome. Practice Bulletin No. 147. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2014; 124: 1042–1054.
- [41] The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. *Nature.* 2013 May 497: 67–73.
- [42] Moifar F, Kremser M-L, Man YG, Zatloukal K, Tavassoli FA, Denk H. Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues. *Gynecol Oncol.* 2004 (95): 662–671.
- [43] Baker P, Oliva E. Endometrial stromal tumors of the uterus: a practical approach using conventional morphology and ancillary techniques. *J Clin Pathol* 2007; 60: 235–243.
- [44] Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, Cin PD, Fletcher JA, & Sklar J. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. *Proc Natl Acad Sci.* 2001 May 22; 98(11): 6348–6353.
- [45] Hrzencjak A. JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas. *J Mol Diagn.* 2005; 7(3): 388–395.
- [46] Abeler VM, Røyne O, Thoresen S, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. *Histopathology.* 2009 Feb; 54(3): 355–364.
- [47] Lee C-H, Zhu M, Ali RH, Gilks CB, Debiec-Rychter M, Nucci MR. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. *Am J Surg Pathol.* 2012; 36(5): 13.
- [48] Lee C-H, Marino-Enriquez A, Chiang S, Gilks CB, van de Rijn M, Oliva E. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. *Am J Surg Pathol.* 2012; 36(10): 9.
- [49] Kurihara S, Oda Y, Ohishi Y, Iwasa A, Takahira T, Kaneki E, Kobayashi H, Wake N, Tsuneyoshi M. Endometrial stromal sarcomas and related high-grade sarcomas: Immunohistochemical and molecular genetic study of 31 cases. *Am J Surg Pathol.* 2008; 32(8): 11.
- [50] Tahlan A, Nanda A, Mohan H. Uterine adenomyoma: a

- clinicopathologic review of 26 cases and a review of the literature. *Int J Gynecol Pathol*. 2006 Oct; 25(4): 361–365.
- [51] Young RH, Treger T, Scully RE. Atypical polypoid adenomyoma of the uterus: a report of 27 cases. *Am J Clin Pathol*. 1986 Aug 1; 86(2): 139–145.
- [52] Longacre TA, Chung H, Rouse RV, Hendrickson MR. Atypical polypoid adenomyofibromas (atypical polypoid adenomyomas) of the uterus: a clinic-pathologic study of 55 cases. *Am J Surg Pathol*. 1996 Jan; 20(1): 1–20.
- [53] Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. *Hum Pathol* 1990 April; 21(4): 363–381.
- [54] Gallardo A, Prat J. A Clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. *Am J Surg Pathol*. 2009; 33(2): 11.
- [55] Szukala SA, Marks JR, Burchette JL, Elbendary AA, Krigman HR. Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases. *Int J Gynecol Cancer*. 1999 Mar; 9(2): 131–136.
- [56] Biscuola M, Van de Vijver K, Castilla MA, Romero-Pérez L, López-García MA, Díaz-Martín J, Matias-Guiu X, Oliva E, Palacios Calvo J. Oncogene alterations in endometrial carcinosarcomas. *Hum Pathol*. 2013; 44, 852–859.
- [57] Ferguson SE, Tomos C, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. *Am J Surg Pathol*. 2007; 31(11): 9.
- [58] American Joint Committee on Cancer. *AJCC Cancer Staging Manual*. 8th edition. Amin MB, Greene FL, Edge SB, editors. Schweiz: Springer. 2017 p. 661–679.
- [59] Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. *Int J Gynecol Pathol*. 2007 Apr; 26(2): 115–123.
- [60] Van der Putten LJM, Van de Vijver K, Bartosch C, Davidson B, Gatus S, Matias-Guiu X, McCluggage WG, Toledo G, Van der Wurff AAM, Pijnenborg JMA, Massuger LFA, Bulten J. Reproducibility of measurement of myometrial invasion in endometrial carcinoma. *Virchows Arch*. 2017; 470(1): 63–68.
- [61] Quick CM, May T, Horowitz NS, Nucci MR. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. *Int J Gynecol Pathol*. 2012 Jul; 31(4): 337.
- [62] Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. *Int J Gynecol Pathol*. 2003 Oct; 22(4): 324–333.
- [63] Murray SK, Young RH. Priority for description of the MELF pattern of myoinvasive endometrioid carcinoma. *Am J Surg Pathol*. 2017 Aug; 41(8): 1150.
- [64] Krishnamurti U, Movahedi-Lankarani S, Birdsong GG, Chapman CN Jr, Djordjevic B, Klepeis V, Longacre TA, Nucci MR, Otis CN. Protocol for the examination of specimens from patients with carcinoma and carcinosarcoma of the endometrium. *Cancer protocols-College of American Pathologists*. Version: Endometrium 4.1.0.1 Protocol Posting Date: August 2019.
- [65] McCluggage W, Hirschowitz L, Wilson G, Oliva E, Soslow R, Zaino R. Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study. *Am J Surg Pathol*. 2011 Feb; 35(2): 289–294.

第3章

子宫内膜癌的分子病理

Molecular Pathology of Endometrial Carcinomas

- [1] Bokhman J V. “Two pathogenetic types of endometrial carcinoma.” 1983. *Gynecol. Oncol.* 15: 10–7.
- [2] Setiawan V W, Yang H P, Pike M C, McCann SE, Yu H, Xiang Y B, Wolk A, Wentzensen N, Weiss N S, Webb P M, van den Brandt P A, van de Vijver K, Thompson P J; Australian National Endometrial Cancer Study Group, Strom B.L, Spurdle A B, Soslow R A, Shu XO, Schairer C, Sacerdote C, Rohan T E, Robien K, Risch H A, Ricceri F, Rebbeck T R, Rastogi R, Prescott J, Polidoro S, Park Y, Olson S H, Moysich K B, Miller A B, McCullough M L, Matsuno R K, Magliocco A M, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV Jr, Kolonel LN, Henderson B E, Hankinson S E, Håkansson N, Goodman M T, Gaudet M M, Garcia-Closas M, Friedenreich C M, Freudenheim J L, Doherty J, De Vivo I, Courneya K S, Cook L S, Chen C, Cerhan J R, Cai H, Brinton L A, Bernstein L, Anderson K E, Anton-Culver H, Schouten L J, Horn-Ross P L. 2013. Type I and II endometrial cancers: have they different risk factors? *J. Clin. Oncol.* 31: 2607–2618.
- [3] Bae H S, Kim H, Young Kwon S, Kim K R, Song J Y, Kim I. Should endometrial clear cell carcinoma be classified as Type II endometrial carcinoma? *Int. J. Gynecol. Pathol.* 2015; 34: 74–84.
- [4] Soslow R A. Endometrial carcinomas with ambiguous features. *Semin. Diagn. Pathol.* 2010; 27: 261–273.
- [5] Clarke B A, Gilks C B. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. *J. Clin. Pathol.* 2010; 63: 410–415.
- [6] Gilks C B, Oliva E, Soslow R A. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. *Am. J. Surg. Pathol.* 2013; 37: 874–881.
- [7] Fader A N, Santin A D, Gehrig P A. Early stage uterine serous carcinoma: management updates and genomic advances. *Gynecol. Oncol.* 2013; 129: 244–250.
- [8] Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack A D, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz C C, Yau C, Laird P W, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. 2013. Integrated genomic characterization of endometrial carcinoma. *Nature* 497: 67–73. Erratum in 2013: *Nature* 8; 500: 242.
- [9] León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, Kommos S, Brucker SY, Carlson JW, Epstein E, Rau TT, Soslow RA, Ganesan R, Matias-Guiu X, Oliva E, Harrison BT, Church DN, Gilks CB, Bosse T. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endo-metrial carcinomas. *J. Pathol.* 2020 Mar; 250(3): 312–322.
- [10] Hussein Y R, Weigelt B, Levine D A, Schoolmeester J K, Dao LN, Balzer BL, Liles G, Karlan B, Köbel M, Lee CH, Soslow RA. 2015. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. *Mod. Pathol.*; 28: 505–514.
- [11] Meng B, Hoang L N, McIntyre J B, Duggan M A, Nelson G S, Lee C H, Köbel M. 2014. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. *Gynecol. Oncol.*; 134: 15–19.
- [12] Carlson J, McCluggage WG. 2019. Reclassifying endometrial carcinomas with a combined morphological and molecular approach. *Curr. Opin. Oncol.* 31: 411–419.
- [13] Imboden, Sara, Denis Nastic, Mehran Ghaderi, Filippa Rydberg, Tilman T. Rau, Michael D. Mueller, Elisabeth Epstein, and Joseph W. Carlson. Phenotype of POLE-mutated endometrial cancer. *PLoS One.* 2019 Mar 27; 14(3): e0214318. PMID: 30917185 PMCID: PMC6436745.
- [14] Stelloo E, Jansen A M L, Osse E M, Nout R A, Creutzberg C L, Ruano D, Church D N, Morreau H, Smit VTHBM, van Wezel T, Bosse T. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. *Ann. Oncol.* 2017; 28: 96–102.
- [15] Hagen C E, Lefferts J, Hornick J L, Srivastava A. 2011. “Null pattern” of immunoreactivity in a Lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation. *Am. J. Surg. Pathol.* 35: 1902–1905.
- [16] Garg K, Soslow R A. 2014. Endometrial carcinoma in women aged 40 years and younger. *Arch. Pathol. Lab. Med.* 138: 335–342.
- [17] Rekhi B, Menon S, Deodhar K K, Ghosh J, Chopra S, Maheshwari A. 2020. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India. *Ann. Diagn. Pathol.* Aug; 47: 151558. doi: 10.1016/j.anndiagpath. 2020. 151558. Epub 2020 Jun 20.
- [18] Cuevas D, Velasco A, Vaquero M, Santacana M, Gatiús S, Eritja N, Estaran E, Matias-Guiu X. 2020. Intratumor

- heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study. *Histopathology* 76: 447–460.
- [19] Bosse T, Davidson B, Euscher E D, Liu C R, Lortet-Tieulent J, Raspollini M R, Singh N. Endometrioid carcinoma of the uterine corpus. In: World Health Organization (WHO) classification of tumors editorial board, editors. *World Health Organization Classification of Tumors*. 5th edition. *Female genital tumors*. Lyon, France: IARC Press; 2020. 252–255.
- [20] Buza N, English D P, Santin A D, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. *Mod Pathol* 2013; 26: 1605–1612.
- [21] An H J, Logani S, Isacson C, Ellenson L H. 2004. Molecular characterization of uterine clear cell carcinoma. *Mod. Pathol.* 17: 530–537.
- [22] DeLair D F, Burke K A, Selenica P, Lim R S, Scott S N, Middha S, Mohanty A S, Cheng D T, Berger M F, Soslow R A, Weigelt B. 2017. The genetic landscape of endometrial clear cell carcinomas. *J. Pathol.* 243: 230–241.
- [23] Kuhn E, Wu R C, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden R B, Kuo K T, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. *J. Natl. Cancer Inst.* 2012; 104: 1503–1513. doi: 10.1093/jnci/djs345. Epub 2012 Aug 23.
- [24] Zhao S, Choi M, Overton J D, Bellone S, Roque D M, Cocco E, Guzzo F, English D P, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi D A, Ratner E, Azodi M, Schwartz P E, Rutherford T J, Stiegler A L, Mane S, Boggon T J, Schlessinger J, Lifton R P, Santin A D. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. *Proc. Natl. Acad. Sci. U S A.* 2013 Feb 19; 110(8): 2916–2921. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.
- [25] Church D N, Stelloo E, Nout R A, Valtcheva N, Depreuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, Lambrechts D, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Creutzberg CL, Bosse T. 2014. Prognostic significance of POLE proofreading mutations in endometrial cancer. *J. Natl. Cancer Inst.* 107: 402 doi: 10.1093/jnci/dju402.
- [26] Stelloo E, Nout R A, Osse E M, Jürgenliemk-Schulz I J, Jobsen J J, Lutgens L C, van der Steen-Banasik E M, Nijman H W, Putter H, Bosse T, Creutzberg C L, Smit V T. 2016 Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. *Clin. Cancer Res.* 22: 4215–4224.
- [27] Yu S, Shao H, Ban X, Zhang H, You Y, Zhou N, Mao X, Zhao H, Chen J, Lu Z. 2019. Detection of POLE Subtypes in High-Grade Endometrioid Carcinoma by BaseScope-ISH Assay. *Front. Oncol.* Sep 4; 9: 831. doi: 10.3389/fonc.2019.00831.
- [28] Talhouk A, McConechy M K, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon J S, Karnezis A N, Huntsman D G, Gilks C B, McAlpine J N. 2017. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. *Cancer* 123: 802–813.
- [29] León-Castillo A, de Boer S M, Powell M E, Mileskin L R, Mackay H J, Leary A, Nijman H W, Singh N, Pollock P M, Bessette P, Fyles A, Haie-Meder C, Smit VTHBM, Edmondson RJ, Putter H, Kitchener H C, Crosbie E J, de Bruyn M, Nout RA, Horeweg N, Creutzberg C L, Bosse T; TransPORTEC consortium. 2020. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. *J. Clin. Oncol.* 38: 3388–3397.
- [30] Dong D, Lei H, Liu D, Bai H, Yang Y, Tang B, Li K, Liu J, Xu G, Xiao X. 2021. POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy. *Front. Oncol.* Mar 19; 11: 640018. doi: 10.3389/fonc.2021.640018.
- [31] Kim S, Jeong S. Mutation Hotspots in the β -Catenin Gene: Lessons from the Human Cancer Genome Databases. *Mol. Cells* 2019; 42: 8–16.
- [32] Kommos F K, Karnezis A N, Kommos F, Talhouk A, Taran FA, Staebler A, Gilks C B, Huntsman D G, Krämer B, Brucker S Y, McAlpine J N, Kommos S. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. *Br. J. Cancer* 2018; 119: 480–486.

第4章

遗传性子宫内膜癌

Hereditary Endometrial Cancer

- [1] Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell*, 1993; 75(5): 1027–1038.
- [2] Lindblom A, Tannergård P, Werelius B, Nordenskjöld M. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. *Nature Genetics*, 1993; 5(3): 279–282.
- [3] Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergård P, Bollag RJ, Godwin AR, Ward DC, Nordenskjöld M, Fishel R, Kolodner R, Liskay RM. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature*, 1994; 368 (6468): 258–261.
- [4] Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Petersen GM, de la Chapelle A, Vogelstein B, Kinzler KW. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. *Nature*, 1994; 371(6492): 75–80.
- [5] Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. *Nature Genetics*, 1997; 17(3): 271–272.
- [6] Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: Functions and mechanisms. *Chemical Reviews*, 2006; 106(2): 302–323.
- [7] Gradia S, Subramanian D, Wilson T, Acharya S, Makhov A, Griffith J, Fishel R. hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA. *Molecular Cell*, 1999; 3(2): 255–261.
- [8] Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. *Science*, 1993; 260(5109): 816–819.
- [9] Kahn RM, Gordhandas S, Maddy BP, Baltich Nelson B, Askin G, Christos PJ, Caputo TA, Chapman-Davis E, Holcomb K, Frey MK. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? *Cancer*, 2019; 125(18): 3172–3183.
- [10] Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: A newly described association with Lynch syndrome. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 2008; 26(36): 5965–5971.
- [11] Rossi L, Le Frere-Belda MA, Laurent-Puig P, Buecher B, De Pauw A, Stoppa-Lyonnet D, Canlorbe G, Caron O, Borghese B, Colas C, Delhomelle H, Chabbert-Buffet N, Grandjouan S, Lecuru F, Bats A-S. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study. *International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society*, 2017; 27(5): 953–960.
- [12] Hachisuga T, Kaku T, Enjoji M. Carcinoma of the lower uterine segment. Clinicopathologic analysis of 12 cases. *International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists*, 1989; 8(1): 26–35.
- [13] Kim MK, Song SY, Do IG, Kim SH, Choi CH, Kim TJ, Lee JW, Bae DS and Kim BG. Synchronous gynecologic malignancy and preliminary results of Lynch syndrome. *Journal of Gynecologic Oncology*, 2011; 22(4): 233–238.
- [14] Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. *BMJ*, 2007; 335(7630): 1134.
- [15] Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. *Lancet*, 2008; 371(9612): 569–578.
- [16] Dashti SG, Chau R, Ouakrim DA, Buchanan DD, Clendenning M, Young JP, Winship IM, Arnold J, Ahnen DJ, Haile RW, Casey G, Gallinger S, Thibodeau SN, Lindor NM, Le Marchand L, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win Ak. Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome. *JAMA*, 2015; 314(1): 61–71.
- [17] Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JWC, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJW, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K,

- Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. *Lancet*, 2011; 378(9809): 2081–2087.
- [18] Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. *The New England Journal of Medicine*, 1980; 302(10): 551–554.
- [19] Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin, M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. *Cancer Prev Res*, (Phila), 2013; 6(8): 774–781.

第5章

子宫内膜癌前病变

Endometrial Cancer Precursors

- Abu-Rustum N R, Zhou Q, Gomez J D, Alektiar K M, Hensley M L, Soslow R A, Levine D A, Chi DS, Barakat R R, Iasonos A. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. *Gynecol. Oncol.* 2010; 116: 399–403.
- Allison, Kimberly H., Susan D. Reed, Lynda F. Voigt, Carolyn D. Jordan, Kathryn M. Newton, and Rochelle L. Garcia. Diagnosis endometrial hyperplasia: why is it so difficult to agreed. *Am. J. Surg. Pathol.* 2008; 32: 691–698.
- Armstrong, Amy J., William W. Hurd, Sonia Elguero, Nichole M. Barker, and Kristine M. Zanotti. Diagnosis and management of endometrial hyperplasia. *J. Minim. Invasive Gynecol.* 2012; 19: 562–571.
- Avci M E, Sadik S, Uçar M G. A prospective study of rollerball endometrial ablation in the management of refractory recurrent symptomatic endometrial hyperplasia without atypia. *Gynecol. Obstet. Invest.* 2012; 74: 282–287.
- Baak J P, Mutter G L. EIN and WHO94. *J. Clin. Pathol.* 2005b; 58: 1–6.
- Baak, J. P., Mutter, G. L., Robboy, S., van Diest, P. J., Uytterlinde, A. M., Ørbo, A., Palazzo, J., Fiane, B., Løvslett, K., Burger, C., Voorhorst, F., & Verheijen, R. H. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994. World Health Organization classification system. *Cancer* 2005; 103: 2304–2312.
- Bergeron, C., Nogales, F. F., Masseroli, M., Abeler, V., DuVillard, P., Müller-Holzner, E., Pickartz, H., & Wells, M. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. *Am. J. Surg. Pathol.* 1999; 23: 1102–1108.
- Clark T J, Voit D, Gupta J K, Hyde C, Song F, Khan K S. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. *JAMA* 2002; 288: 1610–1621.
- Committee on Gynecologic Practice, Society of Gynecologic Oncology. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. *Obstet. Gynecol.* 2015; 125: 1272–1278.
- Creasman W T, Odicino F, Maisonneuve P, Quinn M A, Beller U, Benedet J L, Heintz APM, Ngan HYS, Pecorelli S. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. *Int. J. Gynaecol. Obstet.* 2006; 95: S105–S143.
- De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni G L, Mangili G, Colombo G, Candiani M. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy. *J. Minim. Invasive Gynecol.* 2015 Nov-Dec; 22(7): 1178–1182.
- Dietel M. The histological diagnosis of endometrial hyperplasia. Is there a need to simplify? *Virchows Arch.* 2001; 439: 604–608.
- Edris F, Vilos G A, Al-Mubarak A, Ettler H C, Hollett-Caines J, Abu-Rafea B. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia. *J. Minim. Invasive Gynecol.* 2007; 14: 68–73.
- Ellenson L H, Ronnett B M, Kurman R J. Precursor lesions of endometrial carcinoma. In: Kurman R J, Ellenson L H, Ronnett B M (eds). *Blaustein's Pathology of the Female Genital Tract*. Boston, MA: Springer, 2011; 359–392.
- El-Sharkawy Mohamed, Akmal El-Mazny, Wafaa Ramadan, Dina Hatem, Aly Abdel-Hafiz, Mohamed Hammam and Adel Nada Three-dimensional ultrasonography and power Doppler for discrimination between benign and malignant endometrium in premenopausal women with abnormal uterine bleeding. *BMC Women's Health* (2016) 16: 18.
- Emons, G., Beckmann, M., Schmidt, D., Mallmann, P., et al. New WHO classification of endometrial hyperplasias. *Obstetric Gynecology.* 2015; 75: 135–136.
- Ferreira A M, Westers H, Albergaria A, Seruca R, Hofstra R M. Estrogens, MSI and Lynch syndrome-associated tumors. *Biochim. Biophys. Acta* 2009; 1796: 194–200.
- Gallos I D, Alazzam M, Clark T J, et al. Management of Endometrial Hyperplasia. *RCOG/BSGE Green-top Guideline No. 67.* 2016; 67: 2–30. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guide-lines/gtg_67_endometrial_hyperplasia.pdf.
- Gallos, I. D., Yap, J., Rajkhowa, M., Luesley, D. M., Coomarasamy, A., & Gupta, J. K. (2012). Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial

- hyperplasia: a systematic review and metaanalysis. *Am. J. Obstet. Gynecol.* 2012; 207: 2660–2662.
- Hannemann M M, Alexander H M, Cope N J, Acheson N. Endometrial hyperplasia: a clinician's review. *Obstet. Gynaecol. Reprod. Med.* 2007; 17: 169–172.
- Hecht, J. L., Ince, T. A., Baak, J. P. A., Baker, H. E., Ogden, M. W., & Mutter, G. L. (2005). Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. *Mod. Pathol.* 2005; 18: 324–330.
- Karlsson, B., Granberg, S., Wikland, M., Ylöstalo, P., Torvid, K., Marsal, K., & Valentin, L. (1995). Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? *Am. J. Obstet. Gynecol.* 2000; 182(3): 509–515.
- Kim M J, Kim J J, Kim S M. Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women. *Obstet. Gynecol. Sci.* 2016 May; 59(3): 192–200.
- Kurman R, Carcangiu M, Herrington C, Young R World Health Organisation Classification of Tumors of Female Reproductive Organs, 4th edn. Lyon France: International Agency for Research on. *Cancer* (IARC) Press, 2014.
- Kurman R J, Kaminski P F, Norris H J. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. *Cancer* 1985; 56: 403–412.
- Lacey J V, Chia V M. Endometrial hyperplasia and the risk of progression to carcinoma. *Maturitas* 2009; 20: 39–44.
- Laurelli G, Falcone F, Gallo M S, Scala F, Losito S, Granata V, Cascella M, Greggi S. Long-Term Oncologic and Reproductive Outcomes in Young Women with Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update. *Int. J. Gynecol. Cancer.* 2016 Nov; 26(9): 1650–1657.
- Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. *Histopathology* 2013; 62: 111–123.
- Mazzon I, Corrado G, Masciullo V, Morricono D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. *Fertil. Steril.* 2010 Mar 1; 93(4): 1286–1289. <https://doi.org/10.1016/j.fertnstert.2008.12.009>.
- Mencaglia L. Hysteroscopy and adenocarcinoma. *Obstet. Gynecol. Clin. North Am.* 1995 Sep; 22(3): 573–579.
- Montgomery B E, Daum G S, Dunton C J. Endometrial hyperplasia: a review. *Obstet. Gynecol. Surv.* 2004; 59: 368–378.
- Mourits, M. J., Bijen, C. B., Arts, H. J., ter Brugge, H. G., van der Sijde, R., Paulsen, L., Wijma, J., Bongers, M. Y., Post, W. J., van der Zee, A. G., & de Bock, G. H. (2010). Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. *Lancet Oncol.* 2010; 11: 763–771.
- Murali R, Soslow R A, Weigelt B. Classification of endometrial carcinoma: more than two types. *Lancet Oncol.* 2014; 15: e268–e278.
- Mutter G L. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. *Gynecol. Oncol.* 2000; 76: 287–290.
- Mutter, G. L., Baak, J. P. A., Crum, C. P., Richart, R. M., Ferenczy, A., & Faquin, W. C. (2000). Endometrial precancer diagnosis by histopathology et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. *J. Pathol.* 2000; 190: 462–469.
- Mutter, G. L., Kauderer, J., Baak, J. P. A., & Alberts, D. (2008). Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. *Hum. Pathol.* 2008; 39: 866–874.
- Ordi, J., Bergeron, C., Hardisson, D., McCluggage, W. G., Hollema, H., Felix, A., Soslow, R. A., Oliva, E., Tavassoli, F. A., Alvarado-Cabrero, I., Wells, M., & Nogales, F. F. (2014). Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. *Histopathology* 2014; 64: 284–292.
- Panici, P. B., Basile, S., Maneschi, F., Lissoni, A. A., Signorelli, M., Scambia, G., Angioli, R., Tateo, S., Mangili, G., Katsaros, D., Garozzo, G., Campagnutta, E., Donadello, N., Greggi, S., Melpignano, M., Raspagliesi, F., Ragni, N., Cormio, G., Grassi, R., ... Mangioni, C. Systematic pelvic lymph adenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. *J. Natl. Cancer Inst.* 2008; 100: 1707–1716.
- Randall T C, Kurman R J Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. *Obstet. Gynecol.* 1997 Sep; 90(3): 434–440.
- Reed SD, Newton KM, Clinton WL, Epplen M, Garcia R, Allison K, Voigt LF, Weiss NS. Incidence of endometrial hyperplasia. *Am J Obstet Gynecol.* 2009; 200: 678.
- Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007). Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ* 2007; 335: 1134–1139.
- Ricci, E., Moroni, S., Parazzini, F., Surace, M., Benzi, G., Salerio, B., Polverino, G., & La Vecchia, C. (2002). Risk factors for endometrial hyperplasia: results from a case-control study. *Int. J. Gynecol. Cancer.* 2002; 12: 257–260.
- Salman, M. C., Usubutun, A., Boynukalin, K., & Yuce, K. (2010). Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of coexistent malignancy in endometrial hyperplasia. *J. Gynecol. Oncol.* 2010; 21: 97–101.
- Silverberg S G. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. *Mod. Pathol.* 2000; 13: 309–327.
- Sivridis E, Giatromanolaki A. The endometrial hyperplasias revisited. *Virchows Arch.* 2008; 453: 223–231.
- Tavassoli F, Devilee P (eds.). World Health Organization Classification of Tumours. Pathology and Genetics. *Tumours of the Breast and Female Genital Organs.* IARC Press, Lyon 2003; 217–228.
- Uno L H, Sugimoto O, Carvalho F M, Bagnoli V R, Fonseca A M, Pinotti J A, Morphologic hysteroscopic criteria suggestive of endometrial hyperplasia. *Int. J. Gynecol.*

Obstet. 1995; 49: 35–40.

Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N, Hiura M, Sakamoto A, Tsuda H, Fukunaga M, Kamura T. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J. Clin. Oncol.* 2007 Jul 1; 25(19): 2798–2803.

Wang S, Pudney J, Song J, Mor G, Schwartz P E, Zheng

W. Mechanism involved in the evolution of progestin resistance in human endometrial hyperplasia-precursor of endometrial cancer. *Gynecol. Oncol.* 2003 Feb; 88(2): 108–117.

Zaino R, Carinelli S G, Ellenson L H. Tumours of the uterine Corpus: epithelial Tumours and Precursors. *WHO Press, Lyon* 2014; 125–126.

Zaino R J. Endometrial hyperplasia: is it time for a quantum leap to a new classification? *Int. J. Gynecol. Pathol.* 2000; 19: 314–321.

第6章

子宫内膜癌生物标志物

Endometrial Cancer Biomarkers

- [1] Rojas J, Chávez-Castillo M, Olivar LC, Calvo M, Mejías J, Rojas M, Morillo J, Bermúdez V. Physiologic course of female reproductive function: A molecular look into the prologue of life. *Journal of Pregnancy*. 2015; 2015: 715735.
- [2] Dhillon WS, Chaudhri OB, Thompson EL, Murphy KG, Patterson M, Ramachandran R, Nijher GK, Amber V, Kokkinos A, Donaldson M, Ghatei MA, Bloom SR. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. *J Clin Endocrinol Metab*. 2007; 92(10): 3958–3966.
- [3] Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaldas G, Koch C, Kopp O, Korbonits M, Kovacs CS, Kuohung W, Lafferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trencé DL, Wilson DP, editors. *Endotext [internet]*. South Dartmouth (MA), USA: <https://www.MDtext.com>, Inc.; 2018.
- [4] Young SL. Oestrogen and progesterone action on endometrium: A translational approach to understanding endometrial receptivity. *Reprod Biomed Online*. 2013; 27(5): 497–505.
- [5] Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: The key role of ovarian function. *Menopause*. 2008; 15(4): 603–612.
- [6] Cancer Research UK. *Uterine Cancer Incidence Statistics*. Available at <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer/incidence>. 2014; Accessed July 2022.
- [7] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019; 69(1): 7–34.
- [8] Horn LC, Meinel A, Handzel R, Eibenkel J. Histopathology of endometrial hyperplasia and endometrial carcinoma. An update. *Ann Diagn Pathol*. 2007; 11(4): 297–311.
- [9] Denschlag D, Ulrich U, Emons G. The diagnosis and treatment of endometrial cancer: progress and controversies. *Dtsch Arztebl Int*. 2010; 108(34–35): 571–577.
- [10] Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA. High-grade endometrial carcinomas: Morphologic and immunohistochemical features, diagnostic challenges and recommendations. *Int J Gynecol Pathol*. 2019; 38 Suppl 1(1): S40–S3.
- [11] Buhtoiarova TN, Brenner CA, Singh M. Role of current and emerging biomarkers in resolving persistent clinical dilemmas. *Am J Clin Pathol*. 2016; 145(1): 8–21.
- [12] Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. *Virchows Arch*. 2004; 444(3): 213–223.
- [13] Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. *Cancer*. 2000; 88(4): 814–824.
- [14] Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. *Int J Clin Exp Pathol*. 2009; 2(5): 411–432.
- [15] Okuda T, Sekizawa A, Purwosunu Y, Nagatsuka M, Morioka M, Hayashi M, Okai T. Genetics of endometrial cancers. *Obstet Gynecol Int*. 2010; 2010: 984013.
- [16] Lopez-Reig R, Fernandez-Serra A, Romero I, Zorrero C, Illueca C, Garcia-Casado Z, Poveda A, Lopez-Guerrero JA. Prognostic classification of endometrial cancer using a molecular approach based on a twelve-gene NGS panel. *Sci Rep*. 2019; 9(1): 18093.
- [17] Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. *Nature*. 2013; 497(7447): 67–73.
- [18] Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. *Lancet*. 2016; 387(10023): 1094–108.
- [19] Ritterhouse LL, Howitt BE. Molecular pathology: Predictive, prognostic, and diagnostic markers in uterine tumors. *Surg Pathol Clin*. 2016; 9(3): 405–426.
- [20] Urlick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. *Nat Rev Cancer*. 2019; 19(9): 510–521.

- [21] Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol.* 1983; 15(1): 10–7.
- [22] Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. *Curr Opin Oncol.* 2012; 24(5): 554–563.
- [23] Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. *Lancet Oncol.* 2012; 13(8): e353–361.
- [24] Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. *Histopathology.* 2013; 62(1): 111–123.
- [25] Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. *Nat Rev Clin Oncol.* 2011; 8(5): 261–271.
- [26] Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. *Proc Natl Acad Sci USA.* 2013; 110(8): 2916–2921.
- [27] Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. *Cancer Res.* 2011; 71(12): 4061–4067.
- [28] McConechy MK, Ding J, Cheang MC, Wiegand K, Senz J, Tone A, Yang W, Prentice L, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Use of mutation profiles to refine the classification of endometrial carcinomas. *J Pathol.* 2012; 228(1): 20–30.
- [29] Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC, Program NIHISCCS, Hieter P, Mullikin JC, Merino MJ, Bell DW. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. *Nat Genet.* 2012; 44(12): 1310–1315.
- [30] Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih Ie M. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. *J Natl Cancer Inst.* 2012; 104(19): 1503–1513.
- [31] Oberndorfer F, Moling S, Hagelkruys LA, Grimm C, Polterauer S, Sturdza A, Aust S, Reinthaller A, Mullauer L, Schwameis R. Risk reclassification of patients with endometrial cancer based on tumor molecular profiling: First real world data. *J Pers Med.* 2021; 11(1).
- [32] Sugiyama Y, Gotoh O, Fukui N, Tanaka N, Hasumi K, Takazawa Y, Noda T, Mori S. Two distinct tumorigenic processes in endometrial endometrioid adenocarcinoma. *Am J Pathol.* 2020; 190(1): 234–251.
- [33] Definitions BWG, Atkinson AJ, Jr., Colburn W, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates J, Peck CC, Schooley RT, Spilker B, Woodcock J, Zeger SL. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther.* 2001; 69(3): 89–95.
- [34] Ma X, Ma CX, Wang J. Endometrial carcinogenesis and molecular signaling pathways. *Am J Mol Biol.* 2014; 4(3): 134–149.
- [35] Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. *PLoS One.* 2014; 9(4): e94167.
- [36] Banno K, Yanokura M, Iida M, Masuda K, Aoki D. Carcinogenic mechanisms of endometrial cancer: Involvement of genetics and epigenetics. *J Obstet Gynaecol Res.* 2014; 40(8): 1957–1967.
- [37] Ring KL, Yates MS, Schmandt R, Onstad M, Zhang Q, Celestino J, Kwan SY, Lu KH. Endometrial cancers with activating kras mutations have activated estrogen signaling and paradoxical response to MEK inhibition. *Int J Gynecol Cancer.* 2017; 27(5): 854–862.
- [38] Berg A, Hoivik EA, Mjøs S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Øyan AM, Kalland K-H, Cherniack AD, Beroukhi R, Stefansson I, Mills GB, Krakstad C, Salvesen HB. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. *Oncotarget.* 2015; 6(2): 1327–1339.
- [39] van der Putten LJM, van Hoof R, Tops BBJ, Snijders MPLM, van den Berg-van Erp SH, van der Wurff AAM, Bulten J, Pijnenborg JMA, Massuger LFAG. Molecular profiles of benign and (pre)malignant endometrial lesions. *Carcinogenesis.* 2017; 38: 329–335.
- [40] Boyd J, Berchuck A, Terashima Y, Boyd J. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. *Cancer Res.* 1993; 53(8): 1906–1910.
- [41] Tsuda H, Jiko K, Yajima M, Yamada T, Tanemura K, Tsunematsu R, Ohmi K, Sonoda T, Hirohashi S. Frequent occurrence of c-Ki-ras gene mutations in well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. *Int J Gynecol Pathol.* 1995; 14(3): 255–259.
- [42] Xiong J, He M, Hansen K, Jackson CL, Breese V, Quddus MR, Sung CJ, Lomme MM, Lawrence WD. The clinical significance of K-ras mutation in endometrial “surface epithelial changes” and their associated endometrial adenocarcinoma. *Gynecol Oncol.* 2016; 142(1): 163–168.
- [43] Fujimoto I, Shimizu Y, Hirai Y, Chen JT, Teshima H, Hasumi K, Masubuchi K, Takahashi M. Studies on ras oncogene activation in endometrial carcinoma. *Gynecol Oncol.* 1993; 48(2): 196–202.
- [44] Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. *Cancer Res.* 1992; 52(10): 2777–2781.

- [45] Yeramian A, Moreno-Bueno G, Dolcet X, Catusas L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X. Endometrial carcinoma: molecular alterations involved in tumor development and progression. *Oncogene*. 2013; 32(4): 403–413.
- [46] Ninomiya Y, Kato K, Takahashi A, Ueoka Y, Kamikihara T, Arima T, Matsuda T, Kato H, Nishida J, Wake N. K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. *Cancer Res*. 2004; 64(8): 2759–2765.
- [47] Tu Z, Gui L, Wang J, Li X, Sun P, Wei L. Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor. *Gynecol Oncol*. 2006; 101(2): 274–279.
- [48] Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N, Aoki D. Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review). *Oncol Rep*. 2009; 22(5): 967–972.
- [49] Alomari A, Abi-Raad R, Buza N, Hui P. Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium. *Mod Pathol*. 2014; 27(5): 675–680.
- [50] Sideris M, Emin EI, Abdullah Z, Hanrahan J, Stéfátou KM, Sevas V, Emin E, Hollingworth T, Odejinmi F, Papagrigoriadis S, Vimplis S, Willmott F. The role of KRAS in endometrial cancer: A mini-review. *Anticancer Res*. 2019; 39(2): 533–539.
- [51] Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. *Nat Rev Cancer*. 2015; 15(1): 7–24.
- [52] Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. *Proc Natl Acad Sci USA*. 2008; 105(7): 2652–2657.
- [53] Ma CX, Ellis MJ. The Cancer Genome Atlas: Clinical applications for breast cancer. *Oncology* 2013; 27(12): 1263–1269, 74–79.
- [54] Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: A promising therapeutic target with diagnostic challenges. *Arch Pathol Lab Med*. 2014; 138(3): 343–350.
- [55] van Winkel E, de Leng WWJ, Witteveen PO, Jonges T, Willems SM, Langenberg MHG. Next-generation sequencing in gynaecological tumours: The prognostic and predictive value of the most common mutations found in ovarian, endometrial, and cervical tumours: Literature and the University Medical Centre Utrecht next-generation sequencing data. *Pathobiology* 2017; 84 (339–350).
- [56] Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. *Cancer Res*. 2005; 65(23): 10669–10673.
- [57] Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusunmano K, Mauland KK, Oyan AM, Kalland KH, Lewis AE, Mills GB, Krakstad C, Trovik J, Salvesen HB, Hoivik EA. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. *Sci Rep*. 2017; 7(1): 10240.
- [58] Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheeler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. *Mol Cancer Ther*. 2011; 10(3): 558–565.
- [59] Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bo TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhi R. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. *Proc Natl Acad Sci USA*. 2009; 106(12): 4834–4839.
- [60] Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: Biology driving targeted therapeutics. *Cell Mol Life Sci*. 2008; 65(10): 1566–1584.
- [61] Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol*. 2001; 2(2): 127–137.
- [62] Moasser MM. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene*. 2007; 26(45): 6469–6487.
- [63] Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. *EMBO J*. 2000; 19: 3159–3167.
- [64] Berchuck A, Whitaker R, Olt G, Soper JT, Clarke-Pearson DL, Kamel A, Bast RC, Kerns B, Kinney R, Dodge R, Marks P, McKenzie S, Yin S. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. *Cancer Res*. 1990; 50(13): 4087–4091.
- [65] Hu Y, Bandla S, Godfrey TE, Tan D, Luketich JD, Pennathur A, Qiu X, Hicks DG, Peters JH, Zhou Z. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. *Mod Pathol*. 2011; 24(7): 899–907.
- [66] Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: Clinicopathologic analysis with proposed approach to HER2 assessment. *Appl Immunohistochem Mol Morphol*. 2012; 20(1): 13–24.
- [67] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987; 235(4785): 177–182.
- [68] Díaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. *Gynecol Oncol*. 2006; 100(1): 139–144.
- [69] Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. *J Clin Oncol*. 2004; 22(15): 3126–3132.
- [70] Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM. HER-2 is an independent prognostic factor in endometrial cancer:

- association with outcome in a large cohort of surgically staged patients. *J Clin Oncol*. 2006; 24(15): 2376–2385.
- [71] El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. *Expert Rev Anticancer Ther*. 2012; 12(1): 41–49.
- [72] Hashmi AA, Hussain ZF, Aijaz S, Irfan M, Khan EY, Naz S, Faridi N, Khan A, Edhi MM. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in South Asian head and neck squamous cell carcinoma: Association with various risk factors and clinicopathologic and prognostic parameters. *World J Surg Oncol*. 2018; 16(1): 118.
- [73] Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. *Clin Cancer Res*. 2002; 8(5): 1271–1279.
- [74] Capriglione S, Plotti F, Miranda A, Ricciardi R, Scaletta G, Aloisi A, Guzzo F, Montera R, Angioli R. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. *Tumour Biol*. 2015; 36(6): 4151–4156.
- [75] Dewan R, Dewan A, Hare S, Bhardwaj M, Mehrotra K. Diagnostic performance of serum human epididymis protein 4 in endometrial carcinoma: A pilot study. *J Clin Diagn Res*. 2017; 11(7): XC01–XC5.
- [76] Angioli R, Capriglione S, Scaletta G, Aloisi A, Miranda A, De Cicco Nardone C, Terranova C, Plotti F. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. *Tumour Biol*. 2016; 37(4): 4973–4978.
- [77] Battaglia F, Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Epidermal growth factor receptor expression in gynecological malignancies. *Gynecol Obstet Invest*. 1989; 27(1): 42–44.
- [78] Miyazawa K. Role of epidermal growth factor in obstetrics and gynecology. *Obstet Gynecol*. 1992; 79(6): 1032–1040.
- [79] Arfaoui AT, Mejri S, Belhaj R, Karkni W, Chebil M, Rammeh S. Prognostic value of immunohistochemical expression profile of epidermal growth factor receptor in urothelial bladder cancer. *J Immunoassay Immunochem*. 2016; 37(4): 359–367.
- [80] De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N. The role of the EGFR signaling in tumor microenvironment. *J Cell Physiol*. 2008; 214(3): 559–567.
- [81] Hashmi AA, Hussain ZF, Irfan M, Naeem M, Hashmi SK, Asif H, Baloch S, Faridi N. Epidermal growth factor receptor (EGFR) overexpression in endometrial carcinoma: association with histopathologic parameters. *Surg Exp Pathol*. 2019; 2: 8.
- [82] Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz KC, Press MF. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. *Br J Cancer*. 2009; 100(1): 89–95.
- [83] Matsumoto-Yoshitomi S, Habashita J, Nomura C, Kuroshima K, Kurokawa T. Autocrine transformation by fibroblast growth factor 9 (FGF-9) and its possible participation in human oncogenesis. *Int J Cancer*. 1997; 71(3): 442–450.
- [84] Klagsbrun M. Angiogenic factors: regulators of blood supply-side biology. FGF, endothelial cell growth factors and angiogenesis: a keystone symposium, Keystone, CO, USA, April 1–7, 1991. *New Biol*. 1991; 3(8): 745–749.
- [85] Giatromanolaki A, Sivridis E, Koukourakis MI. Tumour angiogenesis: vascular growth and survival. *APMIS*. 2004; 112(7–8): 431–440.
- [86] Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. *Cancer Res*. 2008; 68(17): 6902–6907.
- [87] Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. *Future Oncol*. 2009; 5(1): 27–32.
- [88] Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struwing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*. 2007; 447(7148): 1087–1093.
- [89] Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet*. 2007; 39(7): 870–874.
- [90] McGrath M, Lee IM, Buring J, Hunter DJ, De Vivo I. Novel breast cancer risk alleles and endometrial cancer risk. *Int J Cancer*. 2008; 123(12): 2961–2964.
- [91] Soufla G, Sifakis S, Spandidos DA. FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium. *Cancer Lett*. 2008; 259(2): 146–155.
- [92] Gatus S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J, Dolcet X, Prat J, Matias-Guiu X. FGFR2 alterations in endometrial carcinoma. *Mod Pathol*. 2011; 24: 1500–1510.
- [93] Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M, Bergsagel PL. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4; 14) myeloma. *Blood*. 2004; 103(9): 3521–3528.
- [94] Bernard-Pierrot I, Brams A, Dunois-Lardé C, Caillaud A, Diez de Medina SG, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D, Radvanyi F. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. *Carcinogenesis*. 2006; 27(4): 740–747.
- [95] Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. *Gynecol Oncol*. 2014; 135(1): 38–43.

- [96] Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/ Gynecologic Oncology Group Study. *Gynecol Oncol*. 2014; 135(3): 441–445.
- [97] Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study. *Lancet Oncol*. 2015; 16(6): 686–694.
- [98] Vergote I, Teneriello M, Powell MA, Miller DS, Garcia AA, Mikheeva ON, Pinter T, Bidzinski M, Cebotaru CL, Fan J, Ren M, Meneses N, Funahashi Y, Kadowaki T, O'Brien JP, Penson RT. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes. *J Clin Oncol*. 2013; 31(15_suppl): 5520.
- [99] Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. *Cancer Chemother Pharmacol*. 2013; 71(5): 1315–1323.
- [100] Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H. Drug-sensitive FGFR2 mutations in endometrial carcinoma. *Proc Natl Acad Sci USA*. 2008; 105(25): 8713–8717.
- [101] Yin Y, Shen WH. PTEN: a new guardian of the genome. *Oncogene*. 2008; 27(41): 5443–5453.
- [102] Abd El-Maqsood NMR, El Gelany S. Differential expression patterns of PTEN in cyclic, hyperplastic and malignant endometrium: Its relation with ER, PR and clinicopathological parameters. *J Egypt Natl Cancer Inst*. 2009; 21(4): 323–331.
- [103] Boruban MC, Altundag K, Kilic GS, Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. *Eur J Cancer Prev*. 2008; 17(2): 133–138.
- [104] Robbe EJ, van Kuijk SM, de Boed EM, Smits LJ, van der Wurff AA, Kruitwagen RF, Pijnenborg JM. Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. *Int J Gynecol Cancer*. 2012; 22(7): 1264–1272.
- [105] Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. *J Cell Physiol*. 2006; 209(1): 13–20.
- [106] Vogelstein B, Kinzler KW. p53 function and dysfunction. *Cell*. 1992; 70(4): 523–526.
- [107] Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao S, Ukita M, Matsuura S. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. *Cancer*. 1995; 76(1): 72–78.
- [108] Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. *Obstet Gynecol*. 1995; 85(5 Pt 1): 729–734.
- [109] Risinger JI, Dent GA, Ignar-Trowbridge D, McLachlan JA, Tsao MS, Senterman M, Boyd J. p53 gene mutations in human endometrial carcinoma. *Mol Carcinog*. 1992; 5(4): 250–253.
- [110] Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. *Br J Cancer*. 1996; 74(4): 562–567.
- [111] Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. *Gynecol Oncol*. 2010; 116(3): 533–538.
- [112] Saffari B, Bernstein L, Hong DC, Sullivan-Halley J, Runnebaum IB, Grill HJ, Jones LA, El-Naggar A, Press MF. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. *Int J Gynecol Cancer*. 2005; 15(5): 952–963.
- [113] Steinbakk A, Skaland I, Gudlaugsson E, Janssen EA, Kjellevoid KH, Klos J, Lovslett K, Fiane B, Baak JP. The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. *Am J Obstet Gynecol*. 2009; 200(1): 78 e1–8.
- [114] D'Andrilli G, Bovicelli A, Paggi MG, Giordano A. New insights in endometrial carcinogenesis. *J Cell Physiol*. 2012; 227(7): 2842–2846.
- [115] Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. *Gynecol Oncol*. 2014; 133(2): 353–361.
- [116] Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell*. 1993; 75(4): 805–816.
- [117] Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. *Nat Rev Cancer*. 2006; 6(6): 459–471.
- [118] Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H, Hoeflich KP. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. *Proc Natl Acad Sci USA*. 2011; 108(17): 7177–7182.
- [119] Vadlamudi RK, Kumar R. P21-activated kinases in human cancer. *Cancer Metastasis Rev*. 2003; 22(4): 385–393.
- [120] Lukas J, Groshen S, Saffari B, Niu N, Reles A, Wen

- WH, Felix J, Jones LA, Hall FL, Press MF. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. *Am J Pathol.* 1997; 150(1): 167–175.
- [121] Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. *EMBO J.* 2002; 21(20): 5437–5447.
- [122] Lu W, Qu JJ, Li BL, Lu C, Yan Q, Wu XM, Chen XY, Wan XP. Overexpression of p21-activated kinase 1 promotes endometrial cancer progression. *Oncol Rep.* 2013; 29(4): 1547–1555.
- [123] Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R, Jones JG. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. *Int J Gynecol Pathol.* 2002; 21(2): 147–154.
- [124] Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. *Proc Natl Acad Sci USA.* 1999; 96(22): 12754–12759.
- [125] Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, Kurachi H, Sasaki M, Wakasa K, Inoue M, Buzard G, Murata Y. Alteration of p16 and p15 genes in human uterine tumours. *Br J Cancer.* 1999; 80(3–4): 458–467.
- [126] Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. *Clin Cancer Res.* 2000; 6(1): 153–159.
- [127] Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. *Chem Rev.* 2006; 106(2): 302–323.
- [128] Larrea AA, Lujan SA, Kunkel TA. SnapShot: DNA mismatch repair. *Cell.* 2010; 141(4): 730 e1.
- [129] Jascur T, Boland CR. Structure and function of the components of the human DNA mismatch repair system. *Int J Cancer.* 2006; 119(9): 2030–2035.
- [130] Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. *Curr Opin Genet Dev.* 1999; 9(1): 89–96.
- [131] Li YC, Korol AB, Fahima T, Nevo E. Microsatellites within genes: Structure, function, and evolution. *Mol Biol Evol.* 2004; 21(6): 991–1007.
- [132] Peltomäki P. DNA mismatch repair and cancer. *Mutat Res Rev Mutat Res.* 2001; 488(1): 77–85.
- [133] Ahadova A, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, Stenzinger A, Burn J, von Knebel Doeberitz M, Blaker H, Kloor M. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. *Int J Cancer.* 2018; 143(1): 139–150.
- [134] Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med.* 2005; 352(18): 1851–1860.
- [135] Ollikainen M, Abdel-Rahman WM, Moisis AL, Lindroos A, Kariola R, Järvelä I, Pöyhönen M, Butzow R, Peltomäki P. Molecular analysis of familial endometrial carcinoma: A manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? *J Clin Oncol.* 2005; 23(21): 4609–4616.
- [136] Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. *Gynecol Oncol.* 2009; 114(1): 128–134.
- [137] Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. *J Clin Oncol.* 2014; 32(2): 90–100.
- [138] Cust AE, Slimani N, Kaaks R, Van Bakel M, Biessy C, Ferrari P, Laville M, Tjønneland A, Olsen A, Overvad K, Lajous M, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Rohrmann S, Nöthlings U, Boeing H, Palli D, Sieri S, Panico S, Tumino R, Sacerdote C, Skeie G, Engeset D, Gram IT, Quirós JR, Jakyszyn P, Sánchez MJ, Larrañaga N, Navarro C, Ardanaz E, Wirfält E, Berglund G, Lundin E, Hallmans G, Bueno-De-Mesquita HB, Du H, Peeters PHM, Bingham S, Khaw KT, Allen NE, Key TJ, Jenab M, Riboli E. Dietary carbohydrates, glycemic index, glycemic load, and endometrial cancer risk within the European prospective investigation into cancer and nutrition cohort. *Am J Epidemiol.* 2007; 166(8): 912–923.
- [139] Garg K, Leitao MM, Jr., Kauff ND, Hansen J, Kosarin K, Shia J, Soslow RA. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. *Am J Surg Pathol.* 2009; 33(6): 925–933.
- [140] Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. *J Clin Oncol.* 2007; 25(33): 5158–5164.
- [141] Kauff ND. How should women with early-onset endometrial cancer be evaluated for Lynch syndrome? *J Clin Oncol.* 2007; 25(33): 5143–5146.
- [142] Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). *Int J Cancer.* 1996; 69(1): 38–43.
- [143] Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ. Clinical significance of microsatellite instability in endometrial carcinoma. *Cancer.* 2000; 89(8): 1758–1764.
- [144] Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, Eisenhauer EA, Oza AM. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies

- of the NCIC Clinical Trials Group (NCIC CTG). *Eur J Cancer*. 2010; 46(8): 1365–1373.
- [145] Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. *Oncogene*. 1998; 17(18): 2413–2417.
- [146] Catusus L, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. *Hum Pathol*. 1998; 29(10): 1160–1164.
- [147] Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med*. 2000; 342(2): 69–77.
- [148] Gadducci A, Cosio S, Genazzani AR. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. *Crit Rev Oncol Hematol*. 2011; 80(2): 181–192.
- [149] Arvanitis DA, Angelakis E, Koumantakis EE, Spandidos DA. Allelic imbalance in hMLH1 or BRCA2 loci associated with response of cervical and endometrial cancer to radiotherapy. *Int J Mol Med*. 2002; 10(1): 55–63.
- [150] Horree N, van Diest PJ, Sie-Go DM, Heintz AP. The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. *Hum Pathol*. 2007; 38(8): 1232–1238.
- [151] Sakuragi N, Salah-eldin AE, Watari H, Itoh T, Inoue S, Moriuchi T, Fujimoto S. Bax, Bcl-2, and p53 expression in endometrial cancer. *Gynecol Oncol*. 2002; 86(3): 288–296.
- [152] Al Kushi A, Lim P, Aquino-Parsons C, Gilks CB. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. *Mod Pathol*. 2002; 15(4): 365–371.
- [153] Yang D, Liu X, Zhang R, Cheng K, Mu J, Fang L, Xie P. Increased apoptosis and different regulation of pro-apoptosis protein bax and anti-apoptosis protein bcl-2 in the olfactory bulb of a rat model of depression. *Neurosci Lett*. 2011; 504(1): 18–22.
- [154] Ohkouchi T, Sakuragi N, Watari H, Nomura E, Todo Y, Yamada H, Fujimoto S. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. *Am J Obstet Gynecol*. 2002; 187(2): 353–359.
- [155] Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med*. 2003; 9(6): 669–676.
- [156] Sanseverino F, Santopietro R, Torricelli M, D'Andrilli G, Russo G, Cevenini G, Bovicelli A, Leoncini L, Scambia G, Petraglia F, Claudio PP, Giordano A. pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. *Cancer Biol Ther*. 2006; 5(1): 84–88.
- [157] Chen CA, Cheng WF, Lee CN, Wei LH, Chu JS, Hsieh FJ, Hsieh CY. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. *Gynecol Oncol*. 2001; 80(2): 207–212.
- [158] Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. *Gynecol Oncol*. 2001; 80(2): 181–188.
- [159] Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. *Tumour Biol*. 2005; 26(2): 81–87.
- [160] Backes FJ, Walker CJ, Goodfellow PJ, Hade EM, Agarwal G, Mutch D, Cohn DE, Suarez AA. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. *Gynecol Oncol*. 2016; 141(2): 312–317.
- [161] Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, Chaturvedi AK, Hildesheim A, Berndt SI, Safaean M, Pinto L, Wentzensen N. Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. *Int J Cancer*. 2017; 140(3): 600–610.
- [162] Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. *Cancer*. 1993; 71(4 Suppl): 1467–1470.
- [163] Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. *Am J Obstet Gynecol*. 2008; 199(5): 543 e1–7.
- [164] Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. *Cancer Res*. 2002; 62(3): 881–886.
- [165] Ito K, Utsunomiya H, Yaegashi N, Sasano H. Biological roles of estrogen and progesterone in human endometrial carcinoma—new developments in potential endocrine therapy for endometrial cancer. *Endocr J*. 2007; 54(5): 667–679.
- [166] McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. *Science*. 2002; 296(5573): 1642–1644.
- [167] Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. *Nat Rev Cancer*. 2006; 6(5): 360–368.
- [168] Ayakannu T, Taylor AH, Marczylo TH, Maccarrone M, Konje JC. Identification of novel predictive biomarkers for endometrial malignancies: N-acylethanolamines. *Front Oncol*. 2019; 9: 430.
- [169] Mitsuhashi Y, Horiuchi A, Miyamoto T, Kashima H, Suzuki A, Shiozawa T. Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells. *Histopathology*. 2012; 60(5): 826–837.
- [170] Borggrefe T, Lauth M, Zwijsen A, Huylebroeck D, Oswald F, Giaimo BD. The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFbeta/BMP and hypoxia pathways. *Biochim Biophys Acta*. 2016;

- 1863(2): 303–313.
- [171] Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. *Biochim Biophys Acta*. 2011; 1815(2): 197–213.
- [172] Daley-Brown D, Oprea-Illies GM, Lee R, Pattillo R, Gonzalez-Perez RR. Molecular cues on obesity signals, tumor markers and endometrial cancer. *Horm Mol Biol Clin Investig*. 2015; 21(1): 89–106.
- [173] Lipsey CC, Harbuzariu A, Daley-Brown D, Gonzalez-Perez RR. Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer. *World J Methodol*. 2016; 6(1): 43–55.
- [174] Gonzalez RR, Leary K, Petrozza JC, Leavis PC. Leptin regulation of the interleukin-1 system in human endometrial cells. *Mol Hum Reprod*. 2003; 9(3): 151–158.
- [175] Monnat RJ, Jr., Chiaverotti TA, Hackmann AF, Maresh GA. Molecular structure and genetic stability of human hypoxanthine phosphoribosyltransferase (HPRT) gene duplications. *Genomics*. 1992; 13(3): 788–796.
- [176] Torres RJ, Puig JG. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. *Orphanet J Rare Dis*. 2007; 2: 48.
- [177] Townsend MH, Anderson MD, Weigel EG, Velazquez EJ, Weber KS, Robison RA, O'Neill KL. Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane. *Onco Targets Ther*. 2017; 10: 1921–1932.
- [178] Townsend MH, Felsted AM, Ence ZE, Piccolo SR, Robison RA, O'Neill KL. Elevated expression of hypoxanthine guanine phosphoribosyltransferase within malignant tissue. *Cancer Clin Oncol*. 2017; 6(2): 19.
- [179] Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. *Oncogene*. 2006; 25(35): 4831–4839.
- [180] Baba Y, Noshio K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. *Neoplasia*. 2009; 11(5): 418–425.
- [181] Goos JA, Coupe VM, Diosdado B, Delis-Van Diemen PM, Karga C, Belien JA, Carvalho B, van den Tol MP, Verheul HM, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ, DeCoDe PETg. Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. *Br J Cancer*. 2013; 109(9): 2445–2452.
- [182] Popanda O, Fox G, Thielmann HW. Modulation of DNA polymerases alpha, delta and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. *Biochim Biophys Acta*. 1998; 1397(1): 102–117.
- [183] Vishwanatha JK, Jindal HK, Davis RG. The role of primer recognition proteins in DNA replication: association with nuclear matrix in HeLa cells. *J Cell Sci*. 1992; 101 (Pt 1): 25–34.
- [184] Kabbage M, Chahed K, Hamrita B, Guillier CL, Trimeche M, Remadi S, Hoebeke J, Chouchane L. Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. *J Biomed Biotechnol*. 2008; 2008: 564127.
- [185] Lay AJ, Jiang XM, Kisker O, Flynn E, Underwood A, Condron R, Hogg PJ. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. *Nature*. 2000; 408(6814): 869–873.
- [186] Zieker D, Konigsrainer I, Tritschler I, Loffler M, Beckert S, Traub F, Nieselt K, Buhler S, Weller M, Gaedcke J, Taichman RS, Northoff H, Brucher BL, Konigsrainer A. Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. *Int J Cancer*. 2010; 126(6): 1513–1520.
- [187] Zieker D, Konigsrainer I, Weinreich J, Beckert S, Glatzle J, Nieselt K, Buhler S, Loffler M, Gaedcke J, Northoff H, Mannheim JG, Wiehr S, Pichler BJ, von Weyhern C, Brucher BL, Konigsrainer A. Phosphoglycerate kinase 1 promoting tumor progression and metastasis in gastric cancer—detected in a tumor mouse model using positron emission tomography/magnetic resonance imaging. *Cell Physiol Biochem*. 2010; 26(2): 147–154.
- [188] Townsend MH, Ence ZE, Felsted AM, Parker AC, Piccolo SR, Robison RA, O'Neill KL. Potential new biomarkers for endometrial cancer. *Cancer Cell Int*. 2019; 19: 19.
- [189] Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. *Br J Pharmacol*. 2011; 163(7): 1447–1463.
- [190] Maccarrone M. Endocannabinoid signaling in cancer: a rather complex puzzle. *Trends Pharmacol Sci*. 2013; 34(8): 426–427.
- [191] Pisanti S, Picardi P, D'Alessandro A, Laezza C, Bifulco M. The endocannabinoid signaling system in cancer. *Trends Pharmacol Sci*. 2013; 34(5): 273–282.
- [192] Maccarrone M, Dainese E, Oddi S. Intracellular trafficking of anandamide: new concepts for signaling. *Trends Biochem Sci*. 2010; 35(11): 601–608.
- [193] Taylor AH, Amoako AA, Bambang K, Karasu T, Gebeh A, Lam PM, Marzcylo TH, Konje JC. Endocannabinoids and pregnancy. *Clin Chim Acta*. 2010; 411(13–14): 921–930.
- [194] Bifulco M, Malfitano AM, Pisanti S, Laezza C. Endocannabinoids in endocrine and related tumours. *Endocr Relat Cancer*. 2008; 15(2): 391–408.
- [195] Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids, and cancer. *Cancer Metastasis Rev*. 2011; 30(3–4): 599–612.
- [196] Royal College of Obstetricians and Gynaecologists/ British Society of Gynaecological Endoscopy Joint G. Management of Endometrial Hyperplasia. In: *Green-top Guideline No. 67*, RCOG/BSGE Joint Guideline; February 2016. Available from https://www.rcog.org.uk/globalassets/documents/guidelines/greentop-guidelines/gtg_67_endometrial_hyperplasia.pdf. Accessed July 2022.
- [197] Gomes MK, Rosa-e-Silva JC, Garcia SB, de Sa Rosa-e-Silva AC, Turatti A, Vieira CS, Ferriani RA. Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium. *Hum Reprod*. 2009; 24(11): 2736–2745.

第 7 章

子宫内膜癌的淋巴显像

Lymphatic Mapping for Endometrial Cancer

- [1] Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. *Int. J. Gynaecol. Obstet.*, 101(2), 205–210 (2008).
- [2] Creasman W. Revised FIGO staging for carcinoma of the endometrium. *Int. J. Gynaecol. Obstet.*, 105(2), 109 (2009).
- [3] Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int. J. Gynaecol. Obstet.*, 105(2), 103–104 (2009).
- [4] Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. *Gynecol. Oncol.*, 109(1), 11–18 (2008).
- [5] Fanning J, Evans MC, Peters AJ, Samuel M, Harmon ER, Bates JS. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. *Gynecol. Oncol.*, 32(3), 288–291 (1989).
- [6] Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. *Br. J. Cancer*, 94(5), 642–646 (2006).
- [7] Kwon JS, Qiu F, Saskin R, Carey MS. Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer? *Obstet. Gynecol.*, 114(4), 736–743 (2009).
- [8] Yoon JH, Yoo SC, Kim WY, Chang SJ, Chang KH, Ryu HS. Para-aortic lymphadenectomy in the management of preoperative grade 1 endometrial cancer confined to the uterine corpus. *Ann Surg Oncol.*, 17(12), 3234–3240 (2010).
- [9] Mariani A, Dowdy SC, Podratz KC. New surgical staging of endometrial cancer: 20 years later. *Int. J. Gynaecol. Obstet.*, 105(2), 110–111 (2009).
- [10] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin.*, 64(1), 9–29 (2014).
- [11] Fotopoulou C, Savvatis K, Kraetschell R, Schefold JC, Lichtenegger W, Schouli J. Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status. *Eur J Obstet Gynecol Reprod Biol.*, 149(2), 199–203 (2010).
- [12] Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. *J. Natl. Cancer Inst.*, 100(23), 1707–1716 (2008).
- [13] ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. *Lancet*, 373(9658), 125–136 (2009).
- [14] May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. *Cochrane Database Syst Rev.*, (1), CD007585 (2010).
- [15] Uccella S, Podratz KC, Aletti GD, Mariani A. Re: Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. *J. Natl. Cancer Inst.*, 101(12), 897–898 (2009).
- [16] Kwon JS, Qiu F, Saskin R, Carey MS. Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer? *Obstet. Gynecol.*, 114(4), 736–743 (2009).
- [17] Creasman WT, Mutch DE, Herzog TJ. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? *Gynecol. Oncol.*, 116(3), 293–294 (2010).
- [18] Gould EA, Winship T, Philbin PH, Kerr H. Observations on a “sentinel node” in the parotid. *Cancer*, 13, 77–78 (1960).
- [19] Stadelmann WK. The role of lymphatic mapping and sentinel lymph node biopsy in the staging and treatment of melanoma. *Clin. Plast. Surg.*, 37(1), 79–99 (2010).
- [20] Quan ML, McCreedy D. The evolution of lymph node assessment in breast cancer. *J. Surg. Oncol.*, 99(4), 194–198 (2009).
- [21] Hassanzade M, Attaran M, Treglia G, Yousefi Z, Sadeghi R. Lymphatic mapping and sentinel node biopsy in squamous cell carcinoma of the vulva: systematic review and meta-analysis of the literature. *Gynecol Oncol.*, 130(1), 237–245 (2013).
- [22] Selman TJ, Mann C, Zamora J, Appleyard TL, Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and metaanalysis. *CMAJ.*, 178(7), 855–862 (2008).
- [23] Diaz JP, Gemignani ML, Pandit-Taskar N, et al. Sentinel lymph node biopsy in the management of early-stage cervical carcinoma. *Gynecol Oncol.*, 120(3), 347–352 (2011).
- [24] Burke TW, Levenback C, Tornos C, Morris M, Wharton

- JT, Gershenson DM. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. *Gynecol. Oncol.*, 62(2), 169–173 (1996).
- [25] Frumovitz M, Bodurka DC, Broaddus RR, et al. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. *Gynecol. Oncol.*, 104(1), 100–103 (2007).
- [26] Mais V, Cirronis MG, Piras B, Silvetti E, Cossu E, Melis GB. Intraoperative lymphatic mapping techniques for endometrial cancer. *Expert Rev Anticancer Ther.*, 11(1), 83–93 (2011).
- [27] Robova H, Rob L, Halaska MJ, Pluta M, Skapa P. Current status of sentinel lymph node mapping in the management of endometrial cancer. *Expert Rev Anticancer Ther.*, 13(1), 55–61 (2013).
- [28] Echt ML, Finan MA, Hoffman MS, Kline RC, Roberts WS, Fiorica JV. Detection of sentinel lymph nodes with lymphazurin in cervical, uterine, and vulvar malignancies. *South. Med. J.*, 92(2), 204–208 (1999).
- [29] Niikura H, Okamura C, Utsunomiya H, et al. Sentinel lymph node detection in patients with endometrial cancer. *Gynecol. Oncol.*, 92(2), 669–674 (2004).
- [30] Raspagliesi F, Ditto A, Kusamura S, et al. Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. *Am. J. Obstet. Gynecol.*, 191(2), 435–439 (2004).
- [31] Fersis N, Gruber I, Relakis K et al. Sentinel node identification and intraoperative lymphatic mapping. First results of a pilot study in patients with endometrial cancer. *Eur. J. Gynaecol. Oncol.*, 25(3), 339–342 (2004).
- [32] Maccauro M, Lucignani G, Aliberti G, et al. Sentinel lymph node detection following the hysteroscopic peritumoral injection of ^{99m}Tc -labelled albumin nanocolloid in endometrial cancer. *Eur. J. Nucl. Med. Mol. Imaging.* 32(5), 569–574 (2005).
- [33] Gien LT, Kwon JS, Carey MS. Sentinel node mapping with isosulfan blue dye in endometrial cancer. *J. Obstet. Gynaecol. Can.*, 27(12), 1107–1112 (2005).
- [34] Altgassen C, Pagenstecher J, Hornung D, Diedrich K, Hornemann A. A new approach to label sentinel nodes in endometrial cancer. *Gynecol. Oncol.*, 105(4), 457–461 (2007).
- [35] Li b, Li XG, Wu LY et al. A pilot study of sentinel lymph nodes identification in patients with endometrial cancer. *Bull. Cancer.*, 94(1), E1–4 (2007).
- [36] Lopes LA, Nicolau SM, Baracat FF, et al. Sentinel lymph node in endometrial cancer. *Int. J. Gynecol. Cancer.*, 17(5), 1113–1117 (2007).
- [37] Perrone AM, Casadio P, Formelli G, et al. Cervical and hysteroscopic injection for identification of sentinel lymph node in endometrial cancer. *Gynecol. Oncol.*, 111(1), 62–67 (2008).
- [38] Robova H, Charvat M, Strnad P, et al. Lymphatic mapping in endometrial cancer: comparison of hysteroscopic and subserosal injection and the distribution of sentinel lymph nodes. *Int. J. Gynecol. Cancer.*, 19(3), 391–394 (2009).
- [39] Zenzola V, Gonzalez C, Lander JS, et al. Use of sentinel lymph node biopsy with patent blue labeling and radiocolloid in patients with endometrial cancer. *Rev Venez Oncol.*, 21(1), 3–10 (2009).
- [40] Feranec R, Mouková L, Staníček J, Stefániková L, Chovanec J. Sentinel lymph node identification using hysteroscopy in patients with endometrial cancer. *Klin. Onkol.*, 23(2), 92–98 (2010).
- [41] Mais V, Peiretti M, Gargiulo T, Parodo G, Cirronis MG, Melis GB. Intraoperative sentinel lymph node detection by vital dye through laparoscopy or laparotomy in early endometrial cancer. *J. Surg. Oncol.*, 101(5), 408–412 (2010).
- [42] Holub Z, Jabor A, Kliment L. Comparison of two procedures for sentinel lymph node detection in patients with endometrial cancer: a pilot study. *Eur. J. Gynaecol. Oncol.*, 23(1), 53–57 (2002).
- [43] Pelosi E, Arena V, Baudino B, et al. Preliminary study of sentinel node identification with ^{99m}Tc colloid and blue dye in patients with endometrial cancer. *Tumori.* 88(3), S9–S10 (2002).
- [44] Gargiulo T, Giusti M, Bottero M, et al. Sentinel lymph node (SLN) laparoscopic assessment in early stage endometrial cancer. *Minerva Gynecol.*, 55(3), 259–262 (2003).
- [45] Pelosi E, Arena V, Baudino B, et al. Pre-operative lymphatic mapping and intra-operative sentinel lymph node detection in early stage endometrial cancer. *Nucl. Med. Commun.*, 24(9), 971–975 (2003).
- [46] Barranger E, Cortez A, Grahek D, Callard P, Uzan S, Darai E. Laparoscopic sentinel node procedure using a combination of patent blue and radiocolloid in women with endometrial cancer. *Ann. Surg. Oncol.*, 11(3), 344–349 (2004).
- [47] Lelievre L, Camatte S, Le Frere-Belda MA, et al. Sentinel lymph node biopsy in cervix and corpus uteri cancers. *Int. J. Gynecol. Cancer.*, 14(2), 271–278 (2004).
- [48] Bats AS, Clément D, Larousserie F et al. La biopsie du ganglion sentinelle dans les cancers de l'endomètre est-elle faisable? [Is sentinel lymph node biopsy in endometrial cancers feasible?] *J. Gynecol. Obstet. Biol. Reprod. (Paris)*, 34(5), 768–774 (2005).
- [49] Depelch Y, Cortez A, Coutant C, et al. The sentinel concept in endometrial cancer: histopatologic validation by serial section and immunohistochemistry. *Ann. Oncol.*, 18(11), 1799–1803 (2007).
- [50] Bats AS, Clément D, Larousserie F, et al. Does sentinel node biopsy improve the management of endometrial cancer? Data from 43 patients. *J. Surg. Oncol.*, 97(2), 141–145 (2008).
- [51] Ballester M, Dubernard G, Rouzier R, Barranger E, Darai E. Use of the sentinel node procedure to stage endometrial cancer. *Ann. Surg. Oncol.*, 15(5), 1523–1529 (2008).
- [52] Barranger E, Depelch Y, Coutant C, Dubernard G, Uzan S, Darai E. Laparoscopic sentinel node mapping using combined detection for endometrial cancer: a study of 33 cases-is it a promising technique? *Am. J. Surg.*, 197(1), 1–7 (2009).

- [53] Vidal-Sicart S, Doménech B, Lujan B, et al. Sentinel node in gynecological cancers. Our experience. *Rev. Esp. Med. Nucl.*, 28(5), 221–228 (2009).
- [54] Torné A, Pahisa J, Vidal-Sicart S, et al. Transvaginal ultrasound-guided myometrial injection of radiotracer (TUMIR): a new method for sentinel lymph node detection in endometrial cancer. *Gynecol Oncol.*, 128(1), 88–94 (2013).
- [55] Dzvincuk P, Pilka R, Kudela M, Koranda P. Sentinel lymph node detection using ^{99m}Tc-nanocolloid in endometrial cancer. *Ceska Gynekol.*, 71(3), 231–236 (2006).
- [56] Delaloye JF, Pampallona S, Chardonnes E, et al. Intraoperative lymphatic mapping and sentinel node biopsy using hysteroscopy in patients with endometrial cancer. *Gynecol. Oncol.*, 106(1), 89–93 (2007).
- [57] Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N, et al. Sentinel node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? *Gynecol. Oncol.*, 113(2), 163–169 (2009).
- [58] Khoury-Collado F, Glaser GE, Zivanovic O, et al. Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? *Gynecol. Oncol.*, 115(3), 453–455 (2009).
- [59] Ballester M, Dubernard G, Lécuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). *Lancet Oncol.*, 12(5), 469–476 (2011).
- [60] Solima E, Martinelli F, Ditto A, et al. Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. *Gynecol Oncol.*, 126(3), 419–423 (2012).
- [61] Ballester M, Naoura I, Chéreau E, et al. Sentinel node biopsy upstages patients with presumed low and intermediate-risk endometrial cancer: results of a multicenter study. *Ann Surg Oncol.*, 20(2), 407–412 (2013).
- [62] How J, Lau S, Press J, et al. Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: A prospective study. *Gynecol Oncol.*, 127(2), 332–337 (2012).
- [63] Holloway RW, Bravo RA, Rakowski JA, et al. Detection of sentinel lymph nodes in patients with endometrial cancer undergoing robotic-assisted staging: a comparison of colorimetric and fluorescence imaging. *Gynecol Oncol.*, 126(1), 25–29 (2012).
- [64] Rossi EC, Jackson A, Ivanova A, Boggess JF. Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imaging: cervical versus hysteroscopic injection. *Int J Gynecol Cancer.*, 23(9), 1704–1711 (2013).
- [65] Sinno AK, Fader AN, Roche KL, Giuntoli RL 2nd, Tanner EJ. A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. *Gynecol Oncol.*, 134(2), 281–286 (2014).
- [66] Desai PH, Hughes P, Tobias DH, et al. Accuracy of robotic sentinel lymph node detection (RSLND) for patients with endometrial cancer (EC). *Gynecol Oncol.*, 135(2), 196–200 (2014).
- [67] Tanner EJ, Sinno AK, Stone RL, Levinson KL, Long KC, Fader AN. Factors associated with successful bilateral sentinel lymph node mapping in endometrial cancer. *Gynecol Oncol.*, 138(3), 542–547 (2015).
- [68] Eitan R, Sabah G, Krissi H, et al. Robotic blue-dye sentinel lymph node detection for endometrial cancer — Factors predicting successful mapping. *Eur J Surg Oncol.*, 41(12), 1659–1663 (2015).
- [69] Paley PJ, Veljovich DS, Press JZ, Isacson C, Pizer E, Shah C. A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging. *Am J Obstet Gynecol.*, 215(1), 117.e1–7 (2016).
- [70] Holloway RW(1), Gupta S(2), Stavitzski NM, et al. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. *Gynecol Oncol.*, 141(2), 206–210 (2016).
- [71] Hagen B, Valla M, Aune G et al. Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm. *Gynecol Oncol.*, 143(3), 479–483 (2016).
- [72] Holloway RW, Ahmad S, Kendrick JE, et al. A Prospective Cohort Study Comparing Colorimetric and Fluorescent Imaging for Sentinel Lymph Node Mapping in Endometrial Cancer. *Ann Surg Oncol.*, 24(7), 1972–1979 (2017).
- [73] Clinton LK, Kondo J, Carney ME, Tauchi-Nishi P, Terada K, Shimizu D. Low-Volume Lymph Node Metastases in Endometrial Carcinoma. *Int J Gynecol Cancer.*, 27(6), 1165–1170 (2017).
- [74] Persson J, Geppert B, Lönnerfors C, Bollino M, Måsbäck A. Description of a reproducible anatomically based surgical algorithm for detection of pelvic sentinel lymph nodes in endometrial cancer. *Gynecol Oncol.*, 147(1), 120–125 (2017).
- [75] Tanner EJ, Ojalvo L, Stone RL, et al. The Utility of Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer. *Int J Gynecol Cancer.*, 27(7), 1416–1421 (2017).
- [76] Backes FJ, Cohen D, Salani R, et al. Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). *Gynecol Oncol.*, 153(3), 496–499 (2019).
- [77] Frimer M, Khoury-Collado F, Murray MP, Barakat RR, Abu-Rustum NR. Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artefact of uterine manipulation? *Gynecol Oncol.*, 119(3), 496–499 (2010).
- [78] Khoury-Collado F, Murray MP, Hensley ML et al. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. *Gynecol Oncol.*, 122(2), 251–254 (2011).
- [79] Barlin JN, Khoury-Collado F, Kim CH et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. *Gynecol Oncol.*, 125(3), 531–535 (2012).
- [80] Leitao MM Jr, Khoury-Collado F, Gardner G et al. Impact

- of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. *Gynecol Oncol.*, 129(1), 38–41 (2013).
- [81] Vidal F, Leguevaque P, Motton S, et al. Evaluation of the Sentinel Lymph Node Algorithm with Blue Dye labeling for Early-Stage Endometrial Cancer in a Multicentric Setting. *Int J Gynecol Cancer*, 23(7), 1237–1243 (2013).
- [82] Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.*, 16(2), 170–199 (2018).
- [83] Kang S, Yoo HJ, Hwang JH, Lim MC, Seo SS, Park SY. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. *Gynecol Oncol.*, 123(3), 522–527 (2011).
- [84] Ansari M, Rad MA, Hassanzadeh M, et al. Sentinel node biopsy in endometrial cancer: systematic review and meta-analysis of the literature. *Eur J Gynaecol Oncol.*, 34(5), 387–401 (2013).
- [85] Ruscito I, Gasparri ML, Braicu EI, et al. Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis. *Ann Surg Oncol.*, 23(11), 3749–3756 (2016).
- [86] Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. *Am J Obstet Gynecol.*, 216(5), 459–476.e10, (2017).
- [87] Wang L, Liu F. Meta-analysis of laparoscopy sentinel lymph node mapping in endometrial cancer. *Arch Gynecol Obstet.*, 298(3), 505–510 (2018).
- [88] Bogani G, Murgia F, Ditto A, Raspagliesi F. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. *Gynecol Oncol.*, 153(3), 676–683 (2019).
- [89] Ballester M, Rouzier R, Coutant C, Kerrou K, Darai E. Limits of lymphoscintigraphy for sentinel node biopsy in women with endometrial cancer. *Gynecol. Oncol.*, 112(2), 348–352 (2009).
- [90] Kraft O, Havel M. Sentinel lymph nodes and planar scintigraphy and SPECT/CT in various types of tumours. Estimation of some factors influencing detection success. *Nucl Med Rev.*, 16(1), 17–25 (2013).
- [91] Frati A, Ballester M, Dubernard G, et al. Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTI-ENDO Study. *Ann. Surg. Oncol.*, 22(6), 1980–1986 (2015).
- [92] Buda A, Elisei F, Arosio M, et al. Integration of hybrid single-photon emission computed tomography/computed tomography in the preoperative assessment of sentinel node in patients with cervical and endometrial cancer: our experience and literature review. *Int J Gynecol Cancer.*, 22(5), 830–835 (2012).
- [93] Pandit-Taskar N, Gemignani ML, Lyall A, Larson SM, Barakat RR, Abu Rustum NR. Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. *Gynecol Oncol.*, 117(1), 59–64 (2010).
- [94] Perissinotti A, Paredes P, Vidal-Sicart S, et al. Use of SPECT/CT for improved sentinel lymph node localization in endometrial cancer. *Gynecol Oncol.*, 129(1), 42–48 (2013).
- [95] Mücke J, Klapdor R, Schneider M, et al. Isthmocervical labelling and SPECT/CT for optimized sentinel detection in endometrial cancer: technique, experience and results. *Gynecol. Oncol.*, 134(2), 287–292 (2014).
- [96] Sawicki S, Kobierski J, Łapińska-Szumczyk S, et al. Comparison of SPECT-CT results and intraoperative detection of sentinel lymph nodes in endometrial cancer. *Nucl. Med. Commun.*, 34(6), 590–596 (2013).
- [97] Elisei F, Crivellaro C, Giuliani D et al. Sentinel-node mapping in endometrial cancer patients: comparing SPECT/CT, gamma-probe and dye. *Ann Nucl Med.*, 31(1), 93–99 (2017).
- [98] Sahbai S, Taran FA, Fiz F, et al. Pericervical Injection of 99mTc-Nanocolloid Is Superior to Peritumoral Injection for Sentinel Lymph Node Detection of Endometrial Cancer in SPECT/CT. *Clin Nucl Med.*, 41(12), 927–932 (2016).
- [99] Sahbai S, Taran FA, Staebler A, et al. Sentinel lymph node mapping using SPECT/CT and gamma probe in endometrial cancer: an analysis of parameters affecting detection rate. *Eur J Nucl Med Mol Imaging.*, 44(9), 1511–1519 (2017).
- [100] Kakhki VRD, Shahriari S, Treglia G, et al. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature. *Int J Gynecol Cancer.*, 23(9), 1536–1543 (2013).
- [101] Signorelli M(1), Crivellaro C, Buda A, et al. Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping. *Clin Nucl Med.*, 40(10), 780–785 (2015).
- [102] Tanaka T, Terai Y, Yamamoto K, Yamada T, Ohmichi M. The diagnostic accuracy of fluorodeoxyglucose-positron emission tomography/computed tomography and sentinel node biopsy in the prediction of pelvic lymph node metastasis in patients with endometrial cancer: A retrospective observational study. *Medicine (Baltimore)*, 97(38), e12522 (2018).
- [103] Stewart KI, Chasen B, Erwin W, et al. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. *Cancer.*, 125(19), 3347–3353 (2019).
- [104] Fasmer KE, Bjørnerud A, Ytre-Hauge S, et al. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. *Acta Radiol.*, 59(8), 1010–1017 (2018).
- [105] Yang T, Tian S, Li Y, et al. Magnetic Resonance Imaging (MRI) and Three-Dimensional Transvaginal Ultrasonography Scanning for Preoperative Assessment

- of High Risk in Women with Endometrial Cancer. *Med Sci Monit.*, 25, 2024–2031 (2019).
- [106] Alcázar JL, Gastón B, Navarro B, Salas R, Aranda J, Guerriero S. Transvaginal ultrasound versus magnetic resonance imaging for preoperative assessment of myometrial infiltration in patients with endometrial cancer: a systematic review and meta-analysis. *J. Gynecol. Oncol.*, 28(6), e86 (2017).
- [107] Eriksson LS, Lindqvist PG, Floter Radestad A, et al. Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists. *Ultrasound Obstet. Gynecol.*, 45(4), 476–482 (2015).
- [108] Green RW, Valentin L, Alcazar JL, et al. Endometrial cancer off-line staging using two-dimensional transvaginal ultrasound and three-dimensional volume contrast imaging: Intermethod agreement, interrater reliability and diagnostic accuracy. *Gynecol. Oncol.*, 150(3), 438–445 (2018).
- [109] Mascilini F, Testa AC, Van Holsbeke C, Ameye L, Timmerman D, Epstein E. Evaluating myometrial and cervical invasion in women with endometrial cancer: comparing subjective assessment with objective measurement techniques. *Ultrasound Obstet. Gynecol.*, 42(3), 353–358 (2013).
- [110] Leone FP, Timmerman D, Bourne T, et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. *Ultrasound Obstet. Gynecol.*, 35(1), 103–112 (2010).
- [111] Alcázar JL, Pascual MÁ, Ajossa S, et al. Reproducibility of the International Endometrial Analysis Group Color Score for Assigning the Amount of Flow Within the Endometrium Using Stored 3-Dimensional Volumes. *J Ultrasound Med.*, 36(7), 1347–1354 (2017).
- [112] Epstein E, Fischerova D, Valentin L, et al. Ultrasound characteristics of endometrial cancer as defined by International Endometrial Tumor Analysis (IETA) consensus nomenclature: prospective multicenter study. *Ultrasound Obstet. Gynecol.*, 51(6), 818–828 (2018).
- [113] Verbakel JY, Mascilini F, Wynants L, et al. Validation of ultrasound strategies to assess tumor extension and to predict high-risk endometrial cancer in women from the prospective IETA (International Endometrial Tumour Analysis) 4 cohort. *Ultrasound Obstet Gynecol.*, 2019 Jun 21. <https://doi.org/10.1002/uog.20374>. [Epub ahead of print]
- [114] Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. *Int J Gynecol Cancer.*, 26(1), 2–30 (2016).
- [115] Neri M, Peiretti M, Melis GB, et al. Systemic therapy for the treatment of endometrial cancer. *Expert Opin Pharmacother.*, 20(16), 2019–2032 (2019).

第 8 章

子宫内膜癌前哨淋巴结

Sentinel Lymph Nodes in Endometrial Cancer

- [1] Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer E J, Thun M J. Cancer statistics, 2005. *CA Cancer J. Clin.* Jan-Feb; 55(1),10–30 (2005) Erratum in: *CA Cancer J. Clin.* 55(4), 259 (2005).
- [2] Creasman W T, Morrow C P, Bundy B N, Homesley H D, Graham J E, Heller P B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. *Cancer* 15; 60(8 Suppl), 2035–2041 (1987).
- [3] Morrow C P, Bundy B N, Kurman R J, Creasman W T, Heller P, Homesley HD, Graham J E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. *Gynecol. Oncol.* 40(1), 55–65 (1991).
- [4] Mariani A, Keeney G L, Aletti G, Webb M J, Haddock M G, Podratz K C. Endometrial carcinoma: paraaortic dissemination. *Gynecol. Oncol.* 92(3), 833–838 (2004).
- [5] Mariani A, Webb M J, Keeney G L, Podratz K C. Routes of lymphatic spread: a study of 112 consecutive patients with endometrial cancer. *Gynecol. Oncol.* 81(1), 100–104 (2001).
- [6] Yokoyama Y, Maruyama H, Sato S, Saito Y. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. *Gynecol. Oncol.* 64(3), 411–417 (1997).
- [7] FIGO stages–1998 revision. *Gynecol. Oncol.* 35, 125–126 (1989).
- [8] Hidaka T T, Kato K, Yonezawa R, Shima T, Nakashima A, Nagira K, Nakamura T, Saito S. Omission of lymphadenectomy is possible for low-risk corpus cancer. *Eur. J. Surg. Oncol.* 33(1), 86–90 (2007).
- [9] Cragun M J, Havrilesky L J, Calingaert B, Synan I, Secord A A, Soper J T, Clarke-Pearson D L, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. *J. Clin. Oncol.* 23(16), 3668–3675 (2005).
- [10] Zaino R J, Kurmann R J, Diana K L, Morrow C P. Prognostic models to predict outcome for women with endometrial adenocarcinoma. *Cancer* 77, 1115–1121 (1996).
- [11] ASTEC study group, Kitchener H, Swart A M, Qian Q, Amos C, Parma MKBr. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. *Lancet* 373(9658), 125–136 (2009).
- [12] Trimble E L, Kosary C, Park R C. Lymph node sampling and survival in endometrial cancer. *Gynecol. Oncol.* 71(3), 340–343 (1998).
- [13] Levenback C F, van der Zee A G J, Rob L, Plante M, Covens A, Schneider A, Coleman R, Solima E, Hertel H, Barranger E, Obermair A, Roy M. Sentinel lymph node biopsy in patients with gynecologic cancers. *Expert Panel Statement from the International Sentinel Node Society Meeting*, February 21, 2008. *Gynecol Oncol* 114(2), 151–156 (2009).
- [14] Plante M, Renaud MC, Tętu B, Harel F, Roy M. Laparoscopic sentinel node mapping in early-stage cervical cancer. *Gynecol. Oncol.* 91(3), 494–503 (2003).
- [15] Rob L, Strnad P, Robova H, Charvat M, Pluta M, Schlegerova D, Hrehorecak M. Study of lymphatic mapping and sentinel node identification in early stage cervical cancer. *Gynecol. Oncol.* 98(2), 281–288 (2005).
- [16] Gortzak-Uzan L, Jimenez W, Nofech-Mozes S, Ismiil N, Khalifa M A, Dubé V, Rosen B, Murphy J, Laframboise S, Covens A. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard? *Gynecol. Oncol.* 116(1), 28–32 (2010).
- [17] Schiavone M B, Scelzo C, Straight C, Zhou Q, Alektiar K M, Makker V, Soslow R A, Iasonos A, Leitao M M, Abu-Rustum N R. Survival of patients with serous uterine carcinoma undergoing sentinel lymph node mapping. *Ann. Surg. Oncol.* 24(7), 1965–1971 (2017).
- [18] Soliman P T, Westin S N, Dioun S, Sun C C, Euscher E, Munsell M F, Fleming N D, Levenback C F, Frumovitz M, Ramirez P T, Lu K H. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. *Gynecol. Oncol.* 146(2), 234–239 (2017).
- [19] Sinno A K, Nickles Fader A, Long Roche K, Giuntoli 2nd R L, Tanner E J. A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. *Gynecol. Oncol.* 134(2), 281–286 (2014).
- [20] Holub Z, Jabor A, Lukac J, Kliment L. Laparoscopic detection of sentinel lymph nodes using blue dye in women with cervical and endometrial cancer. *Med. Sci. Monit.* 10(10), CR587–591 (2004).
- [21] Delpech Y, Cortez A, Coutant C, Callard P, Uzan S, Darai E, Barranger E. The sentinel node concept in endometrial cancer: histopathologic validation by serial section and

- immunohistochemistry. *Ann. Oncol.* 18(11), 1799–1803 (2007).
- [22] Frumovitz M, Plante M, Lee P S, Sandadi S, Lilja J S, Escobar P F, Gien L T, Urbauer D L, Abu-Rustum N R. Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. *Lancet Oncol.* 19, 1394–1403 (2018).
- [23] Barlin J N, Khoury-Collado F, Kim C H, Leitao Jr M M, Chi D S, Sonoda Y, Alektiar K, DeLair DF, Barakat RR, Abu-Rustum NR. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. *Gynecol. Oncol.* 125(3), 531–535 (2012).
- [24] Bats A, Clément D, Larousserie F, Le Frère-Belda M, Pierquet-Ghazzar N, Hignette C, Lécuru F. Does sentinel node biopsy improve the management of endometrial cancer? Data from 43 patients. *J. Surg. Oncol.* 97(2), 141–145 (2008).
- [25] Mais V, Peiretti M, Gargiulo T, Parodo G, Cirronis M G, Melis C B. Intraoperative sentinel lymph node detection by vital dye through laparoscopy or laparotomy in early endometrial cancer. *J. Surg. Oncol.* 101(5), 408–412 (2010).
- [26] Ballester M, Koskas M, Coutant C, Chéreau E, Seror J, Rouzier R, Daraï E. Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy? *BMC Cancer* 10, 465 (2010).
- [27] Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, Querleu D, Golfier F, Leblanc E, Rouzier R, Daraï E. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). *Lancet Oncol.* 12(5), 469–476 (2011).
- [28] Burke T W, Levenback C F, Tornos C, Morris M, Wharton J T, Gershenson D M. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. *Gynecol. Oncol.* 62(2), 169–173 (1996).
- [29] Robova H, Charvat M, Strnad P, Hrehorcak M, Taborska K, Skapa P, Rob L. Lymphatic mapping in endometrial cancer: comparison of hysteroscopic and subserosal injection and the distribution of sentinel lymph nodes. *Int. J. Gynecol. Cancer* 19(3), 391–394 (2009).
- [30] Frumovitz M, Bodurka D C, Broaddus R R, Coleman R L, Sood A K, Gershenson DM, Burke TW, Levenback CF. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. *Gynecol. Oncol.* 104(1), 100–103 (2007).
- [31] Lopes L A F, Nicolau S M, Baracat F F, Baracat E C, Gonçalves W J, Santos HVB, Lopes RG, Lippi UG. Sentinel lymph node in endometrial cancer. *Int. J. Gynecol. Cancer* 17(5), 1113–1117 (2007).
- [32] Altgassen C, Pagenstecher J, Hornung D, Diedrich K, Hornemann A. A new approach to label sentinel nodes in endometrial cancer. *Gynecol. Oncol.* 105(2), 457–461 (2007).
- [33] Li B, Li X G, Wu L Y, W, Li S, Min C, Gao J. A pilot study of sentinel lymph nodes identification in patients with endometrial cancer. *Bull. Cancer* 94(1), E1–4 (2007).
- [34] Niikura H, Okamura C, Utsunomiya H, Yoshinaga K, Akahira J, Ito K, Yaegashi N. Sentinel lymph node detection in patients with endometrial cancer. *Gynecol. Oncol.* 92(2), 669–674 (2004).
- [35] Maccauro M, Lucignani G, Aliberti G, Villano C, Castellani M R, Solima E, Bombardieri E. Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer. *Eur. J. Nucl. Med. Mol. Imaging* 32(5), 569–574 (2005).
- [36] Delaloye J F, Pampallona S, Chardonnes E, Maryse Fiche M, Lehr H, De Grandi P, Bischof Delaloye A. Intraoperative lymphatic mapping and sentinel node biopsy using hysteroscopy in patients with endometrial cancer. *Gynecol. Oncol.* 106(1), 89–93 (2007).
- [37] Perrone A M, Casadio P, Formelli G, Levorato M, Ghi T, Costa S, Meriggiola MC, Pelusi G. Cervical and hysteroscopic injection for identification of sentinel lymph node in endometrial cancer. *Gynecol. Oncol.* 111(1), 62–67 (2008).
- [38] Solima E, Martinelli F, Ditto A, Maccauro M, Carcangiu M, Mariani L, Kusamura S, Fontanelli R, Grijuela B, Raspagliesi F. Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. *Gynecol. Oncol.* 126(3), 419–423 (2012).
- [39] Martinelli F, Ditto A, Bogani G, Roberti Maggiore U L, Signorelli M, Chiappa V, Raspagliesi F. Sentinel lymph node mapping in endometrial cancer: performance of hysteroscopic injection of tracers. *Int. J. Gynecol. Cancer* (2020) published online.
- [40] National Comprehensive Cancer Network. Endometrial cancer (version 3.2019), 2019. Available : www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
- [41] Kang S, Yoo H J, Hwang J H, Lim M, Seo S, Park S. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. *Gynecol. Oncol.* 123(3), 522–527 (2011).
- [42] Holloway R W, Bravo R A, Rakowski J A, James J A, Jeppson C N, Ingersoll SB, Ahmad S. Detection of sentinel lymph nodes in patients with endometrial cancer undergoing robotic-assisted staging: a comparison of colorimetric and fluorescence imaging. *Gynecol. Oncol.* 126(1), 25–29 (2012).
- [43] Rossi E C, Jackson A, Ivanova A, Bogges J F. Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imagining: cervical versus hysteroscopic injection. *Int. J. Gynecol. Cancer.* 23(9), 1704–1711 (2013).

第9章

子宫内膜癌的现代治疗方法

Current Approaches for Treating Female Patients with Endometrial Cancer

- [1] Siegel, Rebecca L., Kimberly D. Miller, Hannah E. Fuchs, and Ahmedin Jemal. "Cancer statistics, 2021." *CA: A Cancer Journal for Clinicians* 71, no. 1 (2021): 7–33.
- [2] Howlander, N., Noone, A. M., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S. F., Kosary, C. L., Yu, M., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Lewis, D. R., Chen, H. S., Feuer, E. J., Cronin, K. A. (eds). *SEER Cancer Statistics Review, 1975–2010*, National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/csr/1975–2010>.
- [3] Gallup, D. G., Stock, R. J. "Adenocarcinoma of the endometrium in women 40 years of age or younger." *Obstet Gynecol.*, 1984, vol. 64, no. 3, 417–420.
- [4] Norris, H. J., Tavassoli, F. A., Kurman, R. J. "Endometrial hyperplasia and carcinoma. Diagnostic considerations." *Am J Surg Pathol.*, 1983, vol. 7, no. 8, 839–847.
- [5] Trimble, Edward L., Linda C. Harlan, Limin X. Clegg, and Jennifer L. Stevens. "Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States." *Gynecologic Oncology* 96, no. 3 (2005): 741–748.
- [6] Creasman, W. T., F. Odicino, P. Maisonneuve, M. A. Quinn, U. Beller, J. L. Benedet, A. P. M. Heintz, H. Y. S. Ngan, and S. Pecorelli. "Carcinoma of the corpus uteri." *International Journal of Gynecology & Obstetrics* 95 (2006): S105–S143.
- [7] Grady, Deborah, Tebeb Gebretsadik, Karla Kerlikowske, Virginia Ernster, and Diana Petitti. "Hormone replacement therapy and endometrial cancer risk: a meta-analysis." *Obstetrics & Gynecology* 85, no. 2 (1995): 304–313.
- [8] Weiderpass, Elisabete, Hans-Olov Adami, John A. Baron, Cecilia Magnusson, Reinhold Bergström, Anders Lindgren, Nestor Correia, and Ingemar Persson. "Risk of endometrial cancer following estrogen replacement with and without progestins." *Journal of the National Cancer Institute* 91, no. 13 (1999): 1131–1137.
- [9] Schapira, D. V., Kumar, N. B., Lyman, G. H., Cavanagh, D., Roberts, W. S., LaPolla. J. Upper-body fat distribution and endometrial cancer risk. *JAMA*, 1991, 266, 1808–1811.
- [10] Renehan, Andrew G., Margaret Tyson, Matthias Egger, Richard F. Heller, and Marcel Zwahlen. "Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies." *The Lancet* 371, no. 9612 (2008): 569–578.
- [11] Fisher, Bernard, Joseph P. Costantino, Carol K. Redmond, Edwin R. Fisher, D. Lawrence Wickerham, Walter M. Cronin, and NSABP contributors. "Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14." *JNCI: Journal of the National Cancer Institute* 86, no. 7 (1994): 527–537.
- [12] Lindor, Noralane M., Gloria M. Petersen, Donald W. Hadley, Anita Y. Kinney, Susan Miesfeldt, Karen H. Lu, Patrick Lynch, Wylie Burke, and Nancy Press. "Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review." *Jama* 296, no. 12 (2006): 1507–1517.
- [13] Lu, Karen H., John O. Schorge, Kerry J. Rodabaugh, Molly S. Daniels, Charlotte C. Sun, Pamela T. Soliman, Kristin G. White, Rajyalakshmi Luthra, David M. Gershenson, and Russell R. Broaddus. "Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer." *Journal of Clinical Oncology* 25, no. 33 (2007): 5158–5164.
- [14] Aarnio, Markku, Risto Sankila, Eero Pukkala, Reijo Salovaara, Lauri A. Aaltonen, Albert de la Chapelle, Päivi Peltomäki, Jukka-Pekka Mecklin, and Heikki J. Järvinen. "Cancer risk in mutation carriers of DNA-mismatch-repair genes." *International Journal of Cancer* 81, no. 2 (1999): 214–218.
- [15] Dunlop, Malcolm G., Susan M. Farrington, Andrew D. Carothers, Andrew H. Wyllie, Linda Sharp, John Burn, Bo Liu, Kenneth W. Kinzler, and Bert Vogelstein. "Cancer risk associated with germline DNA mismatch repair gene mutations." *Human Molecular Genetics* 6, no. 1 (1997): 105–110.
- [16] Bokhman, Jan V., Oleg F. Chepick, Alina T. Volkova, and Alexander S. Vishnevsky. "Adjuvant hormone therapy of primary endometrial carcinoma with oxyprogesterone caproate." *Gynecologic Oncology* 11, no. 3 (1981): 371–378.
- [17] Randall, Marcus E., Virginia L. Filiaci, Hyman Muss, Nick M. Spirtos, Robert S. Mannel, Jeffrey Fowler, J. Tate Thigpen, and Jo Ann Benda. "Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study." *Journal of Clinical Oncology* 24, no. 1 (2006): 36–44.
- [18] Singh, Meenakshi, Richard J. Zaino, Virginia J. Filiaci,

- and Kimberly K. Leslie. "Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study." *Gynecologic Oncology* 106, no. 2 (2007): 325–333.
- [19] Rabban, J. T., Zaloudek, C. J. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis. *Pathology*, 2007, vol. 39, no. 1, 125–133.
- [20] Wheeler, T., Bell, K. A., Kurman R. J., Sherman, M. E. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. *Am J Surg Pathol.*, 2000, vol. 24, no. 6, 797–806.
- [21] Practice, ACOG. ACOG Committee Opinion No. 356: routine cancer screening. *Obstet Gynecol.*, 2006, vol. 108, no. 6, 1611–1613.
- [22] Practice guidelines: uterine corpus—endometrial cancer. Society of Gynecologic Oncologists Medical Practice Committee." *Oncol.*, 1998, vol. 12, no. 1, 122–126.
- [23] Ng, A. B. P. The cellular detection of endometrial carcinoma and its precursors. *Gynec Oncol.*, 1974, vol. 2, no. 2–3, 162–179.
- [24] Ng, A. B. P., Reagan J. W., and Wentz B. W. "Significance of Endometrial Cells in the Detection of Endometrial Carcinoma and Its Precursors." (1974), vol 18, no.5, 356–361.
- [25] Zucker, P. K., Kasdon, E. J., Feldstein. M. L. The validity of Pap smear parameters as predictors of endometrial pathology in menopausal women. *Cancer*, 1985, vol. 56, no. 9, 2256–2263.
- [26] DuBeshter, Brent, Colleen Deuel, Shaun Gillis, Christopher Glantz, Cynthia Angel, and David Guzick. "Endometrial cancer: the potential role of cervical cytology in current surgical staging." *Obstetrics & Gynecology* 101, no. 3 (2003): 445–450.
- [27] Siebers, A. G., A. L. M. Verbeek, L. F. Massuger, J. M. M. Grefte, and J. Bulten. "Normal appearing endometrial cells in cervical smears of asymptomatic postmenopausal women have predictive value for significant endometrial pathology." *International Journal of Gynecologic Cancer* 16, no. 3 (2006), 1069–1074.
- [28] Dijkhuizen, F. Paul H. L. J., Ben W. J. Mol, Hans A. M. Brölmann, and A. Peter M. Heintz. "The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis." *Cancer* 89, no. 8 (2000): 1765–1772.
- [29] American College of Obstetricians and Gynecologists, ACOG committee opinion. No. 336: tamoxifen and uterine cancer. *Obstet Gynecol.*, 2006, vol. 107, no. 6, 1475–1478.
- [30] Runowicz, C. D. Gynecologic surveillance of women on tamoxifen: first do no harm. *J Clin Oncol.*, 2000, vol. 18, no. 20, 3457–3458.
- [31] Berends, Maran J. W., Ying Wu, Rolf H. Sijmons, Tineke van der Sluis, Wietske Boersmavan Ek, Marjolijn J. L. Ligtenberg, Neeltje J. W. Arts et al. "Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis." *Journal of Clinical Oncology* 21, no. 23 (2003): 4364–4370.
- [32] Watson, H. T. Lynch. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. *Cancer*, 1993, vol. 71, no. 3, 677–685.
- [33] Buchanan, Daniel D., Yen Y. Tan, Michael D. Walsh, Mark Clendenning, Alexander M. Metcalf, Kaitin Ferguson, Sven T. Arnold et al. "Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing." *Journal of Clinical Oncology* 32, no. 2 (2014): 90.
- [34] Schmeler, Kathleen M., Henry T. Lynch, Lee-may Chen, Mark F. Munsell, Pamela T. Soliman, Mary Beth Clark, Molly S. Daniels et al. "Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome." *New England Journal of Medicine* 354, no. 3 (2006): 261–269.
- [35] Levine, Douglas A., Oscar Lin, Richard R. Barakat, Mark E. Robson, Deborah McDermott, Lesley Cohen, Jaya Satagopan, Kenneth Offit, and Jeff Boyd. "Risk of endometrial carcinoma associated with BRCA mutation." *Gynecologic Oncology* 80, no. 3 (2001): 395–398.
- [36] Beiner, Mario E., Amy Finch, Barry Rosen, Jan Lubinski, Pal Moller, Parviz Ghadirian, Henry T. Lynch et al. "The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study." *Gynecologic Oncology* 104, no. 1 (2007): 7–10.
- [37] Creasman, William T., C. Paul Morrow, Brian N. Bundy, Howard D. Homesley, James E. Graham, and Paul B. Heller. "Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study." *Cancer* 60, no. S8 (1987): 2035–2041.
- [38] Lurain, JOHN R., Nanette K. Rumsey, Julian C. Schink, C. B. Wallemark, and Joan S. Chmiel. "Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium." *Obstetrics and Gynecology* 74, no. 2 (1989): 175–179.
- [39] Harouny, Victor R., Gregory P. Sutton, Stephen A. Clark, Hans E. Geisler, Frederick B. Stehman, and Clarence E. Ehrlich. "The importance of peritoneal cytology in endometrial carcinoma." *Obstetrics and Gynecology* 72, no. 3 Pt 1 (1988): 394–398.
- [40] Hirai, Y. A. S. U. O., I. K. U. N. O. Fujimoto, K. A. Z. U. H. I. R. O. Yamauchi, K. A. T. S. U. H. I. K. O. Hasumi, K. A. Z. U. M. A. S. A. Masubuchi, and Y. U. U. S. A. K. U. Sano. "Peritoneal fluid cytology and prognosis in patients with endometrial carcinoma." *Obstetrics and Gynecology* 73, no. 3 Pt 1 (1989): 335–338.
- [41] Lurain. J. R. The significance of positive peritoneal cytology in endometrial cancer," *Gynecol Oncol.*, 1992., vol. 46, no. 2, 143–144.
- [42] Takeshima, Nobuhiro, Hidetaka Nishida, Tsutomu Tabata, Yasuo Hirai, and Katsuhiko Hasumi. "Positive peritoneal cytology in endometrial cancer: enhancement of other prognostic indicators." *Gynecologic Oncology* 82, no. 3 (2001): 470–473.
- [43] Kadar, N., Homesley, H. D., Malfetano. J. H. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine

- disease. *Gynecol Oncol.*, 1992, vol. 46, no. 2, 145–149.
- [44] Morrow, C. Paul, Brian N. Bundy, Robert J. Kurman, William T. Creasman, Paul Heller, Howard D. Homesley, and James E. Graham. “Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.” *Gynecologic Oncology* 40, no. 1 (1991): 55–65.
- [45] Zaino, Richard J., Robert J. Kurman, Karen L. Diana, and C. Paul Morrow. “Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage—A gynecologic oncology group study.” *Cancer: Interdisciplinary International Journal of the American Cancer Society* 77, no. 6 (1996): 1115–1121.
- [46] Milosevic, M. F., Dembo, A. J., Thomas. G. M. The clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma. *Int J Gyn Ca.*, 1992, vol. 2, no. 5, 225–235.
- [47] Hirai, Yasuo, Nobuhiro Takeshima, Tomoyasu Kato, and Katsuhiko Hasumi. “Malignant potential of positive peritoneal cytology in endometrial cancer.” *Obstetrics & Gynecology* 97, no. 5 (2001): 725–728.
- [48] Grimshaw, Robert N., W. Carl Tupper, Robert C. Fraser, M. G. Tompkins, and John F. Jeffrey. “Prognostic value of peritoneal cytology in endometrial carcinoma.” *Gynecologic Oncology* 36, no. 1 (1990): 97–100.
- [49] Kasamatsu, T., T. Onda, N. Katsumata, M. Sawada, T. Yamada, R. Tsunematsu, K. Ohmi, Y. Sasajima, and Y. Matsuno. “Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus.” *British Journal of Cancer* 88, no. 2 (2003): 245–250.
- [50] Tebeu, Pierre Marie, Y. Popowski, H. M. Verkooijen, C. Bouchardy, F. Ludicke, M. Usel, and A. L. Major. “Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis.” *British Journal of Cancer* 91, no. 4 (2004): 720–724.
- [51] Havrilesky, Laura J., Janiel M. Cragun, Brian Calingaert, Angeles Alvarez Secord, Fidel A. Valea, Daniel L. Clarke-Pearson, Andrew Berchuck, and John T. Soper. “The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.” *Gynecologic Oncology* 104, no. 2 (2007): 401–405.
- [52] Saga, Y., Imai, M., Jobo, T., et al. Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus? *Gynecol Oncol.*, 2006, vol. 103, no. 1, 277–280.
- [53] Jayot, Aude, Clémentine Owen, Sofiane Bendifallah, Kamila Kolanska, Anne-Sophie Boudy, Cyril Touboul, and Emile Darai. “Relevance of sentinel lymph node biopsy in early endometrial cancer: A series of 249 cases.” *European Journal of Obstetrics & Gynecology and Reproductive Biology* 258 (2021): 208–215.
- [54] Farghaly, S. A. Relevance of Surgical Approach, and Adjuvant Therapy in Survival of Obese Patients with endometrial Cancer. *Am J Obstet Gynecol.*, 2009, 200 (3), P e11.
- [55] National Comprehensive Cancer Network. NCCN physician clinical practice guidelines in oncology: uterine neoplasms. *NCCN Guidelines*, v.2, 2011.
- [56] Elliott, P., D. Green, A. Coates, M. Krieger, P. Russell, M. Copleson, J. Solomon, and M. Tattersall. “The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer.” *International Journal of Gynecologic Cancer* 4, no. 2 (1994).
- [57] Karolewski, K., Z. Kojs, K. Urbański, J. Jakubowicz, P. Blecharz, P. Dymek, and M. Reinfuss. “The efficiency of treatment in patients with uterine-confined endometrial cancer.” *European Journal of Gynaecological Oncology* 27, no. 6 (2006): 579–584.
- [58] Touboul, Emmanuel, Yazid Belkacémi, Laurent Buffat, Elisabeth Deniaud-Alexandre, Jean-Pierre Lefranc, Pierre Lhuillier, Serge Uzan et al. “Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.” *International Journal of Radiation Oncology* Biology Physics* 50, no. 1 (2001): 81–97.
- [59] Mariani, Andrea, Maurice J. Webb, Gary L. Keeney, Michael G. Haddock, Giliola Calori, and Karl C. Podratz. “Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?” *American Journal of Obstetrics and Gynecology* 182, no. 6 (2000): 1506–1519.
- [60] Sorbe, Bengt, Britta Nordström, Johanna Mäenpää, Janez Kuhelj, Dimitrij Kuhelj, Sait Okkan, Jean-Francois Delaloye, and B. Frankendal. “Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study.” *International Journal of Gynecologic Cancer* 19, no. 5 (2009).
- [61] Nout, R. A., Smit, V. T., Putter, H. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial, *Lancet*, 2010, 375, 816–823.
- [62] Lee, Christopher M., Aniko Szabo, Dennis C. Shrieve, O. Kenneth Macdonald, and David K. Gaffney. “Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma.” *Jama* 295, no. 4 (2006): 389–397.
- [63] Kong, A., N. Johnson, P. Cornes, I. Simera, M. Collingwood, and C. Williams. “Adjuvant radiotherapy for stage I endometrial cancer.” *Cochrane Database Syst Rev* (2007), 18, P. CD003916.
- [64] Johnson, N., Cornes. P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis, *BJOG.*, 2007, 114, 1313–1320.
- [65] Creutzberg, C. L., van Putten, W. L., Warlam-Rodenhuis, C. C., et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial, *J Clin Oncol.*, 2004, 22, 1234–1241.
- [66] Morrow, C. Paul, Brian N. Bundy, Howard D. Homesley, William T. Creasman, Ned B. Hornback, Robert Kurman, and J. Tate Thigpen. “Doxorubicin as an adjuvant following surgery and radiation therapy in patients with

- high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study.” *Gynecologic oncology* 36, no. 2 (1990): 166–171.
- [67] Tierney, Ryan M., Matthew A. Powell, David G. Mutch, Randall K. Gibb, Janet S. Rader, and Perry W. Grigsby. “Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer.” *Radiation Medicine* 25, no. 9 (2007): 439–445.
- [68] Farghaly, SA. Radiation Sensitivity of Endometrial Cancer in Vitro. *Gynec Oncol.*, 1992, 47, pp. 130–132.
- [69] Greven, Kathryn, Kathryn Winter, Kelly Underhill, Jim Fontenesci, Jay Cooper, and Tom Burke. “Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer.” *Gynecologic Oncology* 103, no. 1 (2006): 155–159.
- [70] Hogberg, Thomas, Mauro Signorelli, Carlos Freire De Oliveira, Roldano Fossati, Andrea Alberto Lissoni, Bengt Sorbe, Håkan Andersson et al. “Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies.” *European Journal of Cancer* 46, no. 13 (2010): 2422–2431.
- [71] Nomura, H., D. Aoki, F. Takahashi, N. Katsumata, Y. Watanabe, I. Konishi, T. Jobo, M. Hatae, M. Hiura, and N. Yaegashi. “Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).” *Annals of Oncology* 22, no. 3 (2011): 636–642.
- [72] Randall, Marcus E., Virginia L. Filiaci, Hyman Muss, Nick M. Spirtos, Robert S. Mannel, Jeffrey Fowler, J. Tate Thigpen, and Jo Ann Benda. “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.” *Journal of Clinical Oncology* 24, no. 1 (2006): 36–44.
- [73] Secord, Angeles Alvarez, Laura J. Havrilesky, Victoria Bae-Jump, Jeanette Chin, Brian Calingaert, Amy Bland, Teresa L. Rutledge, Andrew Berchuck, Daniel L. Clarke-Pearson, and Paola A. Gehrig. “The role of multimodality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.” *Gynecologic Oncology* 107, no. 2 (2007): 285–291.
- [74] Huh, W. K., J. M. Straughn, A. Mariani, K. C. Podratz, L. J. Havrilesky, A. Alvarez-Secord, M. A. Gold et al. “Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.” *International Journal of Gynecologic Cancer* 17, no. 4 (2007).
- [75] Bristow, Robert E., Antonio Santillan, Marianna L. Zahurak, Ginger J. Gardner, Robert L. Giuntoli II, and Deborah K. Armstrong. “Salvage cytoreductive surgery for recurrent endometrial cancer.” *Gynecologic Oncology* 103, no. 1 (2006): 281–287.
- [76] Thigpen, Tate, Mark F. Brady, Howard D. Homesley, John T. Soper, and Jeffrey Bell. “Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.” *Journal of Clinical Oncology* 19, no. 2 (2001): 364–367.
- [77] Thigpen, J. Tate, Mark F. Brady, Ronald D. Alvarez, Mark D. Adelson, Howard D. Homesley, Alberto Manetta, John T. Soper, and Fred T. Given. “Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.” *Journal of Clinical Oncology* 17, no. 6 (1999): 1736.
- [78] Ma, B. B. Y., Amit Oza, E. Eisenhauer, G. Stanimir, M. Carey, W. Chapman, E. Latta et al. “The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers—a study of the National Cancer Institute of Canada Clinical Trials Group.” *International Journal of Gynecologic Cancer* 14, no. 4 (2004).
- [79] Asbury, Robert F., Virginia L. Brunetto, Roger B. Lee, Gary Reid, and Thomas F. Rocereto. “Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.” *American Journal of Clinical Oncology* 25, no. 6 (2002): 557–560.
- [80] Van Wijk, F. H., M. E. L. Van der Burg, Curt W. Burger, Ignace Vergote, and Helena C. van Doorn. “Management of recurrent endometrioid endometrial carcinoma: an overview.” *International Journal of Gynecologic Cancer* 19, no. 3 (2009).
- [81] Whitney, Charles W., Virginia L. Brunetto, Richard J. Zaino, Samuel S. Lentz, Joel Sorosky, Deborah K. Armstrong, and Roger B. Lee. “Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.” *Gynecologic Oncology* 92, no. 1 (2004): 4–9.
- [82] Fiorica, James V., Virginia L. Brunetto, Parviz Hanjani, Samuel S. Lentz, Robert Mannel, and Willie Andersen. “Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.” *Gynecologic Oncology* 92, no. 1 (2004): 10–14.
- [83] Pandya, Kishan J., B. Y. Yeap, Louis M. Weiner, James E. Krook, John K. Erban, Roger A. Schinella, and Thomas E. Davis. “Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882).” *American Journal of Clinical Oncology* 24, no. 1 (2001): 43–46.
- [84] Rendina, G. M., C. Donadio, M. e-al Fabri, P. Mazzoni, and P. Nazzicone. “Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma.” *European Journal of Obstetrics & Gynecology and Reproductive Biology* 17, no. 4 (1984): 285–291.
- [85] Decruze, S. B., Green, J. A. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. *Int J Gynecol Cancer.*, 2007, 17, 964–978.
- [86] Sovak, Mika A., Martee L. Hensley, Jakob Dupont, Nicole Ishill, Kaled M. Alektiar, Nadeem Abu-Rustum, Richard Barakat et al. “Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV

- endometrial cancer: a retrospective study." *Gynecologic Oncology* 103, no. 2 (2006): 451–457.
- [87] Fleming, G. F., V. L. Filiaci, R. C. Bentley, T. Herzog, J. Sorosky, L. Vaccarello, and H. Gallion. "Phase III randomized trial of doxorubicin+ cisplatin versus doxorubicin+ 24-h paclitaxel+ filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study." *Annals of Oncology* 15, no. 8 (2004): 1173–1178.
- [88] Fleming, Gini F., Virginia L. Brunetto, David Cella, Katherine Y. Look, Gary C. Reid, Adnan R. Munkarah, Richard Kline, Robert A. Burger, Annkathryn Goodman, and R. Tucker Burks. "Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study." *Journal of Clinical Oncology* 22, no. 11 (2004): 2159–2166.
- [89] Mutter, George L., Ming-Chieh Lin, Jeffrey T. Fitzgerald, Jennifer B. Kum, Jan PA Baak, Jacqueline A. Lees, Liang-Ping Weng, and Charis Eng. "Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers." *Journal of the National Cancer Institute* 92, no. 11 (2000): 924–930.
- [90] Colombo, N., S. McMeekin, P. Schwartz, J. Kostka, C. Sessa, P. Gehrig, R. Holloway, P. Braly, D. Matei, and M. Einstein. "A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer." *Journal of Clinical Oncology* 25, no. 18_suppl (2007): 5516.
- [91] Oza, Amit M., Laurie Elit, Ming-Sound Tsao, Suzanne Kamel-Reid, Jim Biagi, Diane Michele Provencher, Walter H. Gotlieb et al. "Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group." *Journal of Clinical Oncology* 29, no. 24 (2011): 3278.
- [92] Oza, A. M., L. Elit, J. Biagi, W. Chapman, M. Tsao, D. Hedley, C. Hansen, J. Dancey, and E. Eisenhauer. "Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer—NCIC IND 160." *Journal of Clinical Oncology* 24, no. 18_suppl (2006): 3003.
- [93] Khalifa, Mahmoud A., Robert S. Mannel, Stuart D. Haraway, Joan Walker, and Kyung-Whan Min. "Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas." *Gynecologic Oncology* 53, no. 1 (1994): 84–92.
- [94] Oza, Amit M., Elizabeth A. Eisenhauer, Laurie Elit, Jean-Claude Cutz, Akira Sakurada, Ming S. Tsao, Paul J. Hoskins et al. "Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148." *Journal of Clinical Oncology* 26, no. 26 (2008): 4319–4325.
- [95] Abeler, Vera M., Ignace B. Vergote, Kjell E. Kj., Zzrstad, and Claes G. Tropé. "Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern." *Cancer: Interdisciplinary International Journal of the American Cancer Society* 78, no. 8 (1996): 1740–1747.
- [96] DiSaia, P. J., Creasman, W. T. *Clinical Gynecologic Oncology*. 6th ed. St. Louis, MO: Mosby Inc, 2002.
- [97] Acharya, Sheetal, Martee L. Hensley, Anthony C. Montag, and Gini F. Fleming. "Rare uterine cancers." *The Lancet Oncology* 6, no. 12 (2005): 961–971.
- [98] Goff, Barbara A., Daniel Kato, Rodney A. Schmidt, Marit Ek, Judith A. Ferry, Howard G. Muntz, Joanna M. Cain, Hisham K. Tamimi, David C. Figge, and Benjamin E. Greer. "Uterine papillary serous carcinoma: patterns of metastatic spread." *Gynecologic Oncology* 54, no. 3 (1994): 264–268.
- [99] Bristow, Robert E., Fariba Asrari, Edward L. Trimble, and F. J. Montz. "Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I–III) disease." *Gynecologic Oncology* 81, no. 2 (2001): 279–286.
- [100] Chan, John K., Vera Loizzi, Mark Youssef, Kathryn Osann, Joanne Rutgers, Steven A. Vasilev, and Michael L. Berman. "Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium." *Gynecologic Oncology* 90, no. 1 (2003): 181–185.
- [101] Sutton, Gregory, Janice H. Axelrod, Brian N. Bundy, Tapan Roy, Howard Homesley, Roger B. Lee, Paola A. Gehrig, and Richard Zaino. "Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group." *Gynecologic Oncology* 100, no. 2 (2006): 349–354.
- [102] Fakiris, Achilles J., David H. Moore, Shailaja R. Reddy, Katherine Y. Look, Constantin T. Yiannoutsos, Marcus E. Randall, and Higinia R. Cardenas. "Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97–01) study." *Gynecologic Oncology* 96, no. 3 (2005): 818–823.
- [103] Huh, Warner K., Matthew Powell, Charles A. Leath III, J. Michael Straughn Jr, David E. Cohn, Michael A. Gold, Camille A. Falkner et al. "Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy." *Gynecologic Oncology* 91, no. 3 (2003): 470–475.
- [104] Dietrich III, C. S., S. C. Modesitt, P. D. DePriest, F. R. Ueland, J. Wilder, M. B. Reedy, E. J. Pavlik et al. "The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)." *Gynecologic Oncology* 99, no. 3 (2005): 557–563.
- [105] Havrilesky, Laura J., Angeles Alvarez Secord, Victoria Bae-Jump, Tina Ayeni, Brian Calingaert, Daniel L. Clarke-Pearson, Andrew Berchuck, and Paola A. Gehrig. "Outcomes in surgical stage I uterine papillary serous carcinoma." *Gynecologic Oncology* 105, no. 3 (2007): 677–682.
- [106] Kelly, Michael G., David M. O'malley, Pei Hui, Jessica McAlpine, Herbert Yu, Thomas J. Rutherford, Masoud Azodi, and Peter E. Schwartz. "Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based

- chemotherapy." *Gynecologic Oncology* 98, no. 3 (2005): 353–359.
- [107] Fader, A. Nickles, R. Drake, D. O'Malley, L. Havrilesky, P. Rose, F. Abushahin, E. Tuller et al. "Effect of adjuvant platinum/taxane chemotherapy with or without radiation therapy in uterine papillary serous carcinoma." In *Gynecologic Oncology*, vol. 108, no. 3, pp. S27–S28. 525 B ST, STE 1900, San Diego, CA 92101–4495 USA: Academic Press Inc. Elsevier Science, 2008.
- [108] Zanotti, Kristine M., Jerome L. Belinson, Alexander W. Kennedy, Kenneth D. Webster, and Maurie Markman. "The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma." *Gynecologic Oncology* 74, no. 2 (1999): 272–277.
- [109] Slomovitz, Brian M., Thomas W. Burke, Patricia J. Eifel, Lois M. Ramondetta, Elvio G. Silva, Anuja Jhingran, Jonathan C. Oh et al. "Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases." *Gynecologic Oncology* 91, no. 3 (2003): 463–469.
- [110] Ramondetta, Lois, Thomas W. Burke, Charles Levenback, Michael Bevers, Diane Bodurka-Bevers, and David M. Gershenson. "Treatment of uterine papillary serous carcinoma with paclitaxel." *Gynecologic Oncology* 82, no. 1 (2001): 156–161.
- [111] Grice, Jeffrey, Marit Ek, Benjamin Greer, Wui-Jin Koh, Howard G. Muntz, Joanna Cain, Hisham Tamimi, Keith Stelzer, David Figge, and Barbara A. Goff. "Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients." *Gynecologic Oncology* 69, no. 1 (1998): 69–73.
- [112] Gehrig, P.A., Morris, D.E., Van Le, L. Uterine serous carcinoma: a comparison of therapy for advanced-stage disease. *Int J Gynecol Cancer.*, 2004, 14(3), 515–520.
- [113] Sutton, Gregory, Janice H. Axelrod, Brian N. Bundy, Tapan Roy, Howard D. Homesley, John H. Malfetano, Borys R. Mychalczak, and Mary E. King. "Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study." *Gynecologic Oncology* 97, no. 3 (2005): 755–763.
- [114] Secord A. A., Angeles Alvarez, Laura J. Havrilesky, Victoria Bae-Jump, Jeanette Chin, Brian Calingaert, Amy Bland, Teresa L. Rutledge, Andrew Berchuck, Daniel L. Clarke-Pearson, and Paola A. Gehrig. "The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer." *Gynecologic Oncology* 107, no. 2 (2007): 285–291.
- [115] Randall, Marcus E., Virginia L. Filiaci, Hyman Muss, Nick M. Spirto, Robert S. Mannel, Jeffrey Fowler, J. Tate Thigpen, and Jo Ann Benda. "Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study." *Journal of Clinical Oncology* 24, no. 1 (2006): 36–44.
- [116] Matthews, Roland P., Juana Hutchinson-Colas, Mitchell Maiman, Rachel G. Fruchter, E. Jason Gates, Darlene Gibbon, Jean Claude Remy, and Alexander Sedlis. "Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women." *Gynecologic Oncology* 65, no. 2 (1997): 206–212.
- [117] Murphy, Kevin T., Jacob Rotmensch, S. Diane Yamada, and Arno J. Mundt. "Outcome and patterns of failure in pathologic stages I–IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy." *International Journal of Radiation Oncology Biology Physics* 55, no. 5 (2003): 1272–1276.
- [118] Thomas, M., A. Mariani, J. D. Wright, E. O. S. Madarek, M. A. Powell, D. G. Mutch, K. C. Podratz, and S. C. Dowdy. "Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review." *Gynecologic Oncology* 108, no. 2 (2008): 293–297.
- [119] Cirisano Jr, Frank D., Stanley J. Robboy, Richard K. Dodge, Rex C. Bentley, Hannah R. Krigman, Ingrid S. Synan, John T. Soper, and Daniel L. Clarke-Pearson. "The outcome of stage I–II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma." *Gynecologic Oncology* 77, no. 1 (2000): 55–65.
- [120] Vergote, I. B., V. M. Abeler, K. E. Kjørstad, and C. Trope. "Clear cell carcinoma of the endometrium: Prognosis, metastatic pattern and treatment modalities. A study of 181 patients." *Giornale Italiano di Oncologia* 15, no. 1 (1995): 65–66.
- [121] Abeler, V. M., Kjørstad, K. E. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. *Gynecol Oncol.*, 1991, 40(3), 207–217.
- [122] Sutton, Gregory, Janice H. Axelrod, Brian N. Bundy, Tapan Roy, Howard D. Homesley, John H. Malfetano, Borys R. Mychalczak, and Mary E. King. "Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study." *Gynecologic Oncology* 97, no. 3 (2005): 755–763.
- [123] Thomakos, N., K. Galaal, K. A. Godfrey, D. Hemming, R. Naik, M. H. Hatem, and A. Lopes. "Primary endometrial squamous cell carcinoma." *Archives of Gynecology and Obstetrics* 278, no. 2 (2008): 177–180.
- [124] Goodman, Annkathryn, Lawrence R. Zukerberg, Laurel W. Rice, Arlan F. Fuller, Robert H. Young, and Robert E. Scully. "Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature." *Gynecologic Oncology* 61, no. 1 (1996): 54–60.
- [125] Kennedy, Andrew S., Leslie R. DeMars, Lisa M. Flannagan, and Mahesh A. Varia. "Primary squamous cell carcinoma of the endometrium: a first report of adjuvant chemoradiation." *Gynecologic Oncology* 59, no. 1 (1995): 117–123.
- [126] Navarra, Isabelle, Massimo Usel, Elisabetta Rapiti, Isabelle Neyroud-Caspar, Marie-Françoise Pelte, Christine Bouchardy, and Patrick Petignat. "Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment?" *Gynecologic Oncology* 114, no. 3 (2009): 448–451.

- [127] Šparac, V., B. Ujević, M. Ujević, Z. Pagon-Belina, and U. Marton. “Successful pregnancy after hysteroscopic removal of grade I endometrial carcinoma in a young woman with Lynch syndrome.” *International Journal of Gynecologic Cancer* 16, no. Suppl 1 (2006).
- [128] Boks, Dominique E. S., Aliana P. Trujillo, Adri C. Voogd, Hans Morreau, Gemma G. Kenter, and Hans F. A. Vasen. “Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer.” *International Journal of Cancer* 102, no. 2 (2002): 198–200.
- [129] Shih, K. K., K. Garg, D. A. Levine, N. D. Kauff, N. R. Abu-Rustum, R. A. Soslow, and R. R. Barakat. “Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40 years of age and younger.” *Gynecologic Oncology* 123, no. 1 (2011): 88–94.
- [130] Howard, David, David James, Kate Murphy, Jezabel Garcia-Parra, Belen Pan-Castillo, Stuart Rex, Annemarie Moul et al. “Dinaciclub, a bimodal agent effective against endometrial cancer.” *Cancers* 13, no. 5 (2021): 1135.
- [131] Musacchio, Lucia, Giuseppe Caruso, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Laura Attademo, Rosa Tambaro et al. “PARP inhibitors in endometrial cancer: current status and perspectives.” *Cancer Management and Research* 12 (2020): 6123.

第 10 章

子宫内膜癌患者的手术治疗

Surgical Procedures for Treating Patients with Endometrial Cancer

- [1] Disaia, PJ, PJ Morrow, DE, Townsend. Cancer of the corpus. *Synopsis of Gynecologic Oncology*, John Wiley and Sons Inc., New York (1975), pp. 111–135.
- [2] Morrow, PJ, JP Curtin. Tumors of the endometrium. *Synopsis of Gynecologic Oncology*, Churchill Livingstone Inc., New York (1998), pp. 151–185.
- [3] Disaia, PJ, WT Creasman. Adenocarcinoma on the uterus. *Clinical Gynecologic Cancer Surgery*, Mosby Inc., St. Louis (2002), pp. 137–171.
- [4] Childers, JM, PR Brzechffa, KD Hatch, and EA Surwit. Laparoscopically assisted surgical staging (LASS) of endometrial cancer. *Gynecol. Oncol.* 1993, pp. 33–e.
- [5] Gemignani, ML, JP Curtin, J Zelmanovich, DA Patel. Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges *Gynecol. Oncol.* 1993, 73, pp. 5–11.
- [6] Manolitas, TP, AJ McCartney. Total laparoscopic hysterectomy in the management of endometrial carcinoma. *Am. Assoc. Gynecol. Laparosc.* 2002, 9, pp. 54–62.
- [7] Scribner, DR, JL Walker, GA Johnson, SD McMeekin, MA Gold, RS Mannel. Surgical management of early-stage endometrial cancer in the elderly: Is laparoscopy feasible?. *Gynecol. Oncol.* 2001, 83, pp. 536–568.
- [8] Possover, M, N Krause, K Plaul, R Kuhne-Heid, A Schneider. Laparoscopic paraaortic and pelvic lymphadenectomy: experience with 150 patients and review of the literature. *Gynecol. Oncol.* 1998, 1, pp. 19–28.
- [9] Barakat, RR, G Lev, AJ Hummer, Y Sonoda, D Schi. Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. *Gynecol. Oncol.* 2007, 105(1), pp. 150–156.
- [10] Bell, MC, J Torgerson, U Seshadri-Kreaden, AW Suttle, S Hunt. Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy, and robotic techniques. *Gynecol. Oncol.* 2008, 111, pp. 407–411.
- [11] Gehrig, PA, A Cantrell, A Shafer, LN Abaid, A Mendivil, JF boggess. What is the optimal minimally invasive procedure for endometrial cancer staging in the obese and morbidly obese woman? *Gynecol. Oncol.* 2008, 111, pp. 41–45.
- [12] DeNardis, SA, RW Holoway, RW Bigsby, D Ppikaart, S Ahmed, NJ finkler. Robotically assisted hysterectomy versus laparoscopic total abdominal hysterectomy and lymphadenectomy for endometrial cancer. *Gynecol. Oncol.* 2008, 111(3), pp. 412–417.
- [13] Boggess, JF, PA Gehrig, L Cantrell, A Shafer, M Ridgway, EN Skinner, WC Fowler. A comparative study for 3 methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. *Am. J. Obstet. Gynecol.* 2008, 199(4), pp. 360–362.
- [14] Seamon, LG, DE Cohn, MS Henretta, KH Kim, MJ Carlson, GS Phillips, JM Fowler. Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy. *Gynecol. Oncol.* 2009, 113, pp. 36–41.
- [15] Magrina, JF. Outcomes of laparoscopic treatment for endometrial cancer. *Curr. Opin. Obstet. Gynecol.* 2005, 17, pp. 343–346.
- [16] Holub, Z. Laparoscopic management of early endometrial cancer: current status. *Gynecol. Surg.* 2006, 3, pp. 245–252.
- [17] Walker, JL, M Piedmonte, NM Spirtos, SM Eisenkop, JB Schlaerth, RS Mannel, G Spiegel, R Barakat, ML Pearl, SK. Sharma. Randomized trial of laparoscopy vs. laparotomy for comprehensive surgical staging of uterine cancer: a Gynecologic Oncology Group Study (LAP2). *J. Clin. Oncol.* 2009, 27, pp. 5331–5336.
- [18] O'Hanlan, KA, GS Huang, AC Garnier, SL Dibble, ML Reuland, L Lopez, RL Pinto. Total laparoscopic hysterectomy versus total abdominal hysterectomy: cohort review of patients with uterine neoplasia. *J. Soc. Laparosc. Surg.* 2005, 9(3), pp. 1–9.
- [19] Frigerio, L, A Gallo, F Ghezzi, G Trezzi, M Lussana, M. Franchi Laparoscopic-assisted vaginal hysterectomy versus abdominal hysterectomy in endometrial cancer. *Int. J. Gynecol. Obstet.* 2006, 93 (3), pp. 209–213.
- [20] Zullo, F, S Palmoba, T Russo, A. Falbo, M. costantino, A. Tolino, E. Zupi, P. Tagliaferri, S. Vennta. A prospective randomized comparison between laparoscopic and laparotomic approaches in women with early stage endometrial cancer: a focus on quality of life. *Am. J. Obstet. Gynecol.* 2005, 193 (4), pp. 1344–1352.
- [21] Childers JM, Surwit EA. Combined laparoscopic and vaginal surgery for the management of two cases of stage I endometrial cancer. *Gynecol. Oncol.* 1992; 45: 46–51.
- [22] Eltabbakh GH, Shamonki MI, Moody JM, LL Garafano. Laparoscopy as the primary modality for the treatment of women with endometrial carcinoma. *Cancer.* 2001; 91(2) : 378–387.
- [23] Kim DY, Kim MK, Kim JH, D.S. Suh, Y.M. Kim, Y.T.

- Kim, J.E.Mok, J.H. Nam. Laparoscopic-assisted vaginal hysterectomy versus abdominal hysterectomy in patients with stage I and II endometrial cancer. *Int. J. Gynecol Cancer*. 2005; 15: 932–937.
- [24] Ghezzi F, Cromi A, Bergamini V, S Uccella, P Bertta, M Franchi, P Bolis. Laparoscopic management of endometrial cancer in no obese and obese women: a consecutive series. *J. Minim. Invasive Gynecol*. 2006; 13: 269–275.
- [25] Yu CK, Cutner A, Mould T, Olaitan A. Total laparoscopic hysterectomy as a primary surgical treatment for endometrial cancer in morbidly obese women. *BJOG*. 2005; 112: 115–117.
- [26] Scribner DR Jr, Walker JL, Johnson GA, McMeekin SD, Gold MA, Mannel RS. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? *Gynecol. Oncol*. 2001; 83: 563–568.
- [27] Palomba S, Falbo A, Mocciaro R, Russo T, Zullo F. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs) *Gynecol. Oncol*. 2009; 112: 415–421.
- [28] Ju W, Myung SK, Kim Y, Choi HJ, Kim SC. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a meta-analysis. *Int. J. Gynecol. Cancer*. 2009; 19: 400–406.
- [29] Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, Spiegel G, Barakat R, Pearl ML, Sharma SK. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. *J. Clin. Oncol*. 2010; 65 (8), pp. 503-505.
- [30] Walker, Joan L, Marion R Piedmonte, Nick M Spirtos, Scott M Eisenkop, John B Schlaerth, Robert S Mannel, Richard Barakat, Michael L Pearl, and Sudarshan K Sharma. "Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study." *Journal of Clinical Oncology* 30, no. 7 (2012): 695.
- [31] Childers JM, Brzechffa PR, Hatch KD, Surwit EA. Laparoscopically assisted surgical staging (LASS) of endometrial cancer. *Gynecol. Oncol*. 1993 Oct; 51(1): 33–38.
- [32] Eltabbakh GH, Shamonki MI, Moody JM, Garafano LL. Laparoscopy as the primary modality for the treatment of women with endometrial carcinoma. *Cancer* 2001 15; 91(2): 378–387.
- [33] Köhler C, Klemm P, Schau A, Possover M, Krause N, Tozzi R, Schneider A. Introduction of transperitoneal lymphadenectomy in a gynecologic oncology center: analysis of 650 laparoscopic pelvic and/or paraaortic transperitoneal lymphadenectomies. *Gynecol. Oncol*. 2004; 95(1): 52–61.
- [34] Magrina JF, Weaver AL. Laparoscopic treatment of endometrial cancer: five-year recurrence and survival rates. *Eur. J. Gynaecol. Oncol*. 2004; 25(4): 439–441.
- [35] Malur S, Possover M, Michels W, Schneider A. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer—a prospective randomized trial. *Gynecol. Oncol*. 2001; 80(2): 239–244.
- [36] Fram KM. Laparoscopically assisted vaginal hysterectomy versus abdominal hysterectomy in stage I endometrial cancer. *Int. J. Gynecol Cancer*. 2002; 12(1): 57–61.
- [37] Scribner DR Jr, Walker JL, Johnson GA, McMeekin SD, Gold MA, Mannel RS. Laparoscopic pelvic and paraaortic lymph node dissection in the obese. *Gynecol. Oncol*. 2002; 84(3): 426–430.
- [38] Scribner DR Jr, Walker JL, Johnson GA, McMeekin SD, Gold MA, Mannel RS. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? *Gynecol. Oncol*. 2001; 83(3): 563–568.
- [39] Haddad, Shadi, Keyvan Ghadimi, Ranna Abrishamkar, and Nazli Sadat Meshinchi Asl. Comparing laparoscopy and laparotomy procedures in the radical hysterectomy surgery for endometrial cancer: a basic review. *American Journal of Translational Research* 13, no. 4 (2021): 2456.
- [40] Farghaly SA. Observation on the role of assisted laparoscopic surgery in patients with early stage endometrial cancer. *Am. J. Obstet Gynecol* 2010; 202(1): e–20.
- [41] Eltabbakh GH. Effect of surgeon's experience on the surgical outcome of laparoscopic surgery for women with endometrial cancer. *Gynecologic Oncology* 2000, 78: 58–61.
- [42] Janda M, Gebiski V, Brand A, Hogg R, Jobling TW, Land R. Quality of life after total laparoscopic hysterectomy versus abdominal hysterectomy for stage I endometrial cancer (LACE): a randomized trial. *Lancet Oncology* 2010, 11: 772–780.
- [43] Office for National Statistics, England. 2010. *Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2007, England*. Series MB1, No. 38. London: National Statistics.
- [44] Welsh Cancer Intelligence and Surveillance Unit. 2010. *Cancer Registrations in Wales 2007*. Cardiff: Welsh Cancer Intelligence and Surveillance Unit.
- [45] Attard Montalto S, Coutts M, Devaja O, Summers J, Jyothirmayi R, Papadopoulos a. Accuracy of frozen section diagnosis at surgery in pre-malignant and malignant lesions of the endometrium. *Eur. J. Gynaecol Oncol*. 2008; 29; 435–440.
- [46] Litta P, Fracas M, Pozzan C, Merlin F, Saccardi C, Sacco G, Mannici D. Laparoscopic management of early stage endometrial cancer. *Eur. J. Gynaecol. Oncol*. 2003; 24: 41–44.
- [47] Ghezzi F, Cromi A, Bergamini V, Uccella S, Beretta P, Franchi M, Bolis P. Laparoscopic management of endometrial cancer in obese and non-obese women: a consecutive analysis. *J Minim. Invasive Gynecol*. 2006; 13: 269–275.
- [48] Scribner DR, Walker JL, Johnson GA, McMeekin SD, Gold MA, Mannel RS. Surgical management of early stage endometrial cancer in the elderly: is it feasible? *Gynecol. Oncol*. 2001; 83: 563–568.
- [49] Holub Z, Jabor A, Bartos P, Eim J, Urbanek S, Pivovaynikova R. Laparoscopic surgery for endometrial cancer: long-term results of a multicentric study. *Eur. J. Gynaecol Oncol*. 2002; 23: 305–310.
- [50] Manolitsas TP, McCartney AJ. Total laparoscopic hysterectomy in the management of endometrial carcinoma. *J. Am. Assoc. Gynecol. Laparosc*. 2002; 9: 54–62.
- [51] Obermair A, Manolitsas TP, Leung Y, Hammond IG,

- McCartney AJ. Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. *Gynecol. Oncol.* 2004; 92: 789–793.
- [52] Kalogiannidis I, Lambrechts S, Amant F, Neven P, VanGorp T, Vergote I. Laparoscopically assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence and long-term outcome. *Am. J. Obstet Gynecol.* 2007; 196: 248.e1–e8.
- [53] Kim DY, Kim MK, Kim JH, Suh DS, Kim YM, Kim YT, Mok JE, Nam JH. Laparoscopic-assisted vaginal hysterectomy versus abdominal hysterectomy in patients with stage I and II endometrial cancer. *Int. J. Gynecol. Cancer.* 2005; 15: 932–937.
- [54] Frigerio L, Gallo A, Ghezzi F, Trezzi G, Lussana M, Franchi M. Laparoscopic-assisted vaginal hysterectomy versus abdominal hysterectomy in endometrial cancer. *Int. J. Gynaecol. Obstet.* 2006; 93: 209–213.
- [55] Tollund L, Hansen B, Kjer JJ. Laparoscopic-assisted vaginal vs. abdominal surgery in patients with endometrial cancer stage I. *Acta Obstet. Gynecol. Scand.* 2006; 85: 1138–1141.
- [56] Gil-Moreno A, Díaz-Feijoo B, Morchón S, Xercavinas J. Analysis of survival after laparoscopic-assisted vaginal hysterectomy compared with the conventional abdominal approach for early-stage endometrial carcinoma: a review of the literature. *J. Minim Invasive Gynecol.* 2006; 13: 26–35.
- [57] Gemignani ML, Curtin JP, Zelmanovich J, Patel DA, Venkatraman E, Barakat RR. Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. *Gynecol. Oncol.* 1999; 73: 5–11.
- [58] Einarsson JI, Matteson KA, Schulkin J, Chavau NR, Sangi-Haghpeykar H. Minimally invasive hysterectomies—a survey on attitudes and barriers among practicing gynecologists. *J. Minim Invasive Gynecol.* 2010; 17: 167–175.
- [59] Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa MS, Jacoby A. Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. *Obstet Gynecol.* 2009; 114: 1041–1048.
- [60] Gehrig PA, Cantrell LA, Shafer A, Abaid LM, Mendivil A, Boggess JF. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman? *Gynecol. Oncol.* 2008; 111: 41–45.
- [61] Seamon LG, Cohn DE, Henretta MS, Kim KH, Carlson MJ, Phillips GS, Fowler JM. Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy? *Gynecol. Oncol.* 2009; 113: 36–41.
- [62] Leitao MM, Jr., Briscoe G, Santos K, Winder A, Jewell EL, Hoskins WJ, Gardner GJ. Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approach. *Gynecol. Oncol.* 2012; 125: 394–399.
- [63] Advincula AP, Wang K. Evolving role and current state of robotics in minimally invasive gynecologic surgery. *J. Minim Invasive Gynecol.* 2009; 16(3): 291–301.
- [64] Decloedt J, Vergote I. Laparoscopy in gynaecologic oncology: a review. *Crit. Rev. Oncol. Hematol.* 1999; 31(1): 15–26.
- [65] Diaz-Arrastia C, Jurnalov C, Gomez G, Townsend C Jr. Laparoscopic hysterectomy using a computer-enhanced surgical robot. *Surg. Endosc.* 2002; 16(9): 1271–1273.
- [66] Gerhig P, Cantrell LA, Shafer A, Abaid LN, Mendivil A, Boggess JF. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman? *Gynecol. Oncol.* 2008; 111: 41–45.
- [67] Seamon LG, Cohn DE, Henretta MS, Kim KH, Carlson MJ, Phillips GS, Fowler JM. Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy? *Gynecol. Oncol.* 2009; 113: 36–41.
- [68] Sert MB, Abeler VM. Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital. *Gynecol. Oncol.* 2011; 121(3): 600–604.
- [69] Estape R, Lambrou N, Diaz R, Dunkin N, Rivera A. A case matched analysis of robotic radical hysterectomy with lymphadenectomy compared with laparoscopy and laparotomy. *Gynecol. Oncol.* 2009; 113(3): 357–361.
- [70] Magrina JF, Kho RM, Weaver AL, Montero RP, Magtiby PM. Robotic radical hysterectomy: comparison with laparoscopy and laparotomy. *Gynecol. Oncol.* 2008; 109(1): 86–91.
- [71] Schreuder HW, Zweemer RP, van Baal WM, Van De Lande J, Dijkstra JC, Verheijen. From open radical hysterectomy to robot-assisted laparoscopic radical hysterectomy for early stage cervical cancer: aspects of a single institution learning curve. *Gynecol. Surg.* 2010; 7(3): 253–258.
- [72] Advincula AP, Wang K. Evolving role and current state of robotics in minimally invasive gynecologic surgery. *J. Minim Invasive Gynecol.* 2009; 16(3): 291–301.
- [73] Lim PC, Kang E, Park do H. Learning curve and surgical outcome for robotic-assisted hysterectomy with lymphadenectomy: case-matched controlled comparison with laparoscopy and laparotomy for treatment of endometrial cancer. *J. Min. Invasive Gynecol.* 2010; 17(6): 739–748.
- [74] Lowe MP, Johnson PR, Kamelle SA, Johnson PR, Tillmanns TD. A multiinstitutional experience with robotic-assisted hysterectomy with staging for endometrial cancer. *Obstet. Gynecol.* 2009; 114: 236–243.
- [75] Seamon LG, Cohn DE, Henretta MS, Kim KH, Carlson MJ, Phillips GS, Fowler JM. Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy? *Gynecol. Oncol.* 2009; 113: 36–41.
- [76] Boggess JF, Gehrig PA, Cantrell L, Shafer AR, Ridgway M, Skinner EN, Fowler WC. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. *Am. J. Obstet Gynecol.* 2008; 199: 360e1–360e9.
- [77] Seamon LG, Bryant SA, Rheaume PS, Kimball KJ, Huh WK, Fowler JM, Phillips GS, Cohn DG. Comprehensive surgical staging for endometrial cancer in obese patients:

- comparing robotics and laparotomy *Obstet Gynecol.* 2009; 114: 16–21.
- [78] Bell MC, Torgerson J, Seshadri-Kreaden U, Suttle AW, Hunt S. Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques *Gynecol. Oncol.* 2008; 111: 407–411.
- [79] Farghaly SA. Current surgical treatment option utilizing robot-assisted laparoscopic surgery in obese patients with endometrial cancer: Farghaly's Technique. *J. Egypt Canc Inst.* 2013; 25(2) 57–61.
- [80] Barnett JC, Judd JP, Wu JM, Scales Jr. CD, Myers ER, Havrillllesky LJ. Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer *Obstet Gynecol.* 2010; 116: 685–693.
- [81] Fader AN, Escobar PF. Laparoendoscopic single-site surgery (LESS) in gynecologic oncology: technique and initial report *Gynecol. Oncol.* 2009; 114: 157–161.
- [82] Kim, TJ, Lee, YY, Cha, HH, Kim, CJ, Choi, CH, Lee, JW, Bae, D-S, Lee, J, & Kim, B-G., Single-port-access laparoscopic-assisted vaginal hysterectomy versus conventional laparoscopic-assisted vaginal hysterectomy: a comparison of perioperative outcomes *Surg. Endosc.* 2010; 24: 2248–2252.
- [83] Tillmanns T, Lowe MP. Safety, feasibility, and costs of outpatient laparoscopic extraperitoneal aortic nodal dissection for locally advanced cervical carcinoma. *Gynecol. Oncol.* 2007; 106: 370–374.
- [84] Franco-Camps S, Cabrera S, Perez-Benavente A, Diaz-Feijoo, Bradburg M, Xercavins J, Gil-Moreno A. Extraperitoneal laparoscopic approach for diagnosis and treatment of aortic lymph node recurrence in gynecologic malignancy. *J. Minim Invasive Gynecol.* 2010; 17: 570–575.
- [85] Occelli B, Narducci F, Lanvin D, Querleu D, Coste E, Castelain B, Gibon D, Leblanc E. De novo adhesions with extraperitoneal endosurgical para-aortic lymphadenectomy versus transperitoneal laparoscopic para-aortic lymphadenectomy: a randomized experimental study. *Am. J. Obstet Gynecol.* 2000; 183: 529–533.
- [86] Leblanc E, Narducci F, Frumovitz M, Lesoin A, Castelain B, Baranzelli MC, Taieb S, Fournier C, Querleu D. Therapeutic value of pretherapeutic extraperitoneal laparoscopic staging of locally advanced cervical carcinoma. *Gynecol. Oncol.* 2007; 105: 304–311.
- [87] Mehra G, Weekes AR, Jacobs IJ, Visvanathan D, Menon UJeyarajah AR. Laparoscopic extraperitoneal paraaortic lymphadenectomy: a study of its applications in gynecological malignancies. *Gynecol. Oncol.* 2004; 93: 189–193.
- [88] Goff BA, Muntz HG, Paley PJ, Tamimi HK, Koh WJ, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. *Gynecol. Oncol.* 1999; 74: 436–442.
- [89] Dargent D, Ansquer Y, Mathevet P. Technical development and results of left extraperitoneal laparoscopic paraaortic lymphadenectomy for cervical cancer. *Gynecol. Oncol.* 2000; 87–92.
- [90] Vergote I, Amant F, Berteloot P, Van Gramberen M. Laparoscopic lower para-aortic staging lymphadenectomy in stage IB2, II, and III cervical cancer. *Int. J. Gynecol. Cancer.* 2002; 12: 22–26.
- [91] Sonoda Y, Leblanc E, Querleu D, Castelain B, Papageorgiou TH, Lambaudie E, Narduccif. Prospective evaluation of surgical staging of advanced cervical cancer via a laparoscopic extraperitoneal approach. *Gynecol. Oncol.* 2003; 91: 326–331.
- [92] Occelli B, Narducci F, Lanvin D, Coste E, Legoupils E, Castelain B, Querleu D. Comparison of transperitoneal versus extraperitoneal laparoscopic para-aortic lymphadenectomy: randomized experimental study [in French]. *Ann. Chir.* 2000; 125: 9–17.
- [93] Ahmed A, Zamba G, DeGeest K, Lynch CF. The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992–2002. *Gynecol. Oncol.* 2008, 111: 35–40.
- [94] Administration on Aging. http://www.aoa.gov/AoARoot/Aging_Statistics/future_growth/future_growth.aspx. 2011.
- [95] FIGO stages 1988: Revision: vulva, ovary, corpus. *Gynecol. Oncol.* 1989, 35: 125–127.
- [96] Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int. J. Gynaecol. Obstet.* 2009, 105(2): 103–104.
- [97] Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD, Berman ML. Vaginal hysterectomy a sprimary treatment of endometrial cancer in medically compromised women, *Obstet. Gynecol* 2001, 97 (5pt1): 707–710.
- [98] Susini T, Massi G, Amunni G, Carriero C, Marchionni M, Tadder G, Scarselli G. Vaginal hysterectomy and abdominal hysterectomy for treatment of endometrial cancer in the elderly. *Gynecol. Oncol.* 2005. 96(2): 362–367.
- [99] Bucy GS, Mendenhall WM, Morgan LS, Chafe WE, Wilkinson EJ, Marcus Jr. RB, Million RR. Clinical stage I and II endometrial carcinoma treated with surgery and/or radiation therapy: analysis of prognostic and treatment-related factors. *Gynecol. Oncol.* 1989, 33(3): 290–295.
- [100] Kim YB, Holschneider CH, Ghosh K, Nieberg TK, Montz FG. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. *Cancer* 1997, 79(2): 320–327.
- [101] Creasman WT, Mutch DE, Herzog TJ. ASTEC lymphadenectomy and radiation therapy studies: Are conclusions valid?. *Gynecol. Oncol.* 2010, 116(3): 293–294.
- [102] Berretta R, Merisio C, Melpignano M, Rolla M, Ceccaroni M, Deloris A, Patrelli TS, Nardell GB. Vaginal versus abdominal hysterectomy in endometrial cancer: a retrospective study in a selective population. *Int. J. Gynecol. Cancer* 2008, 18(4): 797–802.
- [103] Smith SM, Hoffman MS: The role of vaginal hysterectomy in the treatment of endometrial cancer. *Am. J. Obstet. Gynecol.* 2007, 197(2): 202–206.
- [104] Mazzon, I, Corrado, G, Masciullo, V, Morricone, D, Ferrandina, G, Scambia, G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. *Fertil. Steril.* 2010, 93, 1286–1289.

第 11 章

晚期子宫内膜癌的治疗方法

Treatment of Advanced Stage Endometrial Cancer

- [1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. (2015). Global cancer statistics, 2012. *CA Cancer J. Clin.* Vol. 65, pp. 87–108.
- [2] National Cancer Institute. (2010). Endometrial Cancer Treatment, In: *National Cancer Institute, 07.28.2010*, <http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/HealthProfessional/page8>.
- [3] Barlin JN, Ueda SM, Bristow RE. (2009). Cytoreductive surgery for advanced and recurrent endometrial cancer: a review of the literature. *Women's Health.* Vol. 5, pp.403–411.
- [4] Goff BA, Goodman A, Muntz HG. (1972). Surgical stage IV endometrial carcinoma: a study of 47 cases. *Gynecol. Oncol.* Vol. 52, pp. 237–240.
- [5] Chi DS, Welshinger M, Venkatraman ES. (1997). The role of surgical cytoreduction in stage IV endometrial carcinoma. *Gynecol. Oncol.* Vol. 67, pp. 56–60.
- [6] Ueda Y, Enomoto T, Miyatake T (2010). Endometrial carcinoma with extra-abdominal metastasis: improved prognosis following cytoreductive surgery. *Ann. Surg. Oncol.* Vol. 17, pp. 1111–1117.
- [7] Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S. (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. *J. Clin. Oncol.* Vol. 22, pp. 3902–3908.
- [8] Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. *J. Clin. Oncol.* Vol. 22, pp. 2159–2166.
- [9] Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M, Zaino R. (2012) Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecol. Oncol.* Vol. 125, pp. 771–773.
- [10] Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M, Yaegashi N. (2011) Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). *Ann. Oncol.* Vol. 22, pp. 636–642.
- [11] Nagao S, Nishio S, Michimae H, Tanabe H, Okada S, Otsuki T, Tanioka M, Fujiwara K, Suzuki M, Kigawa J. (2013) Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/ Intergroup study. *Gynecol. Oncol.* Vol. 131, pp. 567–573.
- [12] Nagao S, Nishio S, Okada S, Otsuki T, Fujiwara K, Tanabe H, Takano M, Hasumi Y, Takei Y, Hasegawa T, Matsumoto T, Fujiwara K, Takekuma M, Nakamura K, Shimada M, Suzuki M, Kigawa J. (2015) What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/ Intergroup study. *Cancer Chemother. Pharmacol.* Vol. 76, pp. 335–642.
- [13] Ueda Y, Miyake T, Egawa-Takata T, Miyatake T, Matsuzaki S, Yokoyama T, Yoshino K, Fujita M, Enomoto T, Kimura T. (2011) Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin. *Cancer Chemother. Pharmacol.* Vol. 67, pp. 829–835.
- [14] Miyake T, Ueda Y, Egawa-Takata T, Matsuzaki S, Yokoyama T, Miyoshi Y, Kimura T, Yoshino K, Fujita M, Yamasaki M, Enomoto T, Kimura T. (2011) Recurrent endometrial carcinoma: prognosis for patients with recurrence within 6 to 12 months is worse relative to those relapsing at 12 months or later. *Am. J. Obstet. Gynecol.* Vol. 204, pp. 535.e1–5.
- [15] Tanaka Y, Ueda Y, Nakagawa S, Matsuzaki S, Kobayashi E, Shiki Y, Nishio Y, Takemura M, Yamamoto T, Sawada K, Tomimatsu T, Yoshino K, Kimura T. (2018) A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2). *Cancer Chemother. Pharmacol.* Vol. 82, pp. 585–592.
- [16] Harries M, Gore M (2002) Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. *Lancet Oncol.* 3: 537–545.
- [17] Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group Study. (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. *J. Clin. Oncol.* Vol. 24, pp. 36–44.
- [18] de Boer SM, Powell ME, Mileskin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw

- P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol.* Vol. 19, pp. 295–309.
- [19] Matei D, Filiaci VL, Randall M, Steinhoff M, DiSilvestro P, Moxley KM. (2017) A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. *J. Clin. Oncol.* Vol. 35(suppl): abstr 5505.
- [20] Nomura H, Aoki D, Micjima H, Mizuno M, Nakai H, Arai M. (2017) A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043). *J. Clin. Oncol.* Vol. 15(suppl): abstract 5503.
- [21] GOGO-EM3/Intergroup Study, Unpublished.
- [22] Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. *Gynecol. Oncol.* Vol. 150, pp. 274–281.
- [23] Lorusso D, Ferrandina G, Colombo N, Pignata S, Salutati V, Maltese G. et al. (2015). Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. *J. Clin. Oncol.* Vol. 33(suppl): abstr 5502.
- [24] Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. (2018) Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. *J. Clin. Oncol.* Vol. 36, pp. 2044–2051.
- [25] Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancy JE, Eisenhauer EA. (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J. Clin. Oncol.* Vol. 29, pp. 3278–3285.
- [26] Furlow B. (2018) Everolimus plus letrozole effective in endometrial carcinoma. *SGO 2018*.
- [27] Fader AN, Diaz LA, Armstrong DK, Tanner EJ, Uram J, Eyring A, Wang H, Fisher G, Greten T, Le D. (2016). Preliminary results of a phase II study: PD-1 blockade in mismatch repair-deficient, recurrent or persistent endometrial cancer. *SGO 2016*: abstr 5581.
- [28] Barrington DA, Dilley SE, Smith HJ, Straughn JM. (2018) Pembrolizumab in advanced recurrent endometrial cancer; A cost-effectiveness analysis. *Gynecol. Oncol.* Vol. 149(suppl): abstr 46.
- [29] Kauppila A. (1989) Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. *Acta Oncol.* Vol. 28, pp. 561–566.
- [30] Quinn MA, Campbell JJ. (1989) Tamoxifen therapy in advanced/recurrent endometrial carcinoma. *Gynecol. Oncol.* Vol. 32, pp. 1–3.
- [31] Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT. (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. *J. Clin. Oncol.* Vol. 17, pp. 1736–1744.
- [32] Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB; Gynecologic Oncology Group study. (2004) Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol. Oncol.* Vol. 92, pp. 4–9.
- [33] Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. (2000) A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol. Oncol.* Vol. 78, pp. 212–216.
- [34] McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T, Bloss J, Sabbatini P. (2003) A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. *Gynecol. Oncol.* Vol. 90, pp. 64–69.
- [35] Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B. (2014) Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). *BMC Cancer* Vol. 14, pp. 68.
- [36] Emons G, Günthert A, Thiel FC, Camara O, Strauss HG, Breitbach GP, Kölbl H, Reimer T, Finas D, Rensing K; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). (2013) Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie. *Gynecol. Oncol.* Vol. 129, pp. 495–499.
- [37] Kazuko Fujiwara, Tomomi Egawa-Takata, Yutaka Ueda, Toshihiro Kimura, Kiyoshi Yoshino, Masami Fujita, Takashi Miyatake, Yukinobu Ohta, Shoji Kamiura, Takayuki Enomoto, Tadashi Kimura. (2012). Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma. *Arch. Gynecol. Obstet.* Vol. 285, pp. 1447–1453.

第 12 章

子宫内膜癌的辅助治疗

Adjuvant Therapy in Endometrial Cancer

- [1] Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. *Cochrane Database Systematic Review*, 2012, CD003916.
- [2] Onsrud M, Cvancarova M, Hellebust TP, et al. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. *J Clin Oncol*, 2013, 31, 3951.
- [3] Martin-Hirsch PP, Bryant A, Keep SL, et al. Adjuvant progestagens for endometrial cancer. *Cochrane Database Systematic Review*, 2011, CD001040.
- [4] Ann Klopp, MD, PhD et al. The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline. *Practical Radiation Oncology*, May 2014.
- [5] Colombo, N. Creutzberg, C. Amant, F. Bosse, T. González-Martín, A. Ledermann, J. Marth, C. Nout, R. Querleu, D. Mirza, MR. Sessa C. & the ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. *Annals of Oncology*, 27, 16–41, 2016.
- [6] Creutzberg CL et al. Fifteen-year radiotherapy outcomes of the randomised PORTEC-1 for endometrial carcinoma. *Int. J. Radiation Oncology Biol. Phys.*, Vol. 81, No. 4, pp. e631–e638, 2011.
- [7] Keys HM et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. *Gynecologic Oncology*, 92, (2004), 744–751.
- [8] The ASTEC/EN.5 writing committee on behalf of the ASTEC/EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. *Lancet*, 2009, 373, 137–146.
- [9] Nout RA, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an openlabel, non-inferiority, randomised trial. *Lancet*, 2010, 375, 816–823.
- [10] Hogberg T, Signorelli M, et al. *Sequential Adjuvant Chemotherapy and Radiotherapy in Endometrial Cancer – Results from Two Randomised Studies*. Volume 46, Issue 13, September 2010, Pages 2422–2431.
- [11] Randall ME, Filiaci VL, Muss H, et al. Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. *Journal of Clinical Oncology*, 24, no. 1 (January 2006) 36–44.
- [12] Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. *Int J Gynaecol Obstet.*, 2006, 95 Suppl 1, S105–143.
- [13] Creasman WT, Morrow P, Bundy BN, Homesley HD, Graham JE, Heller PB; Surgical Pathology Spread Patterns of Endometrial Cancer: A Gynecologic Oncology Group Study; *Cancer*, 60, 2035–2041, 1987.
- [14] Mundt AJ, Waggoner S, Yamada D, et al. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. *Gynecol Oncol*, 2000, 79: 79.
- [15] Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. *Obstet Gynecol*, 2007, 109, 655.
- [16] Briet JM, Hollema H, Reesink N, et al. Lymphovascular space involvement: an independent prognostic factor in endometrial cancer. *Gynecol Oncol.*, 2005, 96, 799–804.
- [17] Grigsby PW, Perez CA, Kuten A, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. *Int J Radiat Oncol Biol Phys*, 1992, 22, 905.
- [18] Sorbe B, Nordström B, Mäenpää J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. *Int J Gynecol Cancer*, 2009, 19, 873–878.
- [19] Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-I endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. *Lancet*, 2000, 355, 1404–1411.
- [20] Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. *Br J Cancer.*, 2006, 95, 266–271.
- [21] Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk

- endometrial cancer: a Japanese Gynecologic Oncology Group study. *Gynecol Oncol.*, 2008, 108, 226–233.
- [22] Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. *Gynecol Oncol.*, 1990, 36, 166–171.
- [23] Kuoppala T, Maenpaa J, Tomas E, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. *Gynecol Oncol.*, 2008, 110, 190–195.
- [24] Hogberg T, Rosenberg P, Kristensen G, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). *J Clin Oncol*, 2007, 25(18S).
- [25] de Boer et al; Toxicity and Quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial; *Lancet Oncology*, 2016, 17, 1114–1126.
- [26] Matei D, Filiaci V, Randall M, Mutch D, Steinhoff M, Disilvestro P, Moxley K, Kim B, Powell M, O'Malley D, Spiratos N, Tewari K, Richards E, Nakayama J, Miller D. A Randomised phase III trial of cisplatin and tumour volume directed irradiation followed by Carboplatin and Paclitaxel vs Carboplatin and Paclitaxel for Optimally Debulked, Locally Advanced Endometrial Cancer: a Gynecologic Oncology Group/NRG Oncology Study. *J Clin Oncol.*, 2017, 35 (suppl; abstr 5505).
- [27] Randall ME, et al; A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: A Gynecology Oncology Group/NRG study. *ASTRO*, 2017 (Abstract LBA-1).
- [28] Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, Gallion H. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. *Ann Oncol.*, 2004, 15, 1173–1178.
- [29] Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. *J Clin Oncol.*, 2004, 22, 2159–2166.
- [30] GOG 209. Miller DS, Filiaci G, Mannel R, et al. Randomized Phase III Noninferiority Trial of First Line Chemotherapy for Metastatic or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. LBA2. Presented at the 2012 Society of Gynecologic Oncology Annual Meeting, Austin, TX.
- [31] Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M, Yaegashi N. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). *Ann Oncol.*, 2011, 22, 636–642.
- [32] Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, Tokunaga H, Omatsu K, Nakanishi T, Watanabe Y, Saito T, Yaegashi N. A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043). *J Clin Oncol*, 35, 2017 (suppl; abstr 5503).
- [33] Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spiratos NM, Morris RT, DeGeest K, Lee R, Montag A. A randomised phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study; *Gynecol Oncol.*, 2009, 112, 543–552.
- [34] Greven K, Winter K, Underhill K, Fontenesi J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. *Gynecol Oncol*, 2006, 103, 155–159.
- [35] RTOG 9905/GOG 0194. Comparison of radiation therapy with or without combination chemotherapy following surgery in treating patients with stage I or stage II endometrial cancer. Available at <http://www.clinicaltrials.gov/ct/show/NCT00006027>. Accessed January 1, 2018.
- [36] Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol*, 1983, 15: 10.
- [37] Wilczynski M, Danielska J, Wilczynski J. An update of the classical Bokhman's dualistic model of endometrial cancer. *Menopause Rev*, 2016, 15(2), 63–68
- [38] Kosary C. Cancer of the Corpus Uteri. In *SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics*. NCI, SEER Program, National Cancer Institute; Bethesda, MD 2007.
- [39] Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium; *Gynaecol Oncol*, 2004 Dec, 95 (3), 593–596.
- [40] Kelly MG, O'Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. *Gynecol Oncol*, Sep 2005, 98(3), 353–359.
- [41] Fader AN, Drake RD, O'Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, et al. Platinum/taxane-based chemotherapy with or without radiation therapy favourably impacts survival outcomes in stage I uterine papillary serous carcinoma. *Cancer*, May 15, 2009, 115(10), 2119–2127.
- [42] Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. *Gynecol Oncol*, Dec 2011,

- 123(3), 542–547.
- [43] Nguyen JM, Bouchard-Fortier G, Bernardini MQ, Atenafu EG, Han G, Vicus D, et al. Uterine clear cell carcinoma: does adjuvant chemotherapy improve outcomes? *Int J Gynecol Cancer.*, 2017, 27, 69–76.
- [44] de Boer et al.; Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial; *Lancet Oncology*, 2018, S1470–2045(18)30079–2.
- [45] Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy; *Cochrane Database of Systematic Reviews*, 2011, (10) Art No, CD003175.
- [46] Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for endometrial cancer (review); *Cochrane Database of Systematic Reviews*, 2014, (5). Art. No.: CD010681
- [47] Obermair A, Mileskin L, Bolz K, et al. Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. *Gynecol Oncol.*, 2011, 120, 179–184.
- [48] Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL. Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). *Gynecol Oncol.*, 2008, 108, 201–206.
- [49] Einstein MH, Frimer M, Kuo DY, Reimers LL, Mehta K, Mutyala S, Huang GS, Hou JY, Goldberg GL. Phase II Trial of Adjuvant Pelvic Radiation “Sandwiched” Between Combination Paclitaxel and Carboplatin in Women with Uterine Papillary Serous Carcinoma; *Gynecol Oncol.*, 2012 January, 124(1), 21–25.

第 13 章

子宫内膜癌的靶向治疗

Targeted Therapies for Endometrial Cancer

- [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin.* 2018; 68(1): 7–30.
- [2] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* 2011; 61(2): 69–90.
- [3] Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol.* 1983; 15(1): 10–7.
- [4] Setiawan, VW, Yang, HP, Pike, MC, McCann, SE, Yu, H, Xiang, YB, Wolk, A, Wentzensen, N, Weiss, NS, Webb, PM, van den Brandt, PA, van de Vijver, K, Thompson, PJ, The Australian National Endometrial Cancer Study Group, Strom, BL, Spurdle, AB, Soslow, RA, Shu, X, Schairer, C, Horn-Ross, PL. (2013). Type I and II endometrial cancers: have they different risk factors? *J Clin Oncol.* 2013; 31(20): 2607–2618.
- [5] Brinton, LA, Felix, AS, McMeekin, DS, Creasman, WT, Sherman, ME, Mutch, D, Cohn, DE, Walker, JL, Moore, RG, Downs, LS, Soslow, RA, & Zaino, R (2013). Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. *Gynecol Oncol.* 2013; 129(2): 277–284.
- [6] Doll, A, Abal, M, Rigau, M, Monge, M, Gonzalez, M, Demajo, S, Colás, E, Llauradó, M, Alazzouzi, H, Planagumá, J, Lohmann, MA, Garcia, J, Castellví, S., Cajal, JR. y, Gil-Moreno, A, Xercavins, J, Alameda, F, & Reventós, J (2008). *J Steroid Biochem Mol Biol.* 2008; 108(3–5): 221–229.
- [7] Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. *Lancet Oncol.* 2014; 15(7): e268–278.
- [8] Borghi C, Indraccolo U, Scutiero G, Iannone P, Martinello R, Greco P, L Nappi. Biomolecular basis related to inflammation in the pathogenesis of endometrial cancer. *Eur Rev Med Pharmacol Sci.* 2018; 22(19): 6294–6299.
- [9] Gargiulo, Piera, Chiara Della Pepa, Simona Berardi, Daniela Califano, Stefania Scala, Luigi Buonaguro, Gennaro Ciliberto, Peter Brauchli, and Sandro Pignata. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? *Cancer Treat Rev.* 2016; 48: 61–68.
- [10] Hussein, YR, Weigelt, B, Levine, DA, Schoolmeester, JK, Dao, LN, Balzer, BL, Liles, G, Karlan, B, Köbel, M, Lee, CH., & Soslow, RA. (2015) Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. *Mod Pathol.* 2015; 28(4): 505–514.
- [11] Chang Z, Talukdar S, Mullany SA, Winterhoff B. Molecular characterization of endometrial cancer and therapeutic implications. *Curr Opin Obstet Gynecol.* 2019; 31(1): 24–30.
- [12] Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, and Douglas A. Levine. Integrated genomic characterization of endometrial carcinoma. *Nature.* 2013; 497(7447): 67–73.
- [13] Mitamura T, Dong P, Ihira K, Kudo M, Watari H. Molecular-targeted therapies and precision medicine for endometrial cancer. *Jpn J Clin Oncol.* 2019; 49(2): 108–120.
- [14] Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. *J Clin Oncol.* 2006; 24(29): 4783–4791.
- [15] Llauradó, M, Ruiz, A, Majem, B, Ertekin, T, Colás, E, Pedrola, N, Devis, L, Rigau, M, Sequeiros, T, Montes, M, Garcia, M, Cabrera, S, Gil-Moreno, A, Xercavins, J, Castellví, J, Garcia, A, Ramón y Cajal, S, Moreno, G, Alameda, F, Reventós, J. (2012). Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. *Mol Cell Endocrinol.* 2012; 358(2): 244–255.
- [16] Lee YC, Lheureux S, Oza AM. Treatment strategies for endometrial cancer: current practice and perspective. *Curr Opin Obstet Gynecol.* 2017; 29(1): 47–58.
- [17] Lewin SN, Herzog TJ, Barrera Medel NI, Deutsch I, Burke WM, Sun X, Jason D, Wright JD. Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. *Obstet Gynecol.* 2010; 116(5): 1141–1149.
- [18] Dogan NU, Gungor T, Karsli F, Ozgu E, Besli M. To what extent should para-aortic lymphadenectomy be carried out for surgically staged endometrial cancer? *Int J Gynecol Cancer.* 2012; 22(4): 607–610.
- [19] Dizon DS. Treatment options for advanced endometrial carcinoma. *Gynecol Oncol.* 2010; 117(2): 373–381.
- [20] Ross, JS, Schenkein, DP, Pietrusko, R, Rolfe, M, Linette, GP, Stec, J, Stagliano, NE, Ginsburg, GS, Symmans, WF, Puzstai, L, & Hortobagyi, GN (2004) Targeted therapies for cancer 2004. *Am J Clin Pathol.* 2004; 122(4): 598–609.

- [21] Ocana A, Amir E, Vera-Badillo F, Seruga B, Tannock IF. Phase III trials of targeted anticancer therapies: redesigning the concept. *Clin Cancer Res.* 2013; 19(18): 4931–4940.
- [22] Chelariu-Raicu A, Coleman RL, Sood AK. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? *Oncology (Williston Park).* 2019; 33(7).
- [23] Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, DiSilvestro P. (2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med.* 2018; 379(26): 2495–2505.
- [24] Gerber DE. Targeted therapies: a new generation of cancer treatments. *Am Fam Physician.* 2008; 77(3): 311–319.
- [25] Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med.* 1971; 285(21): 1182–1186.
- [26] Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. *Curr Cancer Drug Targets.* 2011; 11(3): 239–253.
- [27] Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, L P Weng, C Eng. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. *J Natl Cancer Inst.* 2000; 92(11): 924–930.
- [28] Boruban MC, Altundag K, Kilic GS, Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. *Eur J Cancer Prev.* 2008; 17(2): 133–138.
- [29] Salvesen, Helga B., Nicola MacDonald, Andy Ryan, Ian J. Jacobs, Eric D. Lynch, Lars A. Akslen, and Soma Das. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. *Int J Cancer.* 2001; 91(1): 22–26.
- [30] Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. *Cancer Res.* 2005; 65(23): 10669–10673.
- [31] Salvesen, HB, Carter, SL, Mannelqvist, M, Dutt, A, Getz, G, Stefansson, IM, Raeder, MB, Sos, ML, Engelsen, IB, Trovik, J, Wik, E, Greulich, H, Bø, TH, Jonassen, I, Thomas, RK, Zander, T, Garraway, LA, Øyan, AM, Sellers, WR., Beroukhim, R. (2009). Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. *Proc Natl Acad Sci USA.* 2009; 106(12): 4834–4839.
- [32] Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature.* 1993; 363(6429): 558–561.
- [33] Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. *Eur J Cancer.* 1997; 33(10): 1572–1577.
- [34] Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. *Nat Rev Cancer.* 2006; 6(3): 184–192.
- [35] Slomovitz, Brian M, Russell R Broaddus, Thomas W Burke, Nour Sneige, Pamela T Soliman, Weiguo Wu, Charlotte C Sun, Mark F Munsell, David M Gershenson, and Karen H Lu. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. *J Clin Oncol.* 2004; 22(15): 3126–3132.
- [36] Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. *Cancer Metastasis Rev.* 2009; 28(1–2): 151–166.
- [37] Yin Y, Solomon G, Deng C, Barrett JC. Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress. *Mol Carcinog.* 1999; 24(1): 15–24.
- [38] Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. *Cancer.* 2000; 88(4): 814–824.
- [39] Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. *J Clin Oncol.* 2009; 27(13): 2278–2287.
- [40] Amit M Oza, Laurie Elit, Ming-Sound Tsao, Suzanne Kamel-Reid, Jim Biagi, Diane Michele Provencher, Walter H Gotlieb, Paul J Hoskins, Prafull Ghatage, Katia S Tonkin, Helen J Mackay, John Mazurka, Joana Sederias, Percy Ivy, Janet E Dancey, Elizabeth A Eisenhauer. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J Clin Oncol.* 2011; 29(24): 3278–3285.
- [41] Brian M Slomovitz, Karen H Lu, Taren Johnston, Robert L Coleman, Mark Munsell, Russell R Broaddus, Cheryl Walker, Lois M Ramondetta, Thomas W Burke, David M Gershenson, Judith Wolf. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. *Cancer.* 2010; 116(23): 5415–5419.
- [42] Ray-Coquard I, L Favier, B Weber, C Roemer-Becuwe, P Bournoux, M Fabbro, A Floquet, F Joly, A Plantade, D Paraiso, E Pujade-Lauraine. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. *Br J Cancer.* 2013; 108(9): 1771–1777.
- [43] Colombo N, McMeekin DS, Schwartz PE, Sessa C, Gehrig PA, Holloway RP Braly, D Matei, A Morosky, PF Dodion, M H Einstein, and F Haluska. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. *Br J Cancer.* 2013; 108(5): 1021–1026.
- [44] Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, S Diane Yamada, Jeanne M Schilder, David E Cohn, Charles R Harrison, Kathleen N Moore, Carol Aghajanian. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2013; 129(1): 22–27.

- [45] Fleming, GF, Filiaci, VL, Marzullo, B, Zaino, RJ, Davidson, SA, Pearl, M, Makker, V, Burke, JJ, Zweig, SL, Van Le, L, Hanjani, P, Downey, G, Walker, JL, Reyes, HD, & Leslie, KK. (2014). Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. *Gynecol Oncol.* 2014; 132(3): 585–592.
- [46] Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Paul J Hoskins, Jim Biagi, Prafull Ghatage, John Mazurka, Diane Provencher, Naomi Dore, Janet Dancey, Anthony Fyles. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. *J Clin Oncol.* 2008; 26(26): 4319–4325.
- [47] Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Parviz Hanjani, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, and Nita J. Maithe. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2013; 129(3): 486–494.
- [48] Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Russell J. Schilder, Joan L. Walker, Krishnansu Tewari, Parviz Hanjani, Ovadia Abulafia, and Peter G. Rose. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. *Gynecol Oncol.* 2012; 127(2): 345–350.
- [49] Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Jonathan S Berek, Julia A Chapman, Paul A DiSilvestro, Ira R Horowitz, James V Fiorica. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2010; 116(1): 15–20.
- [50] Charles L Vogel, Melody A Cobleigh, Debu Tripathy, John C Gutheil, Lyndsay N Harris, Louis Fehrenbacher, Dennis J Slamon, Maureen Murphy, William F Novotny, Michael Burchmore, Steven Shak, Stanford J Stewart, Michael Press. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol.* 2002; 20(3): 719–726.
- [51] Uccelli, Andrea, Thomas Wolff, Paolo Valente, Nunzia Di Maggio, Matteo Pellegrino, Lorenz Gürke, Andrea Banfi, and Roberto Gianni-Barrera. Vascular endothelial growth factor biology for regenerative angiogenesis. *Swiss Med Wkly.* 2019; 149: w20011.
- [52] Aghajanian C, Michael W Sill, Kathleen M Darcy, Benjamin Greer, D Scott McMeekin, Peter G Rose, Jacob Rotmensch, Mack N Barnes, Parviz Hanjani, Kimberly K Leslie. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol.* 2011; 29(16): 2259–2265.
- [53] McMeekin DS, Michael W Sill, Doris Benbrook, Kathleen M Darcy, Deborah J Stearns-Kurosawa, Lynne Eaton, S Diane Yamada, Gynecologic Oncology Group. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2007; 105(2): 508–516.
- [54] Coleman, Robert L, Michael W Sill, Heather A Lankes, Amanda Nickles Fader, Neil J Finkler, James S Hoffman, Peter G Rose, Gregory P Sutton, Charles W Drescher, D Scott McMeekin, Wei Hu, Michael Deavers, Andrew K Godwin, R Katherine Alpaugh, Anil K Sood. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2012; 127(3): 538–543.
- [55] Aghajanian C, Virginia Filiaci, Don S Dizon, Jay W Carlson, Matthew A Powell, Angeles Alvarez Secord, Krishnansu S Tewari, David P Bender, David M O'Malley, Ashley Stuckey, JianJiong Gao, Fanny Dao, Robert A Soslow, Heather A Lankes, Kathleen Moore, Douglas A Levine. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. *Gynecol Oncol.* 2018; 150(2): 274–281.
- [56] Okamoto, Kiyoshi, Kotaro Kodama, Kazuma Takase, Naoko Hata Sugi, Yuji Yamamoto, Masao Iwata, and Akihiko Tsuruoka. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. *Cancer Lett.* 2013; 340(1): 97–103.
- [57] Halla S Nimeiri, Amit M Oza, Robert J Morgan, Dezheng Huo, Laurie Elit, James A Knost, James L Wade 3rd, Edem Agamah, Everett E Vokes, Gini F Fleming. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. *Gynecol Oncol.* 2010; 117(1): 37–40.
- [58] Castonguay V, Vincent Castonguay, Stephanie Lheureux, Stephen Welch, Helen J Mackay, Hal Hirte, Gini Fleming, R Morgan, Lisa Wang, Chantale Blattler, Percy S Ivy, Amit M Oza. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. *Gynecol Oncol.* 2014; 134(2): 274–280.
- [59] Farmer, H, McCabe, N, Lord, CJ, Tutt, ANJ, Johnson, DA, Richardson, TB, Santarosa, M, Dillon, KJ, Hickson, I, Knights, C, Martin, NMB, Jackson, SP, Smith, GCM., & Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature.* 2005; 434(7035): 917–921.
- [60] Dedes KJ, Wetterskog, D, Mendes-Pereira, AM, Natrajan, R, Lambros, MB, Geyer, FC, Vatcheva, R, Savage, K, Mackay, A, Lord, CJ, Ashworth, A, & Reis-Filho, JS (2010) PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. *Sci Transl Med.* 2010; 2(53): 53ra75.
- [61] Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA, Konstantinopoulos PA. Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. *Gynecol Oncol.* 2018;

- 150(2): 219–226.
- [62] Robert, Caroline, Antoni Ribas, Jacob Schachter, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona M McNeil, Michal Lotem, James M G Larkin, Paul Lorigan, Bart Neyns, Christian U Blank, Teresa M Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V Long. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): posthoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncol.* 2019; 20(9): 1239–1251.
- [63] Le, DT, Uram, JN, Wang, H, Bartlett, BR, Kemberling, H, Eyring, AD, Skora, AD, Lubner, BS, Azad, NS, Laheru, D, Biedrzycki, B, Donehower, RC, Zaheer, A, Fisher, GA, Crocenzi, TS, Lee, JJ, Duffy, SM, Goldberg, RM, de la Chapelle, A, Diaz, LA. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med.* 2015; 372(26): 2509–2520.
- [64] Makker, Vicky, Drew Rasco, Nicholas J Vogelzang, Marcia S Brose, Allen L Cohn, James Mier, Christopher Di Simone, David M Hyman, Daniel E Stepan, Corina E Dutcus, Emmett V Schmidt, Matthew Guo, Pallavi Sachdev, Robert Shumaker, Carol Aghajanian, Matthew Taylor. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol.* 2019; 20(5): 711–718.
- [65] Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. *Drug Resist Updat.* 2014; 17(4–6): 89–95.
- [66] Morris RT, Joyrich RN, Naumann RW, Shah NP, Maurer AH, Strauss HW, Uszler JM, Symanowski JT, Ellis PR, Harb WA. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). *Ann Oncol.* 2014; 25(4): 852–858.

第 14 章

是时候重新考量 ErbB 靶向治疗在 子宫内膜癌中的临床作用了吗

Is It Time to Reconsider the Clinical Role of ErbB Targeted Therapy in Endometrial Cancer?

- [1] Casalini P, Iorio M, Galmozzi E, Menard S. Role of HER receptors family in development and differentiation. *J Cell Physiol* 2004; 200(3): 343–350. <https://doi.org/10.1002/jcp.20007>. [published Online First: 2004/07/16].
- [2] Uberall I, Kolar Z, Trojanec R, Berkovcova J, Hajdich M. The status and role of ErbB receptors in human cancer. *Exp Mol Pathol* 2008; 84(2): 79–89. <https://doi.org/10.1016/j.yexmp.2007.12.002>. [published Online First: 2008/02/19].
- [3] Marmor M, Skaria K, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. *Int J Radiat Oncol Biol Phys* 2004; 58(3): 903–913. <https://doi.org/10.1016/j.ijrobp.2003.06.002>. [published Online First: 2004/02/18].
- [4] Adonakis G, Androutsopoulos G, Koumoundourou D, Liava A, Ravazoula P, Kourounis G. Expression of the epidermal growth factor system in endometrial cancer. *Eur J Gynaecol Oncol* 2008; 29(5): 450–454. [published Online First: 2008/12/05].
- [5] Adonakis G, Androutsopoulos G. The role of ErbB receptors in endometrial cancer. In: Saldivar JS, ed. *Cancer of the Uterine Endometrium—Advances and Controversies: InTech* 2012: 23–38.
- [6] Androutsopoulos G, Adonakis G, Gkermepesi M, Gkogkos P, Ravazoula P, Kourounis G. Expression of the epidermal growth factor system in endometrial cancer after adjuvant tamoxifen treatment for breast cancer. *Eur J Gynaecol Oncol* 2006; 27(5): 490–494. [published Online First: 2006/12/05].
- [7] Androutsopoulos G, Adonakis G, Liava A, Ravazoula P, Decavalas G. Expression and potential role of ErbB receptors in type II endometrial cancer. *Eur J Obstet Gynecol Reprod Biol* 2013; 168(2): 204–208.
- [8] Androutsopoulos G, Michail G, Adonakis G, Decavalas G. ErbB receptors and ErbB targeted therapies in endometrial cancer. *J Cancer Ther* 2014; 5(6): 483–492.
- [9] Androutsopoulos G, Adonakis G, Decavalas G. ErbB targeted therapy in endometrial cancer. In: Farghaly S, ed. *Endometrial cancer: current epidemiology, Detection and Management: Nova Science Publishers* 2014.
- [10] Androutsopoulos G, Michail G, Adonakis G, Decavalas G. Molecular biology, expression and clinical significance of ErbB receptors in endometrial cancer. *Hel J Obst Gynecol* 2014; 13(3): 77–83.
- [11] Androutsopoulos G, Adonakis G, Decavalas G. Present and future in endometrial cancer treatment. *Obstet Gynecol Int J* 2015; 2(2): 00031.
- [12] Androutsopoulos G, Michail G, Adonakis G, Decavalas G. Molecular mechanisms, expression and clinical role of ErbB receptors in endometrial cancer. *Int J Clin Ther Diagn* 2015; S1(6): 28–32.
- [13] Androutsopoulos G, Michail G, Adonakis G, Decavalas G. ErbB targeted therapy in endometrial cancer. *Int J Clin Ther Diagn* 2015; S1(2): 5–7.
- [14] Androutsopoulos G, Decavalas G. Endometrial cancer treatment: new insights into the role of erbb receptors. *J Gynecol Women's Health* 2016; 1(1): 555552.
- [15] Androutsopoulos G, Decavalas G. Standard and novel therapies in endometrial cancer. *J Gynecol Women's Health* 2016; 1(3): 555564.
- [16] Androutsopoulos G, Michail G, Decavalas G. New insights in endometrial cancer treatment. *Clinics in Oncology—Endometrial Cancer* 2016; 1: 1040.
- [17] Salomon D, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncol Hematol* 1995; 19(3): 183–232. [published Online First: 1995/07/01].
- [18] Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. *Eur J Cancer* 2001; 37 Suppl 4: S3–8. [published Online First: 2001/10/13].
- [19] Holbro T, Civenni G, Hynes N. The ErbB receptors and their role in cancer progression. *Exp Cell Res* 2003; 284(1): 99–110. [https://doi.org/10.1016/S0014-4827\(02\)00099-X](https://doi.org/10.1016/S0014-4827(02)00099-X).
- [20] Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. *J Clin Oncol* 2005; 23(11): 2445–2459. <https://doi.org/10.1200/JCO.2005.11.890>. [published Online First: 2005/03/09].
- [21] Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification

- through combinatorial ligand-receptor interactions. *FEBS Lett* 1997; 410(1): 83–86. [published Online First: 1997/06/23].
- [22] Normanno N, Bianco C, De Luca A, Maiello M, Salomon D. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. *Endocr Relat Cancer* 2003; 10(1): 1–21. [published Online First: 2003/03/26].
- [23] Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. *Trends Cell Biol* 2006; 16(12): 649–656. <https://doi.org/10.1016/j.tcb.2006.10.008>. [published Online First: 2006/11/07].
- [24] Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. *Philos Trans R Soc Lond B Biol Sci* 1998; 353(1368): 583–605. <https://doi.org/10.1098/rstb.1998.0228>. [published Online First: 1998/05/29].
- [25] Mass R. The HER receptor family: a rich target for therapeutic development. *Int J Radiat Oncol Biol Phys* 2004; 58(3): 932–940. <https://doi.org/10.1016/j.ijrobp.2003.09.093>. [published Online First: 2004/02/18].
- [26] Riese D, Gallo R, Settleman J. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. *Bioessays* 2007; 29(6): 558–565. <https://doi.org/10.1002/Bies.20582>.
- [27] Wieduwilt M, Moasser M. The epidermal growth factor receptor family: biology driving targeted therapeutics. *Cellular and Molecular Life Sciences: CMLS* 2008; 65(10): 1566–1584. <https://doi.org/10.1007/s00018-008-7440-8>. [published Online First: 2008/02/09].
- [28] Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. *Cell* 2002; 110(6): 775–787. [published Online First: 2002/09/26].
- [29] Zhang D, Sliwkowski M, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski P. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. *Proc Natl Acad Sci USA* 1997; 94(18): 9562–9567. [published Online First: 1997/09/02].
- [30] Harari D, Tzahar E, Romano J, Shelly M, Pierce J, Andrews G, Yarden Y. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. *Oncogene* 1999; 18(17): 2681–2689. <https://doi.org/10.1038/sj.onc.1202631>. [published Online First: 1999/05/29].
- [31] Ferguson K, Berger M, Mendrola J, Cho H, Leahy D, Lemmon M. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. *Mol Cell* 2003; 11(2): 507–517. [published Online First: 2003/03/07].
- [32] Dawson J, Berger M, Lin C, Schlessinger J, Lemmon M, Ferguson K. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. *Mol Cell Biol* 2005; 25(17): 7734–7742. <https://doi.org/10.1128/mcb.25.17.7734-7742.2005>. [published Online First: 2005/08/19].
- [33] Ozcan F, Klein P, Lemmon M, Lax I, Schlessinger J. On the nature of low- and high-affinity EGF receptors on living cells. *Proc Natl Acad Sci USA* 2006; 103(15): 5735–5740. <https://doi.org/10.1073/pnas.0601469103>. [published Online First: 2006/03/31].
- [34] Olayioye M, Neve R, Lane H, Hynes N. The ErbB signaling network: receptor heterodimerization in development and cancer. *EMBO J* 2000; 19(13): 3159–3167. <https://doi.org/10.1093/emboj/19.13.3159>. [published Online First: 2000/07/06].
- [35] Qian X, LeVeau C, Freeman J, Dougall W, Greene M. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. *Proc Natl Acad Sci USA* 1994; 91(4): 1500–1504. [published Online First: 1994/02/15].
- [36] Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. *Cell* 2006; 125(6): 1137–1149. <https://doi.org/10.1016/j.cell.2006.05.013>. [published Online First: 2006/06/17].
- [37] Graus-Porta D, Beerli R, Daly J, Hynes N. ErbB-2, the preferred hetero-dimerization partner of all ErbB receptors, is a mediator of lateral signaling. *EMBO J* 1997; 16(7): 1647–1655. <https://doi.org/10.1093/emboj/16.7.1647>. [published Online First: 1997/04/01].
- [38] Garrett T, McKern N, Lou M, Elleman T, Adams T, Lovrecz G, Kofler M, Jorissen R, Nice E, Burgess A, Ward C. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. *Mol Cell* 2003; 11(2): 495–505. [published Online First: 2003/03/07].
- [39] Citri A, Skaria K, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. *Exp Cell Res* 2003; 284(1): 54–65. [published Online First: 2003/03/22].
- [40] Hynes N, Stern D. The biology of erbB-2/neu/HER-2 and its role in cancer. *Biochim Biophys Acta* 1994; 1198(2–3): 165–184. [published Online First: 1994/12/30].
- [41] Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. ErbB receptors: from oncogenes to targeted cancer therapies. *J Clin Invest* 2007; 117(8): 2051–2058. <https://doi.org/10.1172/jci32278>. [published Online First: 2007/08/03].
- [42] Alimandi M, Romano A, Curia M, Muraro R, Fedi P, Aaronson S, Di Fiore P, Kraus M. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. *Oncogene* 1995; 10(9): 1813–1821. [published Online First: 1995/05/04].
- [43] Wallasch C, Weiss F, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. *EMBO J* 1995; 14(17): 4267–4275. [published Online First: 1995/09/01].
- [44] Songyang Z, Shoelson S, Chaudhuri M, Gish G, Pawson

- T, Haser W, King F, Roberts T, Ratnofsky S, Lechleider R, et al. SH2 domains recognize specific phosphopeptide sequences. *Cell* 1993; 72(5): 767–778. [published Online First: 1993/03/12].
- [45] Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. *Clin Cancer Res* 2006; 12(18): 5268–5272. <https://doi.org/10.1158/1078-0432.ccr-05-1554> [published Online First: 2006/09/27].
- [46] Molina J, Adjei A. The Ras/Raf/MAPK pathway. *J Thorac Oncol* 2006; 1(1): 7–9. [published Online First: 2007/04/06].
- [47] Cary L, Han D, Guan J. Integrin-mediated signal transduction pathways. *Histol Histopathol* 1999; 14(3): 1001–1009. <https://doi.org/10.14670/hh-14.1001>. [published Online First: 1999/07/30].
- [48] Stacey D. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. *Curr Opin Cell Biol* 2003; 15(2): 158–163. [published Online First: 2003/03/22].
- [49] Kranenburg O, Gebbink M, Voest E. Stimulation of angiogenesis by Ras proteins. *Biochim Biophys Acta* 2004; 1654(1): 23–37. <https://doi.org/10.1016/j.bbcan.2003.09.004>. [published Online First: 2004/02/27].
- [50] Lowenstein E, Daly R, Batzer A, Li W, Margolis B, Lammers R, Ullrich A, Skolnik E, Bar-Sagi D, Schlessinger J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. *Cell* 1992; 70(3): 431–442. [published Online First: 1992/08/07].
- [51] Batzer A, Rotin D, Urena J, Skolnik E, Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. *Mol Cell Biol* 1994; 14(8): 5192–5201. [published Online First: 1994/08/01].
- [52] Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell* 2000; 103(2): 211–225. [published Online First: 2000/11/01].
- [53] Hallberg B, Rayter S, Downward J. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. *J Biol Chem* 1994; 269(6): 3913–3916. [published Online First: 1994/02/11].
- [54] Marais R, Light Y, Paterson H, Marshall C. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. *EMBO J* 1995; 14(13): 3136–3145. [published Online First: 1995/07/03].
- [55] Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. *Cell Signal* 2001; 13(11): 777–785. [published Online First: 2001/10/05].
- [56] Zhang W, Liu H. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. *Cell Res* 2002; 12(1): 9–18. <https://doi.org/10.1038/sj.cr.7290105>. [published Online First: 2002/04/11].
- [57] Liu P, Cheng H, Roberts T, Zhao J. Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discov* 2009; 8(8): 627–644. <https://doi.org/10.1038/nrd2926>. [published Online First: 2009/08/01].
- [58] Vivanco I, Sawyers C. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nat Rev Cancer* 2002; 2(7): 489–501. <https://doi.org/10.1038/nrc839>. [published Online First: 2002/07/03].
- [59] Shaw R, Cantley L. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature* 2006; 441(7092): 424–430. <https://doi.org/10.1038/nature04869>. [published Online First: 2006/05/26].
- [60] Yu J, Wjasow C, Backer J. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. *J Biol Chem* 1998; 273(46): 30199–30203. [published Online First: 1998/11/07].
- [61] Stokoe D, Stephens L, Copeland T, Gaffney P, Reese C, Painter G, Holmes A, McCormick F, Hawkins P. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. *Science* 1997; 277(5325): 567–570. [published Online First: 1997/07/25].
- [62] Carpenter C, Auger K, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S, Cantley L. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. *J Biol Chem* 1993; 268(13): 9478–9483. [published Online First: 1993/05/05].
- [63] Mattoon D, Lamothe B, Lax I, Schlessinger J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. *BMC Biol* 2004; 2: 24. <https://doi.org/10.1186/1741-7007-2-24>. [published Online First: 2004/11/20].
- [64] Rawlings J, Rosler K, Harrison D. The JAK/STAT signaling pathway. *J Cell Sci* 2004; 117(Pt 8): 1281–1283. <https://doi.org/10.1242/jcs.00963>. [published Online First: 2004/03/17].
- [65] Harrison D. The Jak/STAT pathway. *Cold Spring Harb Perspect Biol* 2012; 4(3) <https://doi.org/10.1101/cshperspect.a011205>. [published Online First: 2012/03/03].
- [66] Zhong Z, Wen Z, Darnell J, Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. *Science* 1994; 264(5155): 95–98. [published Online First: 1994/04/01].
- [67] Yu H, Jove R. The STATs of cancer—new molecular targets come of age. *Nat Rev Cancer* 2004; 4(2): 97–105. <https://doi.org/10.1038/nrc1275>. [published Online First: 2004/02/18].
- [68] Haura E, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. *Nat Clin Pract Oncol* 2005; 2(6): 315–324. <https://doi.org/10.1038/nponc0195>. [published Online First: 2005/11/03].
- [69] Bromberg J. Stat proteins and oncogenesis. *J Clin Invest* 2002; 109(9): 1139–1142. <https://doi.org/10.1172/jci15617>. [published Online First: 2002/05/08].
- [70] Schulze W, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. *Mol Syst Biol* 2005; 1: 2005.0008. <https://doi.org/10.1038/msb4100012>. [published Online First: 2006/05/27].
- [71] Playford M, Schaller M. The interplay between Src and integrins in normal and tumor biology. *Oncogene*

- 2004; 23(48): 7928–7946. <https://doi.org/10.1038/sj.onc.1208080>. [published Online First: 2004/10/19].
- [72] Yeatman T. A renaissance for SRC. *Nat Rev Cancer* 2004; 4(6): 470–480. doi: 10.1038/nrc1366 [published Online First: 2004/06/02].
- [73] Summy J, Gallick G. Treatment for advanced tumors: SRC reclaims center stage. *Clin Cancer Res* 2006; 12(5): 1398–1401. <https://doi.org/10.1158/1078-0432.ccr-05-2692>. [published Online First: 2006/03/15].
- [74] Haura E. SRC and STAT pathways. *J Thorac Oncol* 2006; 1(5): 403–405. [published Online First: 2007/04/06].
- [75] Leu T, Maa M. Functional implication of the interaction between EGF receptor and c-Src. *Front Biosci* 2003; 8: s28–38. [published Online First: 2002/11/29].
- [76] Jorissen R, Walker F, Pouliot N, Garrett T, Ward C, Burgess A. Epidermal growth factor receptor: mechanisms of activation and signalling. *Exp Cell Res* 2003; 284(1): 31–53. [published Online First: 2003/03/22].
- [77] Frame M. Src in cancer: deregulation and consequences for cell behaviour. *Biochim Biophys Acta* 2002; 1602(2): 114–130. [published Online First: 2002/05/22].
- [78] Kamat A, Carpenter G. Phospholipase C-gamma1: regulation of enzyme function and role in growth factor-dependent signal transduction. *Cytokine Growth Factor Rev* 1997; 8(2): 109–117. [published Online First: 1997/06/01].
- [79] Wang Z. ErbB Receptors and Cancer. *Methods Mol Biol* 2017; 1652: 3–35. https://doi.org/10.1007/978-1-4939-7219-7_1. [published Online First: 2017/08/10].
- [80] Wahl M, Nishibe S, Kim J, Kim H, Rhee S, Carpenter G. Identification of two epidermal growth factor-sensitive tyrosine phosphorylation sites of phospholipase C-gamma in intact HSC-1 cells. *J Biol Chem* 1990; 265(7): 3944–3948. [published Online First: 1990/03/05].
- [81] Chattopadhyay A, Vecchi M, Ji Q, Mernaugh R, Carpenter G. The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor. *J Biol Chem* 1999; 274(37): 26091–26097. [published Online First: 1999/09/03].
- [82] Patterson R, van Rossum D, Nikolaidis N, Gill D, Snyder S. Phospholipase C-gamma: diverse roles in receptor-mediated calcium signaling. *Trends Biochem Sci* 2005; 30(12): 688–697. <https://doi.org/10.1016/j.tibs.2005.10.005>. [published Online First: 2005/11/02].
- [83] Marais R, Light Y, Mason C, Paterson H, Olson M, Marshall C. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. *Science* 1998; 280(5360): 109–112. [published Online First: 1998/04/29].
- [84] Schonwasser D, Marais R, Marshall C, Parker P. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isoforms. *Mol Cell Biol* 1998; 18(2): 790–798. [published Online First: 1998/02/03].
- [85] Hofer F, Berdeaux R, Martin G. Ras-independent activation of Ral by a Ca(2+)-dependent pathway. *Curr Biol* 1998; 8(14): 839–842. [published Online First: 1998/07/15].
- [86] Sun L, Carpenter G. Epidermal growth factor activation of NF-kappaB is mediated through Ikappa-Balpa degradation and intracellular free calcium. *Oncogene* 1998; 16(16): 2095–2102. doi: 10.1038/sj.onc.1201731 [published Online First: 1998/05/08].
- [87] McClellan M, Kievit P, Auersperg N, Rodland K. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. *Exp Cell Res* 1999; 246(2): 471–479. <https://doi.org/10.1006/excr.1998.4328>. [published Online First: 1999/02/02].
- [88] Lonardo F, Di Marco E, King C, Pierce J, Segatto O, Aaronson S, Di Fiore P. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. *New Biol* 1990; 2(11): 992–1003. [published Online First: 1990/11/01].
- [89] Moscatello D, Holgado-Madruga M, Godwin A, Ramirez G, Gunn G, Zoltick P, Biegel J, Hayes R, Wong A. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. *Cancer Res* 1995; 55(23): 5536–5539. [published Online First: 1995/12/01].
- [90] Lurje G, Lenz HJ. EGFR signaling and drug discovery. *Oncology* 2009; 77(6): 400–410. <https://doi.org/10.1159/000279388>. [published Online First: 2010/02/05].
- [91] Ross J, Fletcher J. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. *Oncologist* 1998; 3(4): 237–352. [published Online First: 1999/07/01].
- [92] Odicino F, Bignotti E, Rossi E, Pasinetti B, Tassi R, Donzelli C, Falchetti M, Fontana P, Grigolato P, Pecorelli S. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immuno-histochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. *Int J Gynecol Cancer* 2008; 18(1): 14–21. <https://doi.org/10.1111/j.1525-1438.2007.00946.x>. [published Online First: 2007/04/25].
- [93] Wang X, Das S, Damm D, Klagsbrun M, Abraham J, Dey S. Differential regulation of heparin-binding epidermal growth factor-like growth factor in the adult ovariectomized mouse uterus by progesterone and estrogen. *Endocrinology* 1994; 135(3): 1264–1271. [published Online First: 1994/09/01].
- [94] Lemoine N, Barnes D, Hollywood D, Hughes C, Smith P, Dublin E, Prigent S, Gullick W, Hurst H. Expression of the ERBB3 gene product in breast cancer. *Br J Cancer* 1992; 66(6): 1116–1121. [published Online First: 1992/12/01].
- [95] Gasparini G, Gullick W, Maluta S, Dalla Palma P, Caffo O, Leonardi E, Boracchi P, Pozza F, Lemoine N, Bevilacqua P. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma—an immunocytochemical study. *Eur J Cancer* 1994; 30A(1): 16–22. [published Online First: 1994/01/01].
- [96] Gullick W. The c-erbB3/HER3 receptor in human cancer. *Cancer Surv* 1996; 27: 339–349. [published Online First: 1996/01/01].

- [97] Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. *Int J Cancer* 2003; 106(5): 758–765. <https://doi.org/10.1002/ijc.11273>. [published Online First: 2003/07/17].
- [98] Li Q, Zhang R, Yan H, Zhao P, Wu L, Wang H, Li T, Cao B. Prognostic significance of HER3 in patients with malignant solid tumors. *Oncotarget* 2017; 8(40): 67140–67151. <https://doi.org/10.18632/oncotarget.18007>.
- [99] Suo Z, Risberg B, Kalsson M, Willman K, Tierens A, Skovlund E, Nesland J. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. *J Pathol* 2002; 196(1): 17–25. <https://doi.org/10.1002/path.1003>. [published Online First: 2001/12/19].
- [100] Memon A, Sorensen B, Melgard P, Fokdal L, Thykjaer T, Nexø E. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. *Br J Cancer* 2004; 91(12): 2034–2041. <https://doi.org/10.1038/sj.bjc.6602251>. [published Online First: 2004/12/08].
- [101] Barnes N, Khavari S, Boland G, Cramer A, Knox W, Bundred N. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. *Clin Cancer Res* 2005; 11(6): 2163–2168. <https://doi.org/10.1158/1078-0432.CCR-04-1633>. [published Online First: 2005/03/25].
- [102] WHO. Estimated cancer incidence, mortality and prevalence worldwide in 2012. *GLOBOCAN 2012*.
- [103] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136(5): E359–386. <https://doi.org/10.1002/ijc.29210>. [published Online First: 2014/09/16].
- [104] Sorosky J. Endometrial cancer. *Obstet Gynecol* 2012; 120(2 Pt 1): 383–397. <https://doi.org/10.1097/AOG.0b013e3182605bf1>. [published Online First: 2012/07/25].
- [105] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; 63(1): 11–30. <https://doi.org/10.3322/caac.21166>.
- [106] Koufopoulos N, Carrer D, Koureas N, Sofopoulos M, Paraoulakis I, Androutsopoulos G, Arnoyianni N, Zygouris D, Derdelis G, Terzakis E. Pathological data on 19 cases of endometrioid carcinoma of the endometrium in women of reproductive age. *Int J Gynecol Cancer* 2013; 23(8 Suppl 1): 322.
- [107] Androutsopoulos G. Current treatment options in patients with endometrial cancer. *J Community Med Health Educ* 2012; 2(12): e113.
- [108] Androutsopoulos G, Decavalas G. Management of endometrial cancer. *International Journal of Translation & Community Medicine* 2013; 1(1): 101.
- [109] Androutsopoulos G, Decavalas G. Endometrial cancer: current treatment strategies. *World J Oncol Res* 2014; 1(1): 1–4.
- [110] Androutsopoulos G, Michail G, Adonakis G, Decavalas G. Current treatment approach of endometrial cancer. *Int J Clin Ther Diagn* 2015; S1(3): 8–11.
- [111] Androutsopoulos G, Kotsopoulos I, Decavalas G. Fertility preservation in young patients with endometrial cancer. *World J Oncol Res* 2016; 3(1): 36–39.
- [112] Androutsopoulos G, Kotsopoulos I, Decavalas G. The role of lymphadenectomy in patients with endometrial cancer. *J Gynecol Women's Health* 2016; 1(5): 555573.
- [113] Androutsopoulos G, Kotsopoulos I, Adonakis G, Decavalas G. Conservative management of young patients with early stage endometrial cancer. *J Gynecol Women's Health* 2017; 2(3): 555586.
- [114] Androutsopoulos G, Kotsopoulos I, Korompelis P, Decavalas G. Therapeutic dilemmas in young patients with early stage endometrial cancer. *Canc Therapy Oncol Int J* 2017; 5(2): 555658.
- [115] Androutsopoulos G, Kotsopoulos I, Korompelis P, Michail G, Adonakis G, Decavalas G. Conservative therapeutic approach in young patients with endometrial cancer: is it really possible? *Helv J Obst Gynecol* 2017; 16(4): 7–23.
- [116] Bokhman J. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol* 1983; 15(1): 10–17. [published Online First: 1983/02/01].
- [117] Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colás E, Llauradó M, Alazzouzi H, Planagumá J, Lohmann MA, Garcia J, Castellvi S, Ramon y Cajal J, Gil-Moreno A, Xercavins J, Alameda F, J. R. Novel molecular profiles of endometrial cancer—new light through old windows. *J Steroid Biochem Mol Biol* 2008; 108(3–5): 221–229.
- [118] Lax S. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. *Virchows Arch* 2004; 444(3): 213–223. <https://doi.org/10.1007/s00428-003-0947-3>. [published Online First: 2004/01/30].
- [119] Sherman M, Sturgeon S, Brinton L, Potischman N, Kurman R, Berman M, Mortel R, Twiggs L, Barrett R, Wilbanks G. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. *Mod Pathol* 1997; 10(10): 963–968. [published Online First: 1997/11/05].
- [120] Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M, Prat J, Matias-Guiu X, Cigudosa JC, Palacios J. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. *Cancer Res* 2003; 63(18): 5697–5702. [published Online First: 2003/10/03].
- [121] Risinger J, Maxwell G, Chandramouli G, Jazaeri A, Aprelikova O, Patterson T, Berchuck A, Barrett JC. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. *Cancer Res* 2003; 63(1): 6–11. [published Online

- First: 2003/01/09].
- [122] Basil J, Goodfellow P, Rader J, Mutch D, Herzog T. Clinical significance of microsatellite instability in endometrial carcinoma. *Cancer* 2000; 89(8): 1758–1764. [published Online First: 2000/10/24].
- [123] Lax S, Kendall B, Tashiro H, Slebos R, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. *Cancer* 2000; 88(4): 814–824. [published Online First: 2000/02/19].
- [124] Hecht J, Mutter G. Molecular and pathologic aspects of endometrial carcinogenesis. *J Clin Oncol* 2006; 24(29): 4783–4791. <https://doi.org/10.1200/jco.2006.06.7173>. [published Online First: 2006/10/10].
- [125] Bansal N, Yendluri V, Wenham R. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. *Cancer Control* 2009; 16(1): 8–13. [published Online First: 2008/12/17].
- [126] Engelsen I, Akxlen L, Salvesen H. Biologic markers in endometrial cancer treatment. *Apmis* 2009; 117(10): 693–707. <https://doi.org/10.1111/j.1600-0463.2009.02467.x>. [published Online First: 2009/09/25].
- [127] Abeler V, Kjorstad K. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. *Gynecol Oncol* 1991; 40(3): 207–217. [published Online First: 1991/03/01].
- [128] Goff B, Kato D, Schmidt R, Ek M, Ferry J, Muntz H, Cain J, Tamimi H, Figge D, Greer B. Uterine papillary serous carcinoma: patterns of metastatic spread. *Gynecol Oncol* 1994; 54(3): 264–268. doi: 10.1006/gyno.1994.1208 [published Online First: 1994/09/01].
- [129] Hetzel D, Wilson T, Keeney G, Roche P, Cha S, Podratz K. HER-2/neu expression: a major prognostic factor in endometrial cancer. *Gynecol Oncol* 1992; 47(2): 179–185. [published Online First: 1992/11/01].
- [130] Tashiro H, Isacson C, Levine R, Kurman R, Cho K, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. *Am J Pathol* 1997; 150(1): 177–185. [published Online First: 1997/01/01].
- [131] Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. *Obstet Gynecol* 2002; 100(6): 1290–1295. [published Online First: 2002/12/07].
- [132] Santin A, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel E, De Las Casas L, Roman J, Burnett A, Pecorelli S. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. *Cancer* 2005; 104(7): 1391–1397. <https://doi.org/10.1002/cncr.21308>. [published Online First: 2005/08/24].
- [133] Grushko T, Filiaci V, Mundt A, Ridderstrale K, Olopade O, Fleming G. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2008; 108(1): 3–9. <https://doi.org/10.1016/j.ygyno.2007.09.007>. [published Online First: 2007/10/20].
- [134] Geisler J, Geisler H, Melton M, Wiemann M. What staging surgery should be performed on patients with uterine papillary serous carcinoma? *Gynecol Oncol* 1999; 74(3): 465–467.
- [135] ACOG. ACOG practice bulletin #65: management of endometrial cancer. *Obstet Gynecol* 2005; 106(2): 413–425.
- [136] Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC. Current issues in the management of endometrial cancer. *Mayo Clin Proc* 2008; 83(1): 97–112. <https://doi.org/10.4065/83.1.97>. [published Online First: 2008/01/05].
- [137] Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* 2009; 105(2): 103–104. [published Online First: 2009/04/16].
- [138] Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013; 24 Suppl 6: vi33–38. <https://doi.org/10.1093/annonc/mdt353>. [published Online First: 2013/10/23].
- [139] Burke W, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye A, Brewer M, Boruta D, Villella J, Herzog T, Abu Shahin F. Endometrial cancer: a review and current management strategies: part I. *Gynecol Oncol* 2014; 134(2): 385–392. <https://doi.org/10.1016/j.ygyno.2014.05.018>. [published Online First: 2014/06/07].
- [140] Androutsopoulos G, Kotsopoulos I, Decavalas G. Sentinel lymph node mapping and dissection in patients with endometrial cancer. *Trends Gynecol Oncol* 2016; 1(3): e103.
- [141] Androutsopoulos G, Kotsopoulos I, Korompelis P, Michail G, Adonakis G, Decavalas G. Systematic lymphadenectomy or sentinel lymph node dissection in endometrial cancer: a clinical dilemma. *Helv J Obst Gynecol* 2017; 16(1): 14–19.
- [142] Srinivasan R, Benton E, McCormick F, Thomas H, Gullick W. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. *Clin Cancer Res* 1999; 5(10): 2877–2883.
- [143] Ejskjaer K, Sorensen BS, Poulsen SS, Forman A, Nexø E, Mogensen O. Expression of the epidermal growth factor system in endometrioid endometrial cancer. *Gynecol Oncol* 2007; 104(1): 158–167. <https://doi.org/10.1016/j.ygyno.2006.07.015>. [published Online First: 2006/09/12].
- [144] Brys M, Semczuk A, Rechberger T, Krajewska W. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. *Oncol Rep* 2007; 18(1): 261–265. [published Online First: 2007/06/06].

- [145] Reinartz J, George E, Lindgren B, Niehans G. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. *Hum Pathol* 1994; 25(10): 1075–1083. [published Online First: 1994/10/01].
- [146] Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. *Gynecol Oncol* 1994; 53(1): 84–92. <https://doi.org/10.1006/gyno.1994.1092>. [published Online First: 1994/04/01].
- [147] Scambia G, Benedetti Panici P, Ferrandina G, Battaglia F, Distefano M, D'Andrea G, De Vincenzo R, Maneschi F, Ranelletti F, Mancuso S. Significance of epidermal growth factor receptor expression in primary human endometrial cancer. *Int J Cancer* 1994; 56(1): 26–30. [published Online First: 1994/01/02].
- [148] Niikura H, Sasano H, Kaga K, Sato S, Yajima A. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. *Hum Pathol* 1996; 27(3): 282–289. [published Online First: 1996/03/01].
- [149] Konecny G, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz K, Press M. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. *Br J Cancer* 2009; 100(1): 89–95. <https://doi.org/10.1038/sj.bjc.6604814>. [published Online First: 2008/12/18].
- [150] Morrison C, Zanagnolo V, Ramirez N, Cohn D, Kelbick N, Copeland L, Maxwell G, Fowler J. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. *J Clin Oncol* 2006; 24(15): 2376–2385.
- [151] Santin A, Bellone S, Siegel E, Palmieri M, Thomas M, Cannon M, Kay H, Roman J, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. *Am J Obstet Gynecol* 2005; 192(3): 813–818. <https://doi.org/10.1016/j.ajog.2004.10.605>. [published Online First: 2005/03/05].
- [152] Slomovitz B, Broaddus R, Burke T, Sneige N, Soliman P, Wu W, Sun C, Munsell M, Gershenson D, Lu K. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. *J Clin Oncol* 2004; 22(15): 3126–3132. <https://doi.org/10.1200/jco.2004.11.154>. [published Online First: 2004/07/31].
- [153] Lukes A, Kohler M, Pieper C, Kerns B, Bentley R, Rodriguez G, Soper J, Clarke-Pearson D, Bast R, Jr., Berchuck A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. *Cancer* 1994; 73(9): 2380–2385. [published Online First: 1994/05/01].
- [154] Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, Tsuda H, Kasamatsu T. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. *Cancer Sci* 2012; 103(5): 926–932. <https://doi.org/10.1111/j.1349-7006.2012.02240.x>. [published Online First: 2012/02/15].
- [155] Tebbutt N, Pedersen M, Johns T. Targeting the ERBB family in cancer: couples therapy. *Nat Rev Cancer* 2013; 13(9): 663–673. <https://doi.org/10.1038/nrc3559>. [published Online First: 2013/08/21].
- [156] Hall P, Cameron D. Current perspective—trastuzumab. *Eur J Cancer* 2009; 45(1): 12–18. <https://doi.org/10.1016/j.ejca.2008.10.013>. [published Online First: 2008/12/02].
- [157] Santin A, Bellone S, Roman J, McKenney J, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. *Int J Gynaecol Obstet* 2008; 102(2): 128–131. <https://doi.org/10.1016/j.ijgo.2008.04.008> [published Online First: 2008/06/17].
- [158] Trials NC. Phase II study of cetuximab (erbitux) in patients with progressive or recurrent endometrial cancer. *U.S. National Library of Medicine*. <http://www.clinicaltrials.gov/show/NCT003927692006>.
- [159] Slomovitz B, Schmeler K, Miller D. Phase II study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer [abstract]. *Gynecol Oncol* 2010; 116(suppl 1): S13.
- [160] Jewell E, Secord A, Brotherton T, Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. *Int J Gynecol Cancer* 2006; 16(3): 1370–1373. <https://doi.org/10.1111/j.1525-1438.2006.00543.x>. [published Online First: 2006/06/29].
- [161] Vilella J, Cohen S, Smith D, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. *Int J Gynecol Cancer* 2006; 16(5): 1897–902. <https://doi.org/10.1111/j.1525-1438.2006.00664.x>. [published Online First: 2006/10/03].
- [162] Santin A. Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (*Gynecol Oncol.*, 116; 15–20; 2010). *Gynecol Oncol* 2010; 118(1): 95–96; author reply 96–7. <https://doi.org/10.1016/j.ygyno.2010.01.043>. [published Online First: 2010/02/23].
- [163] Fleming G, Sill M, Darcy K, McMeekin D, Thigpen J, Adler L, Berek J, Chapman J, DiSilvestro P, Horowitz I, Fiorica J. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2010; 116(1): 15–20. <https://doi.org/10.1016/j.ygyno.2009.09.025>. [published Online First: 2009/10/21].
- [164] Trials NC. Evaluation of carboplatin/paclitaxel with and without trastuzumab (Herceptin) in uterine serous cancer. *U.S. National Library of Medicine*. <http://clinicaltrials.gov/ct2/show/NCT013670022011>.

- [165] Roque D, Santin A. Updates in therapy for uterine serous carcinoma. *Curr Opin Obstet Gynecol* 2013; 25(1): 29–37. <https://doi.org/10.1097/GCO.0b013e32835af98d>. [published Online First: 2012/11/10].
- [166] Fader A, Roque D, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord A, Havrilesky L, O'Malley D, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi D, Schwartz P, Santin A. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. *J Clin Oncol* 2018; 36(20): 2044–2051. <https://doi.org/10.1200/jco.2017.76.5966>. [published Online First: 2018/03/28].
- [167] Oza A, Eisenhauer E, Elit L, Cutz J, Sakurada A, Tsao M, Hoskins P, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancy J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. *J Clin Oncol* 2008; 26(26): 4319–4325. <https://doi.org/10.1200/jco.2007.15.8808>. [published Online First: 2008/07/02].
- [168] Leslie K, Sill M, Lankes H, Fischer E, Godwin A, Gray H, Schilder R, Walker J, Tewari K, Hanjani P, Abulafia O, Rose P. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. *Gynecol Oncol* 2012; 127(2): 345–350. <https://doi.org/10.1016/j.ygyno.2012.07.127>. [published Online First: 2012/08/14].
- [169] Leslie K, Sill M, Fischer E, Darcy K, Mannel R, Tewari K, Hanjani P, Wilken J, Baron A, Godwin A, Schilder R, Singh M, Maihle N. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 2013; 129(3): 486–494. <https://doi.org/10.1016/j.ygyno.2013.02.019>. [published Online First: 2013/02/27].
- [170] Hogberg T. What is the role of chemotherapy in endometrial cancer? *Curr Oncol Rep* 2011; 13(6): 433–441. <https://doi.org/10.1007/s11912-011-0192-x>.
- [171] Konecny G, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo M, Toft D, Jiang S, Slamon D, Podratz K. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. *Br J Cancer* 2008; 98(6): 1076–1084. <https://doi.org/10.1038/sj.bjc.6604278>. [published Online First: 2008/03/13].
- [172] Gadducci A, Tana R, Cosio S, Fanucchi A, Genazzani A. Molecular target therapies in endometrial cancer: from the basic research to the clinic. *Gynecol Endocrinol* 2008; 24(5): 239–249. <https://doi.org/10.1080/09513590801953556>. [published Online First: 2008/06/24].
- [173] Vandenput I, Vanden Bempt I, Leunen K, Neven P, Berteloot P, Moerman P, Vergote I, Amant F. Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports. *Gynecol Obstet Invest* 2009; 67(1): 46–48. <https://doi.org/10.1159/000161568>. [published Online First: 2008/10/10].
- [174] El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli F, Hui P, Silasi D, Azodi M, Schwartz P, Rutherford T, Pecorelli S, Santin A. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. *Br J Cancer* 2010; 102(1): 134–143. <https://doi.org/10.1038/sj.bjc.6605448>. [published Online First: 2009/11/19].
- [175] El-Sahwi K, Santin A. ErbB2 overexpression in uterine serous cancer: a molecular target for trastuzumab therapy. *Obstet Gynecol Int* 2011; 2011: 128295. <https://doi.org/10.1155/2011/128295>. [published Online First: 2011/08/31].
- [176] Fader A, Santin A, Gehrig P. Early stage uterine serous carcinoma: management updates and genomic advances. *Gynecol Oncol* 2013; 129(1): 244–250. <https://doi.org/10.1016/j.ygyno.2013.01.004>. [published Online First: 2013/01/17].

第 15 章

子宫内膜癌患者的生活质量

Quality of Life in Women with Endometrial Cancer

- [1] Velikova, G., S. Sheppard, L. Campbell, A. Smith, N. Awad, P. Selby, and J. Brown. 2008. "Randomized trial of quality-of-life measurement in oncology practice: Do oncologists need to know?" *J Clin Oncol* 26: ASCO Annual Meeting, May 20 suppl; abstr 9586.
- [2] Ferrans, Carol E. 2005. "Definitions and conceptual models of quality of life." In *Outcomes Assessment in Cancer: Measures, Methods and Applications*, edited by Joseph Lipscombe, Carol C Gotay and C. F. Snyder, 14–30. Cambridge: Cambridge University Press.
- [3] Osoba, D. 1994. "Lessons learned from measuring health-related quality of life in oncology." *J Clin Oncol* 12 (3): 608–616. <https://doi.org/10.1200/jco.1994.12.3.608>.
- [4] Revicki, D. A., D. Osoba, D. Fairclough, I. Barofsky, R. Berzon, N. K. Leidy, and M. Rothman. 2000. "Recommendations on health-related quality of life research to support labeling and promotional claims in the United States." *Qual Life Res* 9(8): 887–900.
- [5] Ackerman, Phillip L., and Ruth Kanfer. 2009. "Test length and cognitive fatigue: An empirical examination of effects on performance and test-taker reactions." *Journal of Experimental Psychology: Applied* 15 (2): 163–181. <https://doi.org/10.1037/a0015719>.
- [6] Jones, J. M., C. J. McPherson, C. Zimmermann, G. Rodin, L. W. Le, and S. R. Cohen. 2011. "Assessing agreement between terminally ill cancer patients' reports of their quality of life and family caregiver and palliative care physician proxy ratings." *Journal of Pain & Symptom Management* 42 (3): 354–365. <https://doi.org/10.1016/j.jpainsymman.2010.11.018>.
- [7] Petersen, M. A., H. Larsen, L. Pedersen, N. Sonne, and M. Groenvold. 2006. "Assessing health-related quality of life in palliative care: comparing patient and physician assessments." *European Journal of Cancer* 42 (8): 1159–1166.
- [8] Food and Drug Administration. 2009. "Patient reported outcome measures: Use in medical product development to support labelling claims." *Federal Register, The Daily Journal of the United States Government*.
- [9] Morice, P., A. Leary, C. Creutzberg, N. Abu-Rustum, and E. Darai. 2016. "Endometrial cancer." *Lancet* 387 (10023): 1094–1108. [https://doi.org/10.1016/s0140-6736\(15\)00130-0](https://doi.org/10.1016/s0140-6736(15)00130-0).
- [10] Pakish, J. B., K. H. Lu, C. C. Sun, J. K. Burzawa, A. Greisinger, F. A. Smith, B. Fellman, D. L. Urbauer, and P. T. Soliman. 2016. "Endometrial Cancer Associated Symptoms: A Case-Control Study." *Journal of Women's Health* 25 (11): 1187–1192. <https://doi.org/10.1089/jwh.2015.5657>.
- [11] National Cancer Institute. 2018. "Endometrial Cancer Treatment (PDQ)-Patient Version." National Institutes of health, accessed 29th January. <https://www.cancer.gov/types/uterine/patient/endometrial-treatment-pdq>.
- [12] Yavas, G., N. U. Dogan, C. Yavas, N. Benzer, D. Yuce, and C. Celik. 2012. "Prospective assessment of quality of life and psychological distress in patients with gynecologic malignancy: A 1-year prospective study." *International Journal of Gynecological Cancer* 22 (6): 1096–1101. <https://www.doi.org/10.1097/IGC.0b013e3182559c03>.
- [13] de Boer, S. M., R. A. Nout, I. M. Jurgenliemk-Schulz, J. J. Jobsen, L. C. H. W. Lutgens, E. M. Van Der Steen-Banasik, J. W. M. Mens, A. Slot, M. C. Stenfert Kroese, S. Oerlemans, H. Putter, K. W. Verhoeven-Adema, H. W. Nijman, and C. L. Creutzberg. 2015. "Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: Results from the randomized PORTEC-2 trial." *International Journal of Radiation Oncology Biology Physics* 93 (4): 797–809. <https://www.doi.org/10.1016/j.ijrobp.2015.08.023>.
- [14] Au, Heather-Jane, Jolie Ringash, Michael Brundage, Michael Palmer, Harriet Richardson, and Ralph M. Meyer. 2010. "Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG." *Expert Rev Pharm Out* 10 (2): 119–128. <https://www.doi.org/10.1586/erp.10.15>.
- [15] Brenner, M. H., B. Curbow, and M. W. Legro. 1995. "The proximal-distal continuum of multiple health outcome measures: the case of cataract surgery." *Med Care* 33 (4 Suppl): As236–244.
- [16] Park, D. A., D. H. Lee, S. W. Kim, and S. H. Lee. 2016. "Comparative safety and effectiveness of robot-assisted laparoscopic hysterectomy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis." *European Journal of Surgical Oncology* 42 (9): 1303–1314. <https://www.doi.org/10.1016/j.ejso.2016.06.400>.
- [17] Joly, F., J. McAlpine, R. Nout, E. Avall-Lundqvist, E. Shash, and M. Friedlander. 2014. "Quality of life and patient-reported outcomes in endometrial cancer clinical trials: A call for action!" *International Journal of Gynecological Cancer* 24(9): 1693–1699. <https://www.doi.org/10.1016/j.ijgco.2014.06.001>.

- org/10.1097/IGC.0000000000000299.
- [18] Piovano, E., L. Fusco, C. B. Poma, A. Ferrero, S. Perotto, E. Tripodi, E. Volpi, V. Zanfagnin, and P. Zola. 2014. "Complications after the treatment of endometrial cancer: A prospective study using the French-Italian glossary." *International Journal of Gynecological Cancer* 24 (3): 418–426. <https://www.doi.org/10.1097/IGC.0000000000000094>.
- [19] Wei, J., W. Zhang, L. Feng, and W. Gao. 2017. "Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review." *Medicine (United States)* 96(37) (no pagination) (e8034). <https://www.doi.org/10.1097/MD.00000000000008034>.
- [20] Janda, M., V. Gebiski, A. Brand, R. Hogg, T. W. Jobling, R. Land, T. Manolitsas, A. McCartney, M. Nascimento, D. Neesham, J. L. Nicklin, M. K. Oehler, G. Otton, L. Perrin, S. Salfinger, I. Hammond, Y. Leung, T. Walsh, P. Sykes, H. Ngan, A. Garrett, M. Laney, T. Y. Ng, K. Tam, K. Chan, C. D. H. Wrede, S. Pather, B. Simcock, R. Farrell, and A. Obermair. 2010. "Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): A randomised trial." *The Lancet Oncology* 11 (8): 772–780. <https://www.doi.org/10.1016/S1470-2045%2810%2970145-5>.
- [21] Berretta, R., S. Gizzo, M. Noventa, V. Marrazzo, L. Franchi, C. Migliavacca, M. Michela, C. Merisio, A. B. Modena, and T. S. Patrelli. 2015. "Quality of Life in Patients Affected by Endometrial Cancer: Comparison Among Laparotomy, Laparoscopy and Vaginal Approach." *Pathology and Oncology Research* 21(3): 811–816. <https://www.doi.org/10.1007/s12253-014-9895-2>.
- [22] Abitbol, J., R. Cohn, S. Hunter, M. Rombaldi, E. Cohen, R. Kessous, N. Large, A. Reiss, S. Lau, S. Salvador, and W. H. Gotlieb. 2017. "Minimizing pain medication use and its associated costs following robotic surgery." *Gynecologic Oncology* 144(1): 187–192. <https://www.doi.org/10.1016/j.ygyno.2016.11.014>.
- [23] Lau, S., S. Aubin, Z. Rosberger, I. Gourdji, J. How, R. Gotlieb, N. Drummond, I. Eniu, J. Abitbol, and W. Gotlieb. 2014. "Health-Related Quality of Life Following Robotic Surgery: A Pilot Study." *Journal of Obstetrics and Gynaecology Canada* 36 (12): 1071–1078. <https://www.doi.org/10.1016/S1701-2163%2815%2930384-4>.
- [24] Arms, R. G., C. C. Sun, J. K. Burzawa, N. D. Fleming, A. M. Nick, V. Rallapalli, S. N. Westin, L. A. Meyer, P. T. Ramirez, and P. T. Soliman. 2015. "Improvement in quality of life after robotic surgery results in patient satisfaction." *Gynecologic Oncology* 138 (3): 727–730. <https://www.doi.org/10.1016/j.ygyno.2015.07.013>.
- [25] Gala, R. B., R. Margulies, A. Steinberg, M. Murphy, J. Lukban, P. Jeppson, S. Aschkenazi, C. Olivera, M. South, L. Lowenstein, J. Schaffer, E. M. Balk, and V. Sung. 2014. "Systematic review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy." *J Minim Invasive Gynecol* 21 (3): 353–361. <https://www.doi.org/10.1016/j.jmig.2013.11.010>.
- [26] Chiou, H. Y., L. H. Chiu, C. H. Chen, Y. K. Yen, C. W. Chang, and W. M. Liu. 2015. "Comparing robotic surgery with laparoscopy and laparotomy for endometrial cancer management: a cohort study." *International Journal of Surgery* 13: 17–22. <https://www.doi.org/10.1016/j.ijso.2014.11.015>.
- [27] Leitao Jr, M. M., V. Malhotra, G. Briscoe, R. Suidan, P. Dholakiya, K. Santos, E. L. Jewell, C. L. Brown, Y. Sonoda, N. R. Abu-Rustum, R. R. Barakat, and G. J. Gardner. 2013. "Postoperative pain medication requirements in patients undergoing computer-assisted ("Robotic") and standard laparoscopic procedures for newly diagnosed endometrial cancer." *Annals of Surgical Oncology* 20 (11): 3561–3567. <https://www.doi.org/10.1245/s10434-013-3064-9>.
- [28] Eklind, S., A. Lindfors, P. Sjoli, and P. Dahm-Kahler. 2015. "A prospective, comparative study on robotic versus open-surgery hysterectomy and pelvic lymphadenectomy for endometrial carcinoma." *Int J Gynecol Cancer* 25 (2): 250–256. doi: 10.1097/igc.0000000000000357.
- [29] Herling, S. F., C. Palle, A. M. Moeller, and T. Thomsen. 2016. "The experience of robotic-assisted laparoscopic hysterectomy for women treated for early-stage endometrial cancer: A qualitative study." *Cancer Nursing* 39 (2): 125–133. <https://www.doi.org/10.1097/NCC.0000000000000260>.
- [30] Hoekstra, A. V., A. Jairam-Thodla, A. Rademaker, D. K. Singh, B. M. Buttin, J. R. Lurain, J. C. Schink, and M. P. Lowe. 2009. "The impact of robotics on practice management of endometrial cancer: transitioning from traditional surgery." *Int J Med Robot* 5 (4): 392–397. <https://www.doi.org/10.1002/rcs.268>.
- [31] Lindqvist, E., M. Wedin, M. Fredrikson, and P. Kjolhede. 2017. "Lymphedema after treatment for endometrial cancer—A review of prevalence and risk factors." *European Journal of Obstetrics Gynecology and Reproductive Biology* 211: 112–121. <https://www.doi.org/10.1016/j.ejogrb.2017.02.021>.
- [32] Honerlaw, K. R., M. E. Rumble, S. L. Rose, C. L. Coe, and E. S. Costanzo. 2016. "Biopsychosocial predictors of pain among women recovering from surgery for endometrial cancer." *Gynecologic Oncology* 140 (2): 301–306. <https://www.doi.org/10.1016/j.ygyno.2015.09.005>.
- [33] Biglia, N., V. Zanfagnin, A. Daniele, E. Robba, and V. E. Bounous. 2017. "Lower body lymphedema in patients with gynecologic cancer." *Anticancer Research* 37(8): 4005–4015. <https://www.doi.org/10.21873/anticancer.11785>.
- [34] Beesley, V. L., I. J. Rowlands, S. C. Hayes, M. Janda, P. O'Rourke, L. Marquart, M. A. Quinn, A. B. Spurdle, A. Obermair, A. Brand, M. K. Oehler, Y. Leung, L. McQuire, and P. M. Webb. 2015. "Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer." *Gynecologic Oncology* 136 (1): 87–93. <https://www.doi.org/10.1016/j.ygyno.2014.11.006>.
- [35] Rowlands, I. J., V. L. Beesley, M. Janda, S. C. Hayes, A. Obermair, M. A. Quinn, A. Brand, Y. Leung, L. McQuire, and P. M. Webb. 2014. "Quality of life of women with lower limb swelling or lymphedema 3–5 years following endometrial cancer." *Gynecologic Oncology* 133 (2):

- 314–318. <https://doi.org/10.1016/j.ygyno.2014.03.003>.
- [36] Machida, H., M. S. Hom, M. Maeda, J. J. Yeo, C. S. Ghattas, B. H. Grubbs, and K. Matsuo. 2016. “Signs and Symptoms of Venous Thromboembolism and Survival Outcome of Endometrial Cancer.” *International Journal of Gynecological Cancer* 26 (5): 924–932. <https://doi.org/10.1097/IGC.0000000000000684>.
- [37] Creutzberg, C. L., and R. A. Nout. 2011. “The role of radiotherapy in endometrial cancer: Current evidence and trends.” *Current Oncology Reports* 13 (6): 472–478. <https://doi.org/10.1007/s11912-011-0191-y>.
- [38] Kong, A., I. Simera, M. Collingwood, C. Williams, and H. Kitchener. 2007. “Adjuvant radiotherapy for stage I endometrial cancer: Systematic review and meta-analysis.” *Annals of Oncology* 18 (10): 1595–1604. <https://doi.org/10.1093/annonc/mdm066>.
- [39] Kong, A., N. Johnson, H. C. Kitchener, and T. A. Lawrie. 2012. “Adjuvant radiotherapy for stage I endometrial cancer: An updated cochrane systematic review and meta-analysis.” *Journal of the National Cancer Institute* 104 (21): 1625–1634. <https://doi.org/10.1093/jnci/djs374>.
- [40] Chen, C. C., L. Wang, C. H. Lu, J. C. Lin, and J. S. Jan. 2014. “Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy.” *Journal of the Formosan Medical Association* 113 (12): 949–955. <https://doi.org/10.1016/j.jfma.2013.09.013>.
- [41] Karabuga, H., M. Gultekin, G. Tulunay, K. Yuce, A. Ayhan, D. Yuce, and F. Yildiz. 2015. “Assessing the quality of life in patients with endometrial cancer treated with adjuvant radiotherapy.” *International Journal of Gynecological Cancer* 25 (8): 1526–1533. <https://doi.org/10.1097/IGC.0000000000000509>.
- [42] Alongi, F., R. Mazzola, F. Ricchetti, S. Fersino, N. G. Levra, A. Fiorentino, S. Naccarato, G. Sicignano, G. Di Paola, R. Ruggieri, S. Gori, and M. Ceccaroni. 2015. “Volumetric-modulated arc therapy with vaginal cuff simultaneous integrated boost as an alternative to brachytherapy in adjuvant irradiation for endometrial cancer: A prospective study.” *Anticancer Research* 35 (4): 2149–2155.
- [43] Mirabeau-Beale, K. L., and A. N. Viswanathan. 2014. “Quality of life (QOL) in women treated for gynecologic malignancies with radiation therapy: A literature review of patient-Reported outcomes.” *Gynecologic Oncology* 134 (2): 403–409. <https://doi.org/10.1016/j.ygyno.2014.05.008>.
- [44] Abayomi, J., J. Kirwan, and A. Hackett. 2009. “The prevalence of chronic radiation enteritis following radiotherapy for cervical or endometrial cancer and its impact on quality of life.” *European Journal of Oncology Nursing* 13 (4): 262–267. <https://doi.org/10.1016/j.ejon.2009.02.007>.
- [45] Van De Poll-Franse, L. V., J. M. A. Pijnenborg, D. Boll, M. C. Vos, H. Van Den Berg, M. L. M. Lybeert, K. De Winter, and R. F. P. M. Kruitwagen. 2012. “Health related quality of life and symptoms after pelvic lymphadenectomy or radiotherapy vs. no adjuvant regional treatment in early-stage endometrial carcinoma: A large population-based study.” *Gynecologic Oncology* 127 (1): 153–160. <https://doi.org/10.1016/j.ygyno.2012.06.007>.
- [46] Nout, R. A., L. V. Van De Poll-Franse, M. L. M. Lybeert, C. C. Warlam-Rodenhuis, J. J. Jobsen, J. W. M. Mens, L. C. H. W. Lutgens, B. Pras, W. L. J. Van Putten, and C. L. Creutzberg. 2011. “Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial.” *Journal of Clinical Oncology* 29 (13): 1692–1700. <https://doi.org/10.1200/JCO.2010.32.4590>.
- [47] Keys, H. M., V. L. Brunetto, R. J. Zaino, N. M. Spirtos, J. D. Bloss, A. Pearlman, MA Maiman, JG Bell, and Gynecologic Oncology Group. 2004. “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study.” *Gynecol Oncol* 92 (3): 744–751.
- [48] Nout, R. A., V. T. H. B. M. Smit, H. Putter, I. M. Jurgenliemk-Schulz, J. J. Jobsen, L. C. H. W. Lutgens, E. M. van der Steen-Banasik, J. W. M. Mens, A. Slot, M. S. Kroese, B. N. F. M. van Bunningen, A. C. Ansink, W. L. J. van Putten, and C. L. Creutzberg. 2010. “Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.” *The Lancet* 375 (9717): 816–823. <https://doi.org/10.1016/S0140-6736%2809%2962163-2>.
- [49] Nout, R. A., H. Putter, I. M. Jurgenliemk-Schulz, J. J. Jobsen, L. C. H. W. Lutgens, E. M. Van Der Steen-Banasik, J. W. M. Mens, A. Slot, M. C. Stenfert Kroese, H. W. Nijman, L. V. Van De Poll-Franse, and C. L. Creutzberg. 2012. “Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.” *European Journal of Cancer* 48 (11): 1638–1648. <https://doi.org/10.1016/j.ejca.2011.11.014>.
- [50] Damast, S., K. M. Alektiar, S. Goldfarb, A. Eaton, S. Patil, J. Mosenkis, A. Bennett, T. Atkinson, E. Jewell, M. Leitao, R. Barakat, J. Carter, and E. Basch. 2012. “Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy.” *International Journal of Radiation Oncology Biology Physics* 84 (2): e187–e193. <https://doi.org/10.1016/j.ijrobp.2012.03.030>.
- [51] Dandapani, S. V., Y. Zhang, R. Jennelle, and Y. G. Lin. 2015. “Radiation-Associated Toxicities in Obese Women with Endometrial Cancer: More Than Just BMI?” *Scientific World Journal* 2015 (no pagination) (483208). <https://doi.org/10.1155/2015/483208>.
- [52] Foerster, R., L. Schnetzke, T. Bruckner, N. Arians, H. Rief, J. Debus, and K. Lindel. 2016. “Prognostic factors for long-term quality of life after adjuvant radiotherapy in women with endometrial cancer.” *Strahlentherapie und Onkologie* 192 (12): 895–904. <https://doi.org/10.1007/s00066-016-1037-1>.
- [53] Le, Tien, Chantal Menard, Rajiv Samant, E. Choan, Laura Hopkins, Wylam Faught, and Michael Fung-Kee-Fung. 2009. “Longitudinal Assessments of Quality of Life in

- Endometrial Cancer Patients: Effect of Surgical Approach and Adjuvant Radiotherapy.” *International Journal of Radiation Oncology *Biology*Physics* 75(3): 795–802. <https://doi.org/10.1016/j.ijrobp.2008.11.018>.
- [54] Humber, C. E., J. F. Tierney, R. P. Symonds, M. Collingwood, J. Kirwan, C. Williams, and J. A. Green. 2007. “Chemotherapy for advanced, recurrent or metastatic endometrial cancer: A systematic review of Cochrane collaboration.” *Annals of Oncology* 18 (3): 409–420. <https://doi.org/10.1093/annonc/mdl417>.
- [55] Gao, H., M. Xiao, H. Bai, and Z. Zhang. 2017. “Sexual Function and Quality of Life Among Patients With Endometrial Cancer After Surgery.” *International Journal of Gynecological Cancer* 27 (3): 608–612. <https://doi.org/10.1097/IGC.0000000000000905>.
- [56] McGarvey, E. L., L. D. Baum, R. C. Pinkerton, and L. M. Rogers. 2001. “Psychological sequelae and alopecia among women with cancer.” *Cancer Pract* 9(6): 283–289.
- [57] Komen, Manon M. C., Carolien H. Smorenburg, Corina J. G. van den Hurk, and Johan W. R. Nortier. 2013. “Factors Influencing the Effectiveness of Scalp Cooling in the Prevention of Chemotherapy-Induced Alopecia.” *The Oncologist* 18 (7): 885–891. <https://doi.org/10.1634/theoncologist.2012-0332>.
- [58] Tajeja, N., and H. Groninger. 2016. “Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines.” *Postgrad Med J* 92(1083): 34–40. <https://doi.org/10.1136/postgradmedj-2014-132969>.
- [59] Lohr, L. 2008. “Chemotherapy-induced nausea and vomiting.” *Cancer Journal* 14(2): 85–93.
- [60] Jim, Heather S. L., Brent Small, Leigh Anne Faul, Jamie Franzen, Sachin Apte, and Paul B. Jacobsen. 2011. “Fatigue, Depression, Sleep, and Activity During Chemotherapy: Daily and Intraday Variation and Relationships Among Symptom Changes.” *Annals of Behavioral Medicine: A Publication of the Society of Behavioral Medicine* 42 (3): 321–333. <https://doi.org/10.1007/s12160-011-9294-9>.
- [61] Cella, D., H. Huang, H. D. Homesley, A. Montag, R. Salani, K. De Geest, R. Lee, and N. M. Spirtos. 2010. “Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.” *Gynecologic Oncology* 119 (3): 538–542. <https://doi.org/10.1016/j.ygyno.2010.08.022>.
- [62] de Boer, S. M., M. E. Powell, L. Mileskin, D. Katsaros, P. Bessette, C. Haie-Meder, P. B. Ottevanger, J. A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M. H. Baron, H. C. Kitchener, H. W. Nijman, R. F. Kruitwagen, R. A. Nout, K. W. Verhoeven-Adema, V. T. Smit, H. Putter, and C. L. Creutzberg. 2016. “Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.” *The Lancet Oncology* 17 (8): 1114–1126. <https://doi.org/10.1016/S1470-2045%2816%2930120-6>.
- [63] Matsuda, T., T. Takayama, M. Tashiro, Y. Nakamura, Y. Ohashi, and K. Shimozuma. 2005. “Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients—evaluation of appropriate research design and methodology to measure symptoms.” *Breast Cancer* 12 (4): 279–287.
- [64] Ahles, T. A., J. C. Root, and E. L. Ryan. 2012. “Cancer- and cancer treatment-associated cognitive change: an update on the state of the science.” *J Clin Oncol* 30(30): 3675–3686. <https://doi.org/10.1200/jco.2012.43.0116>.
- [65] Vardy, J. L., M. M. Stouten-Kemperman, G. Pond, C. M. Booth, S. B. Rourke, H. M. Dhillon, A. Dodd, A. Crawley, and I. F. Tannock. 2017. “A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer.” *Brain Imaging Behav.* <https://doi.org/10.1007/s11682-017-9728-5>.
- [66] Bruner, D. W., A. Barsevick, C. Tian, M. Randall, R. Mannel, D. E. Cohn, J. Sorosky, and N. M. Spirtos. 2007. “Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study.” *Quality of Life Research* 16 (1): 89–100. <https://doi.org/10.1007/s11136-006-9003-5>.
- [67] Blinman, P., L. Mileskin, P. Khaw, G. Goss, C. Johnson, A. Capp, S. Brooks, G. Wain, I. Kolodziej, A. S. Veillard, R. O’Connell, C. L. Creutzberg, and M. R. Stockler. 2016. “Patients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial.” *British Journal of Cancer* 115 (10): 1179–1185. <https://doi.org/10.1038/bjc.2016.323>.
- [68] Manley, K., K. Edey, J. Braybrooke, and J. Murdoch. 2012. “Hormone replacement therapy after endometrial cancer.” *Menopause International* 18 (4): 134–138. <https://doi.org/10.1258/mi.2012.012024>.
- [69] del Carmen, M. G., and L. W. Rice. 2017. “Management of menopausal symptoms in women with gynecologic cancers.” *Gynecologic Oncology*. 25. <https://doi.org/10.1016/j.ygyno.2017.06.013>.
- [70] Hill, D. A., M. Crider, and S. R. Hill. 2016. “Hormone Therapy and Other Treatments for Symptoms of Menopause.” *American Family Physician* 94 (11): 884–889.
- [71] Martin-Hirsch, P. P., A. Bryant, S. L. Keep, H. C. Kitchener, and R. Lilford. 2011. “Adjuvant progestagens for endometrial cancer.” *Cochrane Database Syst Rev* (6): Cd001040. <https://doi.org/10.1002/14651858.CD001040.pub2>.
- [72] Barakat, R. R., B. N. Bundy, N. M. Spirtos, J. Bell, and R. S. Mannel. 2006. “Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study.” *J Clin Oncol* 24 (4): 587–592. <https://doi.org/10.1200/jco.2005.02.8464>.
- [73] Lee, W. L., F. K. Lee, W. H. Su, K. H. Tsui, C. D. Kuo, S. L. E. Hsieh, and P. H. Wang. 2012. “Hormone therapy for younger patients with endometrial cancer.” *Taiwanese Journal of Obstetrics and Gynecology* 51 (4): 495–505. <https://doi.org/10.1016/j.tjog.2012.09.003>.
- [74] Straubhar, A., A. P. Soisson, M. Dodson, and E. Simons. 2017. “Successful treatment of low-grade endometrial

- cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.” *Gynecologic Oncology Reports* 21: 10–12. <https://doi.org/10.1016/j.gore.2017.05.003>.
- [75] Falcone, F., G. Laurelli, S. Losito, M. Di Napoli, V. Granata, and S. Greggi. 2017. “Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.” *Journal of Gynecologic Oncology* 28 (1): e2. <https://doi.org/10.3802/jgo.2017.28.e2>.
- [76] Laurelli, G., F. Falcone, M. S. Gallo, F. Scala, S. Losito, V. Granata, M. Cascella, and S. Greggi. 2016. “Long-Term Oncologic and Reproductive Outcomes in Young Women with Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update.” *International Journal of Gynecological Cancer* 26 (9): 1650–1657. <https://doi.org/10.1097/IGC.0000000000000825>.
- [77] Angarita, A. M., C. A. Johnson, A. N. Fader, and M. S. Christianson. 2016. “Fertility Preservation: A Key Survivorship Issue for Young Women with Cancer.” *Front Oncol* 6: 102. <https://doi.org/10.3389/fonc.2016.00102>.
- [78] Chan, J. L., J. Letourneau, W. Salem, A. P. Cil, S. W. Chan, L. M. Chen, and M. P. Rosen. 2017. “Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients.” *J Cancer Surviv* 11 (1): 58–63. <https://doi.org/10.1007/s11764-016-0563-2>.
- [79] Ferrandina, G., M. Petrillo, G. Mantegna, G. Fuoco, S. Terzano, L. Venditti, A. Marcellusi, R. De Vincenzo, and G. Scambia. 2014. “Evaluation of quality of life and emotional distress in endometrial cancer patients: a 2-year prospective, longitudinal study.” *Gynecol Oncol* 133 (3): 518–525. <https://doi.org/10.1016/j.ygyno.2014.03.015>.
- [80] Simard, S., B. Thewes, G. Humphris, M. Dixon, C. Hayden, S. Mireskandari, and G. Ozakinci. 2013. “Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies.” *J Cancer Surviv* 7 (3): 300–322. <https://doi.org/10.1007/s11764-013-0272-z>.
- [81] Aerts, Leen, Paul Enzlin, Johan Verhaeghe, Willy Poppe, Ignace Vergote, and Frederic Amant. 2015. “Sexual functioning in women after surgical treatment for endometrial cancer: A prospective controlled study.” *Journal of Sexual Medicine* 12 (1): 198–209. <https://doi.org/10.1111/jsm.12764>.
- [82] Rowlands, I. J., C. Lee, V. L. Beesley, P. M. Webb, and Group On behalf of the Australian National Endometrial Cancer Study. 2014. “Predictors of sexual well-being after endometrial cancer: results of a national self-report survey.” *Supportive Care in Cancer* 22 (10): 2715–2723. <https://doi.org/10.1007/s00520-014-2263-7>.
- [83] Rowlands, I. J., M. Janda, L. McKinnon, P. M. Webb, V. L. Beesley, and Group on behalf of the Australian National Endometrial Cancer Study. 2015. “Prevalence, predictors, and correlates of supportive care needs among women 3–5 years after a diagnosis of endometrial cancer.” *Supportive Care in Cancer* 23 (5): 1205–1214. <https://doi.org/10.1007/s00520-014-2456-0>.
- [84] Nicolaije, K. A. H., O. Husson, N. P. M. Ezendam, M. C. Vos, R. F. P. M. Kruitwagen, M. L. M. Lybeert, and L. V. van de Poll-Franse. 2012. “Endometrial cancer survivors are unsatisfied with received information about diagnosis, treatment and follow-up: A study from the population-based PROFILES registry.” *Patient Education and Counseling* 88(3): 427–435. <https://doi.org/10.1016/j.pec.2012.05.002>.
- [85] Rowlands, I. J., C. Lee, V. L. Beesley, M. Janda, C. M. Nagle, and P. M. Webb. 2015. “Womens Perceptions of their lifestyle and quality of life several years after a diagnosis of endometrial cancer.” *Cancer Nursing* 38 (1): E21–E28. <https://doi.org/10.1097/NCC.0000000000000129>.
- [86] Rossi, A., C. E. Garber, G. Kaur, X. Xue, G. L. Goldberg, and N. S. Nevadunsky. 2017. “Physical activity-related differences in body mass index and patient-reported quality of life in socioculturally diverse endometrial cancer survivors.” *Supportive Care in Cancer* 25 (7): 2169–2177. <https://doi.org/10.1007/s00520-017-3622-y>.
- [87] Babatunde, O. A., S. A. Adams, O. Orekoya, K. Basen-Engquist, and S. E. Steck. 2016. “Effect of Physical Activity on Quality of Life as Perceived by Endometrial Cancer Survivors: A Systematic Review.” *International Journal of Gynecological Cancer* 26 (9): 1727–1740. <https://doi.org/10.1097/IGC.0000000000000821>.
- [88] Smits, A., A. Lopes, N. Das, R. Bekkers, L. Massuger, and K. Galaal. 2015. “The effect of lifestyle interventions on the quality of life of gynaecological cancer survivors A systematic review and meta-analysis.” *Gynecologic Oncology* 139(3): 546–552. <https://doi.org/10.1016/j.ygyno.2015.10.002>.
- [89] Koutoukidis, D. A., M. T. Knobf, and A. Lanceley. 2015. “Obesity, diet, physical activity, and health-related quality of life in endometrial cancer survivors.” *Nutrition Reviews* 73 (6): 399–408. <https://doi.org/10.1093/nutrit/nuu063>.
- [90] Armbruster, S. D., J. Song, A. Bradford, C. L. Carmack, K. H. Lu, and K. M. Basen-Engquist. 2016. “Sexual health of endometrial cancer survivors before and after a physical activity intervention: A retrospective cohort analysis.” *Gynecologic Oncology* 143 (3): 589–595. <https://doi.org/10.1016/j.ygyno.2016.09.016>.
- [91] Oldenburg, C. S., D. Boll, K. A. H. Nicolaije, M. C. Vos, J. M. A. Pijnenborg, J. W. Coebergh, S. Beijer, L. V. Van De Poll-Franse, and N. P. M. Ezendam. 2013. “The relationship of body mass index with quality of life among endometrial cancer survivors: A study from the population-based PROFILES registry.” *Gynecologic Oncology* 129 (1): 216–221. <https://doi.org/10.1016/j.ygyno.2012.12.041>.
- [92] Aaronson, N. K., S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N. J. Duez, A. Filiberti, H. Flechtner, S. B. Fleishman, and J. C. de Haes. 1993. “The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.” *J Natl Cancer I* 85(5): 365–376.
- [93] Flechtner, H., and A. Bottomley. 2006. “Quality of life assessment and research in the EORTC (European Organisation for Research and Treatment of Cancer).” *Oncologie* 8 (5): 443–446. <https://doi.org/10.1007/s10269-006-0412-4>.
- [94] Cherny, N. I., R. Sullivan, U. Dafni, J. M. Kerst, A.

- Sobrero, C. Zielinski, E. G. de Vries, and M. J. Piccart. 2015. "A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)." *Ann Oncol* 26 (8): 1547–1573. <https://doi.org/10.1093/annonc/mdv249>.
- [95] Schnipper, L. E., N. E. Davidson, D. S. Wollins, C. Tyne, D. W. Blayney, D. Blum, A. P. Dicker, P. A. Ganz, J. R. Hoveman, R. Langdon, G. H. Lyman, N. J. Meropol, T. Mulvey, L. Newcomer, J. Peppercorn, B. Polite, D. Raghavan, G. Rossi, L. Saltz, D. Schrag, T. J. Smith, P. P. Yu, C. A. Hudis, R. L. Schilsky, and Oncology American Society of Clinical. 2015. "American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options." *J Clin Oncol* 33 (23): 2563–2577. <https://doi.org/10.1200/jco.2015.61.6706>.
- [96] Gilbert, A., D. Sebag-Montefiore, S. Davidson, and G. Velikova. 2015. "Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic." *Gynecol Oncol* 136 (3): 429–439.
- [97] Snyder, C. F., N. K. Aaronson, A. K. Choucair, T. E. Elliott, J. Greenhalgh, M. Y. Halyard, R. Hess, D. M. Miller, B. B. Reeve, and M. Santana. 2012. "Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations." *Qual Life Res* 21 (8): 1305–1314. <https://doi.org/10.1007/s11136-011-0054-x>.
- [98] Valderas, J. M., A. Kotzeva, M. Espallargues, G. Guyatt, C. E. Ferrans, M. Y. Halyard, D. A. Revicki, T. Symonds, A. Parada, and J. Alonso. 2008. "The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature." *Qual Life Res* 17 (2): 179–193. <https://doi.org/10.1007/s11136-007-9295-0>.
- [99] Mapi Research Trust. 2016. "PROQOLID Patient-Reported Outcome and Quality of Life Instruments Database," Accessed 28th November 2016.
- [100] King, M. T. 2011. "A point of minimal important difference (MID): a critique of terminology and methods." *Expert Rev Pharmacoecon Outcomes Res* 11 (2): 171–184. <https://doi.org/10.1586/erp.11.9>.
- [101] Streiner, D. L., and G. R. Norman. 1996. *Health Measurement Scales: a Practical Guide to their Development and Use*. Oxford: Oxford University Press.
- [102] Aaronson, N., J. Alonso, A. Burnam, K. N. Lohr, D. L. Patrick, E. Perrin, and R. E. Stein. 2002. "Assessing health status and quality-of-life instruments: attributes and review criteria." *Qual Life Res* 11 (3): 193–205.
- [103] Cella, D., D. S. Tulsky, R. Gray, B. Sarafian, S. Lloyd, E. Linn, A. Bonomi, M. Silberman, S. B. Yellen, P. Winicour, J. Brannon, K. Eckberg, S. Purl, C. Blendowski, M. Goodman, M. Barnicle, I. Stewart, M. McHale, P. Bonomi, E. Kaplan, S. Taylor, C. Thomas, and J. Harris. 1993. "The Functional Assessment of Cancer Therapy (FACT) scale: Development and validation of the general measure." *J Clin Oncol* 11 (3): 570–579.
- [104] Greimel, E., A. Nordin, A. Lanceley, C. L. Creutzberg, L. V. van de Poll-Franse, V. B. Radisic, R. Galalae, C. Schmalz, E. Barlow, P. T. Jensen, A. C. Waldenstrom, K. Bergmark, W. C. Chie, K. Kuljanic, A. Costantini, S. Singer, D. Koensgen, U. Menon, and F. Daghofer. 2011. "Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)." *Eur J Cancer* 47 (2): 183–190. <https://doi.org/10.1016/j.ejca.2010.08.014>.
- [105] Calhoun, E. A., E. E. Welshman, C. H. Chang, J. R. Lurain, D. A. Fishman, T. L. Hunt, and D. Cella. 2003. "Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy." *Int J Gynecol Cancer* 13 (6): 741–748.
- [106] Cancer Australia. 2017. "Follow-up care for women with low-risk endometrial cancer: A guide for General Practitioners 2017." *Cancer Australia*, accessed 23 January. <https://canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/follow-care-women-low-risk-endometrial-cancer-guide-general-practitioners-2017>.
- [107] McAlpine, J. N., E. Greimel, L. A. Brotto, R. A. Nout, E. Shash, E. Avall-Lundqvist, M. L. Friedlander, and F. Joly. 2014. "Quality of life research in endometrial cancer what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic cancer InterGroup Symptom Benefit Working Group brainstorming session, leiden 2012." *International Journal of Gynecological Cancer* 24 (9): 1686–1692. <https://doi.org/10.1097/IGC.0000000000000245>.
- [108] Lockett, T., and M. T. King. 2010. "Choosing patient-reported outcome measures for cancer clinical research—practical principles and an algorithm to assist non-specialist researchers." *Eur J Cancer* 46 (18): 3149–3157. <https://doi.org/10.1016/j.ejca.2010.08.002>.
- [109] Snyder, C. F., M. E. Watson, J. D. Jackson, D. F. Cella, and M. Y. Halyard. 2007. "Patient-Reported Outcome Instrument Selection: Designing a Measurement Strategy." *Value in Health* 10: S76–S85. <https://doi.org/10.1111/j.1524-4733.2007.00270.x>.
- [110] Lockett, T., M. T. King, P. N. Butow, M. Oguchi, N. Rankin, M. A. Price, N. A. Hackl, and G. Heading. 2011. "Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations." *Ann Oncol* 22 (10): 2179–2190. <https://doi.org/10.1093/annonc/mdq721>.
- [111] Mercieca-Bebber, R., M. J. Palmer, M. Brundage, and M. Calvert. 2016. "Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review." *BMJ Open* 6(6): e010938. <https://doi.org/10.1136/bmjopen-2015-010938>.
- [112] Aaronson, N. K., T. E. Elliott, J. Greenhalgh, M. Y. Halyard, R. Hess, D. M. Miller, B. B. Reeve, M. Santana, and C. Snyder. 2015. *User's Guide to Implementing Patient-Reported Outcomes Assessment in Clinical Practice*, Version 2: January: International Society for Quality of Life Research.